



Serum and Glucocorticoid-Regulated Kinase Signaling in Breast Cancer

Citation

Gasser, Jessica Ann. 2014. Serum and Glucocorticoid-Regulated Kinase Signaling in Breast Cancer. Doctoral dissertation, Harvard University.

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:11745712>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Serum and Glucocorticoid-Regulated Kinase Signaling in Breast Cancer

A dissertation presented

by

Jessica Ann Gasser

to

The Division of Medical Sciences

in partial fulfillment of the requirements

for the degree of

Doctor of Philosophy

in the subject of

Cell and Developmental Biology

Harvard University

Cambridge, Massachusetts

December 2013

© 2013 Jessica Ann Gasser

All rights reserved.

Serum and Glucocorticoid-Regulated Kinase Signaling in Breast Cancer

Abstract

Oncogenic activating mutations in *PIK3CA*, the gene encoding the catalytic subunit of phosphoinositide 3-kinase (PI 3-K), are highly prevalent in breast cancer. The protein kinase Akt is considered to be the primary effector of *PIK3CA*, though the mechanisms by which PI 3-K mediates tumorigenic signals in an Akt-independent manner remain obscure. My studies show that the serum and glucocorticoid-regulated kinases (SGKs) can function as effectors of PI 3-kinase and transduce signals to phenotypes associated with malignancy. We show that SGK3 is amplified in breast cancer and identify the mechanism by which SGK3 is activated downstream of *PIK3CA*, specifically through the catalytic activity of the phosphoinositide phosphatase INPP4B. Expression of INPP4B promotes SGK3 activation and in turn inhibits Akt phosphorylation. In breast cancer cell lines with elevated levels of INPP4B, SGK3 is required for proliferation in 3D and also for invasive migration. SGK3 phenotypes are in part mediated by phosphorylation of the substrate protein N-myc downstream regulated 1 (NDRG)1, an established metastasis suppressor. The phosphorylation of NDRG1 leads to recruitment by F-box and WD repeat domain-containing 7 (FBW7), the

substrate recognition domain of the Skp, Cullin, F-box containing (SCF) complex.

Binding of FBW7 to NDRG1 promotes its polyubiquitination and subsequent degradation by the 26S proteasome. By contrast, our studies also show that the related SGK1 isoform is polyubiquitinated by the functional E3 ubiquitin ligase Rictor-Cullin-1 complex, leading to SGK1 degradation. Proteasomal degradation of SGK1 by Rictor-Cullin-1 is the first identified mTORC2-independent function of the Rictor protein. Moreover, the deregulation of SGK1 ubiquitination highlights a mechanism of SGK1 overexpression in breast cancers.

Taken together, these findings highlight novel post-translational modifications of SGK isoforms converging on the theme of ubiquitination and degradation. Alterations in ubiquitination status lead to the deregulation of cellular phenotypes such as proliferation and migration. The data presented in this thesis also highlight a mechanism by which SGK isoforms transduce oncogenic PI3-kinase signaling in breast cancer. The oncogenic potential of SGK signaling is further emphasized by the aberrant expression levels of SGK1 and SGK3 in breast cancers.

TABLE OF CONTENTS

CHAPTER I: INTRODUCTION.....	1
1. MECHANISMS OF PI 3-KINASE ACTIVATION	2
The Akt Kinase as a Transducer of PI 3-K Signaling	5
Alternate PI 3-K Pathway Effectors	12
Oncogenic PI 3-K Pathway Mutations	13
The Inositol Polyphosphate Phosphatase INPP4B.....	16
2. SERUM AND GLUCOCORTICOID- REGULATED KINASES.....	19
Serum and Glucocorticoid- regulated Kinase Activation Mechanisms	22
Serum and Glucocorticoid- regulated Kinase 3 Regulation	24
3. N-MYC DOWN-REGULATED GENE 1	26
NDRG1 Regulation During the Epithelial-Mesenchymal Transition.....	29
Clinical Significance of NDRG1 Expression and Function.....	30
4. THE UBIQUITIN PROTEASOME SYSTEM	34
E3 Ligases.....	38
5. CONTRIBUTION OF THIS THESIS	42
CHAPTER II: SGK3 MEDIATES INPP4B-DEPENDENT PI 3-KINASE SIGNALING IN BREAST CANCER	44
1. ABSTRACT.....	45
2. INTRODUCTION	46
3. MATERIAL AND METHODS	50
4. RESULTS	59
5. DISCUSSION.....	90
6. CONCLUSIONS.....	95

CHAPTER III: RICTOR FORMS A COMPLEX WITH CULLIN-1 TO PROMOTE SGK1 UBIQUITINATION AND DESTRUCTION	97
1. ABSTRACT.....	98
2. INTRODUCTION	99
3. MATERIAL AND METHODS	103
4. RESULTS	106
5. DISCUSSION	120
6. CONCLUSIONS.....	122
 CHAPTER IV: DISCUSSION AND FUTURE DIRECTIONS.....	 123
1. SUMMARY OF THESIS.....	124
2. DISCUSSION.....	126
3. FUTURE DIRECTIONS	135
4. FINAL NOTE.....	142
 BIBLIOGRAPHY	 144

FIGURES AND TABLES

CHAPTER I

FIGURE 1-1: The phosphatidylinositol 3-kinase cascade	4
FIGURE 1-2: Activation mechanism of Akt.....	7
FIGURE 1-3: PI 3-K catalyzed inositol phospholipid pathways	8
FIGURE 1-4: Serum and Glucocorticoid-regulated Kinase Isoforms.....	20
FIGURE 1-5: NDRG family isoforms	27
FIGURE 1-6: NDRG1 3X decapeptide conservation	28
FIGURE 1-7: EMT	31
FIGURE 1-8: Ubiquitin Reaction Pathways	35
FIGURE 1-9: SCF Family of E3 ligases.....	40

CHAPTER II

FIGURE 2-1: SGK3 is amplified in cancer.....	60
FIGURE 2-2: SGK3 is focally amplified in breast cancer.....	61
FIGURE 2-3: SGK3 expression analysis in cell lines	63
TABLE 2-1: Table of breast cancer cell lines.....	64
FIGURE 2-4: Inhibitor analysis of SGK3 signaling	66
FIGURE 2-5: Oncogenic PIK3CA mutants hyperactivate SGK3	68
FIGURE 2-6: INPP4B positively regulates SGK3 activity	69
FIGURE 2-7: INPP4B catalytic activity specifically promotes SGK3 phosphorylation.....	70
FIGURE 2-8: VPS34 loss does not affect SGK3 phosphorylation.....	71
FIGURE 2-9: INPP4B silencing attenuate SGK3 phosphorylation	73
FIGURE 2-10: shRNA-resistant INPP4B allele rescues SGK3 phosphorylation ..	74
FIGURE 2-11: INPP4B silencing inhibits SGK3 activity	75
FIGURE 2-12: SGK3 promotes anchorage independent growth.....	76
FIGURE 2-13: SGK3 regulates 3D growth of breast cancer cells	78
FIGURE 2-14: SGK3 regulates 3D growth of PIK3CA mutant breast cancer cells.....	79
FIGURE 2-15: SGK3 promotes breast cancer cell invasive migration	80
FIGURE 2-16: NDRG1 is degraded by the 26S proteasome.....	82
FIGURE 2-17: FBW7 regulates NDRG1 expression at the protein level	83
FIGURE 2-18: FBW7 regulates NDRG1 protein levels in breast cancer cells.....	84
FIGURE 2-19: GSK3 and SGK3 have additive effects on NDRG1 degradation.....	86
FIGURE 2-20: NDRG1 is an FBW7 substrate	87
FIGURE 2-21: NDRG1 inhibits breast cancer cell migration	89

CHAPTER III

FIGURE 3-1: SGK1 expression is regulated by the Rictor pathway	107
FIGURE 3-2: Rictor promotes SGK1 ubiquitination in a Cullin-1 dependent manner	109
FIGURE 3-3: Rictor interacts with Cullin-1 and Rbx1	111
FIGURE 3-4: Rictor is phosphorylated at T1135	114
FIGURE 3-5: Phosphorylation of Rictor at T1135 disrupts the interaction between Rictor and Cullin-1	116
FIGURE 3-6: Phosphorylation of Rictor at T1135 reduces the ability of Rictor to ubiquitinate SGK1	118
FIGURE 3-7: Proposed model for the Rictor/ Cullin-1 pathway to control SGK1 turnover	119

CHAPTER IV

FIGURE 4-1: Model of PI 3-K regulation of Metastasis Suppressor NDRG1 through SGK3	131
FIGURE 4-2: Phospho-site analysis for NDRG1	139

ABBREVIATIONS

4E-BP	4E-Binding Protein
AAA	ATPases Associated with diverse cellular Activities
AGC	PKA, PKG, PKC
Akt/PKB	Protein Kinase B
AMPK	5' AMP-activated protein Kinase
ARF	ADP Ribosylation Factor
ATP	Adenosine Triphosphate
BAD	BCL-2 Agonist of cell Death
BMX	Bone Marrow kinase on chromosome X
BTK	Bruton's Tyrosine Kinase
C-terminal	COOH- terminal
C-myc	Cellular v-myc myelocytomatosis viral oncogene homolog
CD44	Cluster of Differentiation 44
CHIP	Carboxyl terminus of Hsc70-Interacting Protein
CK	Cytokeratin
DUB	De-Ubiquitinating enzyme
EGF	Epidermal Growth Factor
EGFR	Epidermal Growth Factor Receptor
EMT	Epithelial- Mesenchymal Transition
ER	Estrogen Receptor
ERK	Extracellular-Regulated Kinase
FBW7	F-Box and WD repeat domain-containing 7
FBXL	F-box and leucine rich repeats
FBXO	F-box and other domains
FBXW	F-box and WD40 repeats
FGF	Fibroblast-derived Growth Factor
FOXO3A	Forkhead box O 3a
FSH	Follicle Stimulated Hormone
GEF	Guanine nucleotide Exchange Factor
GFP	Green Fluorescent Protein
GPCR	G-protein coupled receptors
GRP1	General Receptor for 3-Phosphoinositides 1
GSK3 β	Glycogen Synthase Kinase β
GTP	Guanosine 5'-Triphosphate
HDM2	Human Double Minute 2
HECT	Homologous to E6 –associated protein C-Terminus
HER2/ ERBB2	Human Epidermal growth factor Receptor 2
HIF1	Hypoxia-Inducible Factor 1
HM	Hydrophobic Motif
HSC70	Heat-Shock Cognate Protein 70

IFN γ	Interferon Gamma
IGF	Insulin-like growth factor
IGF1-R	Insulin-like Growth Factor 1-Receptor
ILK	Integrin-Linked Kinase
INPP4A	Inositol Polyphosphate-4-Phosphatase type I
INPP4B	Inositol Polyphosphate-4-Phosphatase type II
ITK	Interleukin-2-inducible T-cell Kinase
JAMM/MPN+	Jab1, Mov34, MPR1 Pad1 N-Terminal
LOH	Loss of Heterozygosity
LRP6	Low-density lipoprotein Receptor-related Protein 6
MAPK	Mitogen-Activated Protein Kinase
mLST8/G β L	G protein β -subunit-like protein
MMP7	Matrix Metalloproteinase 7
mTOR	mammalian Target of Rapamycin
mTORC1	mammalian Target of Rapamycin Complex 1
mTORC2	mammalian Target of Rapamycin Complex 2
N-terminal	NH2-terminal
N-myc	Neuroblastoma-derived Myelocytomatosis
NDRG	N-myc Down-Regulated Gene
NEDD-4	Neural precursor cell Expressed Developmentally Down-regulated protein 4
NFAT	Nuclear Factor of activated-T cells
OTU	Ovarian Tumor-like protease
PDGF	Platelet-derived Growth Factor
PDGF-R	Platelet-Derived Growth Factor- Receptor
PDK-1	Phosphoinositide-Dependent Kinase-1
PH	Pleckstrin homology
PHLPP	PH domain and Leucine rich Protein Phosphatase
PI 3-K	Phosphoinositide 3- Kinase
PIF	PDK-1 Interacting Fragment
PKC	Protein Kinase C
PLC γ	Phospholipase C γ
PR	Progesterone Receptor
PRAS40	Proline-Rich Akt Substrate of 40 kDa
PROTOR	protein observed with Rictor-1
PTEN	Phosphatase and Tensin homolog
PX	Phox Homology
RAC	Ras-related C3 botulinum toxin substrate
RING	Really Interesting New Gene
RTK	Receptor Tyrosine Kinase
S6K	p70 ribosomal S6Kinase
SCF	Skp, Cullin, F-box containing
SGK1	Serum and Glucocorticoid- Regulated Kinase1
SGK2	Serum and Glucocorticoid- Regulated Kinase2

SGK3	Serum and Glucocorticoid- Regulated Kinase3
SH	Src Homology
SHIP	SH2 domain-containing Inositol Phosphatase
SKP2	S phase Kinase-associated Protein 2
STAT	Signal Transducer and Activator of Transcription
T-ALL	T-cell Acute Lymphoblastic Leukemia
TAPP	Tandem PH-domain containing Protein
TCF	T-Cell Factor
TGF β	Transforming Growth Factor β
TIRF	Total Internal Reflection Fluorescence
TNBC	Triple-Negative Breast Cancer
TSC	Tuberous Sclerosis Complex
UCH	Ubiquitin C-terminal Hydrolase
UPS	Ubiquitin Proteasome System
USP	Ubiquitin-Specific Proteases
VPS34	Vacuolar Protein Sorting 34
WNK1	With No lysine (K) 1
WNT	Wingless-related integration site

ACKNOWLEDGEMENTS

I must begin by thanking Alex Toker for the opportunity to join his laboratory 6 years ago. He has been my PI and he has been my mentor. Alex has patiently guided my scientific development, as I learned to deal with the trials, tribulations, and joys of cellular biology. His perpetual excitement for the day's experiments and his unwavering encouragement has never gone unnoticed.

In addition to guidance, Alex has provided me with an amazing working environment through the group of scientists he has recruited to his laboratory. The Toker lab has evolved over the course of my 6 years and every single person had an immense impact on the scientist I have become. I am lucky to have had the opportunity to work alongside Rebecca, Gary, Sivan, Sokha, Maria, Amy, Jess α , Claudine, Emilie, Kristin, Colin, Heather, Kali, Evan, Abbe, Whitney, Casey, Hannah, and Aura. I also would like to extend my gratitude towards the Wei lab. My collaborations with Wenyi and friendships with Hiro, Alan, Daming, and Hide guided my understanding of science, grad school, and the life thereafter.

I have a huge debt of gratitude for my Dissertation Advisory Committee: Lewis Cantley, Wade Harper, and John Blenis. I cannot imagine a group of scientists I could have learned more from. Their constant enthusiasm for both an individual experiment and the big picture analysis of cancer biology was truly inspiring. I can only hope as I

go forth into the world that I have gained a small spec of their comprehensive abilities to build a career in science.

My family has been my stable core throughout my thesis work. My parents, Kenneth and Cynthia, were always there to talk about my troubles and excitement. They have stood by my side everyday from 1000 miles away. They will always inspire me to be a better person and scientist. My grandfather, father, and brother have each pursued Ph.D.'s in science and they have been my role models. They molded my thought process from a young age to think, as a scientist should, with logic, reason and purpose. They also each possessed passion for science, an attribute that cannot be learned. My brother, Adam, and I have pursued our Ph.D.'s in the topic of cancer biology simultaneously. Retrospectively, I cannot imagine a better way to have stumbled, walked, and ran through the Ph.D. journey than to do it side-by-side with him. I have learned so much from his perspective and love of medicine. I hope to make a difference in cancer biology in the way that I already know he will.

My husband, Michael, deserves both a huge thanks and a fabulous award for his patience, understanding, and unwavering support as I spent long nights and weekends in lab. He truly listens as I come home each night and tell him the thrilling events of my day in lab. Thank you for being you.

CHAPTER 1

INTRODUCTION

1. MECHANISMS OF PI 3-KINASE ACTIVATION

Phosphoinositide 3-Kinase (PI 3-K) is a lipid kinase family divided into 3 classes: class I, II, and III. Class IA PI 3-Ks are heterodimeric enzymes composed of regulatory and catalytic subunits that are activated upon growth factor stimulation of Receptor Tyrosine Kinases (RTK) and G-Protein Coupled Receptors (GPCR). The p85 α (p85 α , p50 α , p55 α), p85 β , and p55 γ regulatory subunits are encoded by three distinct genes *PIK3R1*, *PIK3R2*, and *PIK3R3* and are collectively referred to as p85. The regulatory subunits are capable of binding the catalytic subunits p110 α , p110 β , and p110 δ encoded by *PIK3CA*, *PIK3CB*, *PIK3CD*, respectively (Courtney et al., 2010; Hawkins et al., 2006). p85 subunits contain Src Homology 2 (SH)2 and SH3 domains that bind phosphorylated tyrosine residues of RTKs or their adaptor proteins (Manning and Cantley, 2007). RTKs such as Insulin-like Growth Factor 1-Receptor (IGF1-R) and Platelet-Derived Growth Factor-Receptor (PDGF-R) harbor intrinsic tyrosine kinase activity and upon growth factor-induced dimerization of the receptor, the dimers transphosphorylate tyrosine residues in the cytoplasmic tail regions (Hawkins et al., 2006). The p85 regulatory subunits function to inhibit the activity of the p110 catalytic subunit until the SH2 domain of p85 binds phosphotyrosines on the RTK, within the common consensus sequence pYXXM (Y, tyrosine; X, any amino acid; M, methionine) (Hawkins et al., 2006; Okkenhaug, 2013). The binding of p85 to RTKs elicits the release of intermolecular p110 inhibition, thus activating PI 3-K and downstream signaling (Courtney et al., 2010). *In vitro* PI 3-K phosphorylates the 3' position of the inositol ring of the phosphoinositides PI (phosphatidylinositol), PI(3)P

(phosphatidylinositol (3) phosphate) and PI(4,5)P₂ (phosphatidylinositol (4,5) bisphosphate) (Toker, 2000). However in cells, class I PI 3-K primarily phosphorylates the substrate PI(4,5)P₂ to generate PI(3,4,5)P₃ (Miller et al., 2011; Toker, 2000). In turn, PI(3,4,5)P₃ recruits downstream effector proteins that harbor lipid binding domains, thus transducing the PI 3-K signal to secondary signal relay pathways (**Figure 1-1**). In addition to RTK regulation, PI 3-K is localized by Ras binding to p110 effectively localizing PI 3-K to the plasma membrane (Courtney et al., 2010; Hawkins et al., 2006). p110 β is unique as a Class 1A PI 3-K to be recruited and activated by GPCRs. In response to GPCR ligand stimulation, Class 1B PI 3-K also interconverts PI(3,4,5)P₃ from PI(4,5)P₂. Unlike Class IA enzymes, Class 1B PI 3-K consists of heterodimers of p110 γ encoded by the *PIK3CG* gene and the regulatory subunits p87 or p101. Class 1B PI 3-K are predominantly expressed in immune cells and are known for roles in inflammatory diseases and immunity (Hawkins et al., 2006). Class IA PI 3-K is the class most prominently implicated in cancer etiology and progression by transducing growth factor responses as well mediating oncogenic signaling (Yuan and Cantley, 2008).

Class II PI 3-kinases generate PI(3)P and PI(3,4)P₂ from PI and PI(3)P and lack any known regulatory domains. PI 3-K-C2 α , PI 3-K-C2 β , and PI 3-K-C2 δ are class II enzymes and possess a C2 domain (Hawkins et al., 2006; Okkenhaug, 2013). Little is known about the functional roles of Class II PI 3-K, although they are known to be activated by insulin signaling and as such they modulate PI 3-K signaling in insulin-responsive cells and tissues (Okkenhaug, 2013).




Figure 1-1: The phosphoinositide 3-kinase cascade

The phosphoinositide 3-kinase (PI3-K) signaling cascade. PI3-K signaling impacts on cell growth, survival, and metabolism. Arrows represent activation, while bars reflect inhibition. (*) p110 alpha, beta, or delta. Taken from (Courtney et al., 2010).

Class III PI 3-kinases exclusively produce PI(3)P from PI, and are composed of a VPS34 catalytic domain and p150 regulatory domain (Backer, 2008). The primary role of Class III PI 3-kinases and the lipid product PI(3)P is to modulate endosomal protein sorting and membrane trafficking (Backer, 2008; Okkenhaug, 2013).

The Akt Kinase as a Transducer of PI 3-K Signaling

A major effector of the PI 3-K signaling axis is the serine/threonine protein kinase Akt, also known as Protein Kinase B (PKB) (Luo et al., 2003). Under basal serum-starved conditions Akt is a cytosolic enzyme. Upon activation of PI 3-K, Akt translocates to the plasma membrane by binding PI(3,4,5)P₃ and PI(3,4)P₂ through the amino-terminal Pleckstrin Homology (PH) domain (Luo et al., 2003). As discussed above, PI(3,4,5)P₃ is generated by Class I PI 3-K, whereas PI(3,4)P₂ is synthesized by Class II PI 3-K. An alternate route for PI(3,4)P₂ accumulation is dephosphorylation of PI(3,4,5)P₃ by the SH2 domain-containing Inositol 5' Phosphatases (SHIP) 1 and 2, which are PI(3,4,5)P₃ 5' inositol phosphatases (Choi et al., 2002; Elong Edimo et al., 2013; Scheid et al., 2002). Subsequent to the lipid binding-induced conformational change, Akt is phosphorylated at two critical residues in the catalytic domain, Thr308 in the activation loop and Ser473 in the Hydrophobic Motif (HM) (Luo et al., 2003; Toker, 2000). Thr308 (in Akt1) is phosphorylated by the Phosphoinositide-Dependent Kinase - 1 (PDK-1), which is also recruited to PI(3,4,5)P₃ and PI(3,4)P₂ through its carboxyl-terminal PH domain (Mora et al., 2004). PDK-1 is a constitutively active protein kinase primarily due to autophosphorylation at the activation loop residue Ser241 (Mora et al.,

2004). The HM of Akt isoforms (Ser473 in Akt1) is phosphorylated by the mammalian Target Of Rapamycin Complex 2 (mTORC2), although a number of other kinases have been shown to replace the function of mTORC2 as the Ser473 kinases, including Protein Kinase C (PKC), Integrin-Linked Kinase (ILK) and Akt itself (Lu et al., 2006; Miller et al., 2011; Xia et al., 2004). Regardless of the mechanism, phosphorylation of Akt by mTORC2 promotes a conformational change allowing PDK-1 access to the Akt activation loop (**Figure 1-2**) (Sarbasov et al., 2005). Both Ser473 and Thr308 phosphorylation are required for maximal Akt catalytic activity (Courtney et al., 2010; Woodgett, 2005). Upon activation, Akt is locked in the catalytically-active conformation and loses the PI(3,4,5)P3 or PI(3,4)P2 binding requirement (Mora et al., 2004; Sarbasov et al., 2005). Newly activated Akt then translocates to numerous intracellular compartments to interact and phosphorylate an array of substrates critical for metabolism, growth, and survival (Luo et al., 2003). Importantly, the levels PI(3,4,5)P3 in all cells and tissues are negatively regulated by the tumor suppressor Phosphatase and Tensin homolog deleted on chromosome ten (PTEN). PTEN converts PI(3,4,5)P3 back to PI(4,5)P2 effectively terminating PI 3-K signaling (**Figure 1-3**) (Li et al., 1997; Maehama and Dixon, 1998). As discussed below, inactivation of PTEN is a frequent event in cancer and leads to constitutive PI(3,4,5)P3 levels and hyperactivation of Akt (Engelman et al., 2006). Alternately, a distinct tumor suppressor Inositol Polyphosphate 4-Phosphatase type II (INPP4B) also negatively regulates Akt by dephosphorylating PI(3,4)P2 at the 4' position effectively generating PI(3)P (Fedele et al., 2010; Gewinner et al., 2009).




Figure 1-2: Activation mechanism of Akt

The generation of PI(3,4,5)P₃ from PI(4,5)P₂ by PI 3-K recruits Akt to the membrane. Here, it is phosphorylated by PDK-1 and mTORC2 required for maximal Akt activation. Adapted from (Pearce et al., 2010).




Figure 1-3: PI 3-K catalyzed inositol phospholipid pathways

The main metabolic pathways that interconvert inositol phospholipids in eukaryotic cells are shown. Class I phosphoinositide 3-kinases (PI 3-Ks) are activated by cell surface receptors to make phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P₃) and, indirectly, PtdIns(3,4)P₂; these two lipids are intracellular signals that carry important information through the receptor signaling network. Class III and probably class II PI3Ks make PI(3)P and play a key part in regulatory networks controlling vesicular trafficking through the endosome–lysosome system. DAG, diacylglycerol; FAB1, PI(3)P 5-kinase; INPP5, inositol polyphosphate 5-phosphatase; MTM, myotubularin; PLC, phospholipase C; PTEN, phosphatase and tensin homologue; SHIP, SH2 domain-containing inositol 5'-phosphatase. Adapted from (Vanhaesebroeck et al., 2012).

Again, inactivation mutations or loss of heterozygosity (LOH) of *INPP4B* leads to increased accumulation of PI(3,4)P2 and constitutive Akt activation (Gewinner et al., 2009).

There are three Akt isoforms encoded by three distinct genes: Akt1/PKB α , Akt2/PKB β and Akt3/PKB γ . All three isoforms are basophilic-directed serine/threonine protein kinases that share a conserved consensus substrate phosphorylation motif, with Arginine at the -3 and -5 position and a preference for hydrophobic residues at +1, relative to the Ser/Thr phospho-acceptor residue (Murray et al., 2004; Tessier and Woodgett, 2006b). Akt1, Akt2 and Akt3 are ubiquitously expressed in all tissues and organs in humans. Akt isoforms are members of the AGC (PKA, PKG, PKC) family of kinases and share certain common elements in their mechanisms of regulation, since most AGC kinases are phosphorylated at their activation loop residues by PDK-1 and at the HM motif by mTORC2. Although all three Akt isoforms are activated by identical mechanisms through lipid binding and PDK-1- and mTORC2-catalyzed phosphorylation, Akt1, Akt2 and Akt3 have multiple non-redundant roles in signaling and pathophysiology. One clear example of Akt isoform-specific signaling was first identified in breast cancer cells, whereby Akt1 and Akt2 possess opposing roles in the regulation of cell migration and invasion (Toker and Yoeli-Lerner, 2006). Akt2 functions to promote invasive migration in part by the induction of β 1 integrin expression (Arboleda et al., 2003). Conversely, Akt1 inhibits migration, invasion and even metastatic dissemination *in vivo*, in part through the degradation of Nuclear Factor of activated-T cells (NFAT), modulation of the Extracellular-Regulated Kinase (ERK) pathway, and inhibition of actin

bundling (Toker and Yoeli-Lerner, 2006; Yoeli-Lerner et al., 2005). Akt isoform signaling specificity is also mediated through inactivation of its catalytic activity by protein phosphatases. Specifically, Akt signaling is terminated by the PH domain and Leucine-rich Protein Phosphatases 1 and 2 (PHLPP)1/2 (Brognard and Newton, 2008; Brognard et al., 2007). PHLPPs are a family of serine/threonine phosphatases that dephosphorylate Akt isoforms at Ser473. Interestingly, PHLPP1 has been shown to dephosphorylate Akt2 and Akt3 at S474 and Ser472, respectively, whereas PHLPP2 dephosphorylates Akt1 and Akt3 at their corresponding HM residue (Brognard and Newton, 2008; Brognard et al., 2007).

Akt transduces the PI 3-K signal in both normal physiological conditions as well as pathophysiological settings by phosphorylating a wide range of substrates that control virtually all aspects of cell biology, including but not limited to cell motility, growth, proliferation and survival (Luo et al., 2003). The first identified function for Akt in both cancer cells and neuronal tissues is induction of cell survival mechanisms under conditions of stress, mediated by the phosphorylation of substrates involved in apoptosis such as BCL-2 Agonist of cell Death (BAD) (Datta et al., 1997), that promotes cell survival subsequent to Akt-mediated phosphorylation. Cell cycle progression is also mediated by Akt signaling, and phosphorylation of the F-box protein S phase Kinase-associated Protein 2 (SKP2) by Akt promotes the formation of the Skp, Cullin, F-box containing (SCF) complex, an E3 ligase leading to p27 degradation, thus promoting cell cycle progression (Gao et al., 2009). Forkhead box O 3A (FOXO3A) phosphorylation by Akt promotes FOXO3A nuclear export and cytoplasmic retention leading to inhibition of

transcription of genes that control cell cycle arrest and apoptosis, effectively promoting survival (Singh et al., 2010). Akt is directly involved in the activation of the mammalian Target of Rapamycin Complex 1 (mTORC1), and does so by phosphorylating the Tuberous Sclerosis Complex (TSC)1/TSC2, leading to TSC inhibition and subsequent downstream activation of mTORC1 (Luo et al., 2003). The activation of mTORC1 in turn integrates critical cellular growth signals including feedback inactivation of the PI 3-K and Akt pathway. mTORC1 activation is further facilitated through Akt-mediated phosphorylation of Proline-Rich Akt Substrate of 40 kDa (PRAS40) leading to binding of 14-3-3 and release of mTORC1 inhibition (Vander Haar et al., 2007).

Although many of the over 200 substrates of Akt are likely to be phosphorylated by all three Akt isoforms, a number of studies have uncovered a number of Akt isoform-specific substrates that explain, in part, the non-redundant function of Akt's in phenotypes associated with malignancy. For example, Akt1 exclusively phosphorylates palladin, an actin bundling protein, and this event mediates the ability of Akt1 to function as a suppressor of breast cancer cell invasive migration. Similarly, SKP2 has been shown to be an exclusive Akt1 substrate. Akt2 specific substrates include AS160 in the regulation of glucose transport and Myosin5a in the regulation of glut4 vesicular translocation (Chin and Toker, 2011; Toker, 2012). To date, no Akt3-specific substrates have been identified, although these are likely to exist.

Alternate PI 3-K Pathway Effectors

Although Akt is generally considered to be the primary effector of PI 3-Kinase, it is by no means the exclusive transducer of PI(3,4)P₂ and PI(3,4,5)P₃. Since PI 3-K signal relay is initiated by PI(3,4)P₂ and PI(3,4,5)P₃ accumulation at the plasma membrane, a rate limiting event in PI 3-K signal relay is the recruitment of effectors to the plasma membrane. Other than Akt and PDK-1, other PH domain-containing proteins have been identified and are recruited by binding to PI(3,4,5)P₃ and PI(3,4)P₂, although it is worth noting that all PH domains bind phosphoinositides selectively or with high affinity. Of the ones that do, the Tec family of non-receptor protein tyrosine kinases, including Tec, Bruton's Tyrosine Kinase (BTK), Interleukin-2-Inducible T-cell Kinase (ITK), and Bone Marrow kinase on chromosome X (BMX), bind to PI(3,4,5)P₃ through their PH domains (Vargas et al., 2013). Moreover, the PH domain of BTK is critical for *in vitro* kinase activity and substrate recognition and binding (Saito et al., 2001). Another class of effectors are Guanine Nucleotide Exchange Factors (GEFs) for small Guanosine 5'-Triphosphate (GTP)ases, whereby recruitment positions the GEF in proximity with its GTPase in addition to relieving PH domain inhibition of the catalytic region (Cherfils and Zeghouf, 2013; Stalder and Antonny, 2013). The GEFs of the small GTPase ADP Ribosylation Factor (ARF) and also Ras-related C3 botulinum toxin substrate (RAC) control ARF and RAC activity thus regulating cytoskeletal changes leading to lamellipodia formation in a manner that is PI 3-K-dependent (DiNitto et al., 2007; Stalder and Antonny, 2013). Regulation of cytoskeletal dynamics by PI 3-K is also mediated by Tandem PH-domain containing Proteins 1/2 (TAPP)1/2, that contain both amino-

terminal and carboxyl-terminal PH domains (Hogan et al., 2004). In addition, General Receptor for 3-Phosphoinositides 1 (GRP1) is the GEF that modulates the activation of ARF6, whereby the PH domain is critical for GRP1 localization in the activation of ARF6, leading to Glut4 vesicle formation and metabolic homeostasis (Langille et al., 1999). Therefore, effectors of PI(3,4)P2 and PI(3,4,5)P3 other than Akt and PDK-1 modulate a large network of downstream secondary signal relay pathways that in turn control numerous cellular processes from metabolism to growth and cell motility. However, it is generally considered in the field that many other effectors of PI 3-K exist in cells that respond to PI(3,4)P2 and PI(3,4,5)P3, and ascribing phenotypes linked to PI 3-K in pathophysiology to specific effectors remains a challenge in the field.

Oncogenic PI 3-K Pathway Mutations

The functional importance of PI 3-K signaling in cancer is most obviously evident by the number of oncogenic mutations that exist in genes that encode proteins that both regulate PI 3-K, PI 3-K itself and effectors of PI 3-K. *PIK3CA* is one of the most frequently mutated genes in breast cancer, with a mutation rate approximating 35% especially in hormone receptor positive breast tumors (Yuan and Cantley, 2008). The majority of *PIK3CA* mutations exist in two hotspot regions of exon 9 and exon 20, within the helical and catalytic domains, respectively. E542K, E545K, and H1047R mutations account for 80% of the *PIK3CA* mutations in breast cancer (Courtney et al., 2010; Miller et al., 2011). These hotspot mutations are gain-of-function mutations that cause hyperactivation of p110 α and downstream signaling by alleviating the inhibitory effects

of the SH2 domain of p85 under basal conditions. *PIK3CA* mutations are also frequent in other solid tumors, including endometrial carcinoma and colon carcinoma. Somatic mutations in Akt genes have also been identified, albeit at lower frequency than *PIK3CA* mutations. The Akt1 E17K mutation is oncogenic and promotes constitutive Akt signaling in the absence of growth factors (Brugge et al., 2007). This mutation at E17 within the PH domain of Akt causing hyperactivation of the kinase, likely due to reduced specificity for PI(3,4,5)P3 and PI(3,4)P2 such that the enzyme can interact with the more abundant PI(4,5)P2. In breast cancer Akt1 E17K mutations have been identified at a frequency of 1.5-8%, depending on the study (Yuan and Cantley, 2008). A recent whole cancer genome sequencing study identified an Akt2 E17K mutation in one patient, and an Akt3 E17K mutation has been described in the metastatic setting of a breast cancer patient. Interestingly, E17K mutations in Akt3 appear to occur with high frequency in melanoma (Davies et al., 2008).

PTEN inactivation is the most common PI 3-K pathway mutation across combined cancer subsets, with an inactivation frequency in breast cancer of approximately 30% (Miller et al., 2011). *PTEN* inactivation leads to hyperactivation of the PI 3-K pathway since the major mechanism of PI 3-K signal termination, PI(3,4,5)P3 dephosphorylation, is absent. However, even in the context of *PTEN* inactivation, PI(3,4,5)P3 must still be synthesized, and generally *PIK3CA* mutations and *PTEN* inactivation are not synonymous, at least in breast cancer. Instead, studies have shown that the primary route of PI(3,4,5)P3 synthesis in *PTEN*-deficient tumors is the *PIK3CB* isoforms (Wee et al., 2008). Ultimately, elevated levels of PI(3,4,5)P3 lead to constitutive downstream Akt

activation and substrate phosphorylation. *PTEN* inactivation occurs via distinct epigenetic and somatic mechanisms including missense mutations, truncation, homozygous and heterozygous deletion, and epigenetic silencing. Germline *PTEN* mutations lead to hamartoma syndromes of Cowden disease, Bannayan-Riley-Ruvalcaba syndrome and (Hobert and Eng, 2009; Song et al., 2012).

Since p21 Ras binding to p110 α controls PI 3-K activation, Ras mutations contribute to pathway activation. Ras mutation across all cancer occur prominently at a frequency of approximately 30% (Adjei, 2001). In breast cancer, Ras mutations are relatively infrequent but nonetheless significant with about 5% hyperactivation across all molecular subtypes (Miller et al., 2011). PI 3-K is critical for tumor initiation in Ras-mutant tumors, however, established tumors show reduced dependence on PI 3-K. Pan-PI 3-K inhibitors alone may not be sufficient to abrogate late stage Ras-mediated tumorigenesis, but may underscore a potential preventative opportunity.

Since Class 1 PI 3-Ks are activated downstream of RTKs, amplification of these receptors also leads to PI 3-K pathway hyperactivation in solid tumors. The Human Epidermal growth factor Receptor 2 (HER2/ ERBB2) is a member of the ErbB family of receptors and overexpression or amplification of HER2 is detected in approximately 20% of all breast cancers (Yuan and Cantley, 2008). HER2 amplification leads to hyperactivation of not only PI 3-K but also PKC, ERK, Phospholipase C γ (PLC γ) and Signal Transducer and Activator of Transcription (STAT) pathways (Masuda et al., 2012). RTK amplification therefore leads to widespread deregulation and uncontrolled cell growth, making them a logical focus for therapeutic intervention. HER2 is the target

for monoclonal antibody drugs such as Herceptin and Pertuzumab (Rexer and Arteaga, 2013).

The Inositol Polyphosphate Phosphatase INPP4B

The importance of INPP4B in PI 3-K signaling was recently appreciated since inactivation of this putative tumor suppressor leads to elevated PI(3,4)P₂ levels and consequent Akt hyperactivation, leading to increased cell proliferation and tumor initiation (Gewinner et al., 2009). The same studies also highlighted the fact that INPP4B is lost by genetic inactivation in basal-like/triple negative breast cancer (Fedele et al., 2010; Gewinner et al., 2009). Breast cancer is subdivided into molecular subtypes with distinct profiles: triple-negative breast cancer (TNBC) or basal-like, HER2 positive, Luminal A and Luminal B. TNBC lack estrogen receptor (ER), progesterone receptor (PR), and HER2 (Patani et al., 2013). Basal-like breast cancers are further distinguished from triple negative subtype by immunohistochemical or gene expression analysis establishing basal biomarkers such as Epidermal Growth Factor Receptor (EGFR) and/or basal cytokeratins (CK5/6, CK14, CK17) (Patani et al., 2013). Basal-like breast cancers also typically display a high mitotic index and histological grade, and are associated with more aggressive tumors. HER2+ve breast cancers overexpress HER2, but not ER or PR. Luminal subtype A breast cancers express ER and/or PR but not HER2 and have low Ki67, while Luminal B cancers express ER and/or PR and maintain high Ki67 (Patani et al., 2013). TNBC accounts for 15% of all breast cancer and are associated with poor prognosis. 55% of TNBC and 88% of basal-like carcinomas

display LOH of INPP4B (Fedele et al., 2010; Gewinner et al., 2009). These findings argue that LOH of INPP4B is restricted to ER-ve tumors. Furthermore, INPP4B loss is seen in 49% of *PTEN*-null tumors (Fedele et al., 2010). Therefore, the correlation of INPP4B LOH combined with *PTEN* inactivation status implies that the concurrent loss of both phosphatases leads to hyperactivation of Akt in aggressive basal-like or TNBC, such that these tumors may particularly benefit PI 3-K-directed therapies.

The tumor suppressor activity of INPP4B has been proposed to be due to its ability to dephosphorylate PI(3,4)P₂ into PI(3)P, such that *INPP4B* LOH causes constitutive elevated levels of PI(3,4)P₂ (Gewinner et al., 2009). Although two isoforms exist, Inositol Polyphosphate-4-Phosphatase type I (INPP4A) and INPP4B. INPP4A is exclusively localized to neuronal tissues with no evidence of functional expression in cancer (Fedele et al., 2010). By contrast, INPP4B is defined as a tumor suppressor in breast, ovarian, prostate carcinomas and melanomas (AgoulNIK et al., 2011). INPP4B inactivation correlates with poor prognosis for long-term survival and highly metastatic tumor potential. Interestingly, additional associations for INPP4B are documented in breast cancer, whereby 60% of cancers with *BRCA1* germline mutations also have *INPP4B* LOH (Gewinner et al., 2009). One study has shown that INPP4B knockdown with shRNA in breast cancer cells *in vitro* induces anchorage-independent cell growth (Fedele et al., 2010). Moreover, INPP4B overexpression in xenograft models inhibits the growth of *BRCA1* mutant cells (Gewinner et al., 2009).

Since *INPP4B* is lost by LOH with high frequency TNBC/basal like cancers, INPP4B expression has been proposed as a biomarker for Luminal A and Luminal B

subtypes. Specifically, a statistically significant expression of INPP4B in ER+ve has been described (Fedele et al., 2010). Moreover, ER has been demonstrated to mediate the transcriptional induction of *INPP4B* (Fedele et al., 2010). Importantly, *PIK3CA* oncogenic mutations are mutually exclusive with *INPP4B* LOH, corroborating previous studies identifying 47% of ER+ve breast cancer tumors as *PIK3CA* mutant (Miller et al., 2011). INPP4B expression correlates with 75% of breast cancers that express ER and/or PR (Miller et al., 2011).

2. SERUM AND GLUCOCORTICOID-REGULATED KINASES

Serum and Glucocorticoid-Regulated Kinase 1 (*SGK1*) was initially identified in a rat mammary tumor cell line as a glucocorticoid-induced gene (Tessier and Woodgett, 2006b). SGKs are also in the AGC kinase family and comprise three isoforms each encoded by distinct genes: SGK1, Serum and Glucocorticoid-Regulated Kinase 2 (SGK2) and Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) (**Figure 1-4**). SGK2 and SGK3 were cloned and characterized due to high sequence similarity to SGK1. SGK1 and SGK3 isoforms are ubiquitously expressed, unlike SGK2, which is restricted to the liver, kidney, pancreas, and brain (Tessier and Woodgett, 2006b). SGK isoforms share a combined amino acid sequence identity of ~80% within the catalytic domains and ~50% within the carboxyl-terminal region. SGK isoforms share an overall ~50% homology with the catalytic domains of Akt isoforms. Structurally, three SGK isoforms diverge from one another at the amino-terminus. Specifically, the amino-terminus of SGK1 localizes it to the endoplasmic reticulum for subsequent degradation. SGK2 on the other hand has a blunted amino-terminus with no known functions. SGK3 has a Phox Homology (PX) domain that binds exclusively to PI(3)P (Tessier and Woodgett, 2006a). SGK isoforms share the same substrate consensus phosphorylation motif as Akt, RXRXXS/T (Murray et al., 2004). The only known distinction between the Akt and SGK consensus motifs is the +1 hydrophobic residue that is exclusive to Akt. To date, there is only one SGK substrate that is exclusive to the SGK family and is not targeted by Akt isoforms, N-myc Down-Regulated Gene (NDRG)1 (Tessier and Woodgett, 2006b). NDRG1 was originally identified as an SGK substrate using the KESTREL




Figure 1-4: Serum and Glucocorticoid-regulated Kinase Isoforms

SGK family isoforms share ~80% sequence homology in their catalytic domains and ~50% sequence homology in their C-terminal region (Tessier and Woodgett, 2006b). They diverge in their N-terminal regions where SGK3 possesses a PX domain and SGK1 has 6 N-terminal Lysines (K) that target it for polyubiquitination and degradation by the 26S proteasome. SGK isoforms have two phosphorylation sites required for maximal activation: PDK-1 regulated catalytic domain site (SGK1, T256; SGK2, T193; SGK3, T320) and Hydrophobic motif site regulated by MTORC2, only formally demonstrated (SGK1, S422).

technology by the Cohen laboratory (Murray et al., 2004). SGK isoforms also phosphorylate known Akt substrates such as FOXO3A, Glycogen Synthase Kinase β (GSK-3 β), Raf, Neural precursor cell Expressed Developmentally Down-regulated protein 4-2 (NEDD4-2), and TSC2, highlighting redundancy in Akt and SGK downstream signaling mechanisms (Tessier and Woodgett, 2006b). SGK knockout mice have yielded little information regarding physiological functions, although SGK1 knockout mice have sodium balance intolerances, and SGK3-null mice have defective hair follicle development (Lang et al., 2006; McDonald, 2008). Double knockouts have not yet been made and SGK2 null mice have also not been generated.

Interestingly, SGK1 is the only SGK isoform induced by serum and/or glucocorticoids, such that the name 'SGK' is somewhat of a misnomer. A variety of other mechanisms lead to transcriptional induction of SGK1, including p53, Transforming Growth Factor β (TGF β), Fibroblast-derived Growth Factor (FGF), Platelet-derived Growth Factor (PDGF), Follicle Stimulated Hormone (FSH), hyperosmotic stress, hypoxia, heat shock, UV irradiation and DNA damage (Tessier and Woodgett, 2006b). SGK1 expression is very transient and this underlies its mechanism of regulation. SGK1 is poly-ubiquitinated by NEDD4-2 and Carboxyl terminus of HSC70-Interacting Protein (CHIP) E3 ligases, leading to degradation by the 26S proteasome (Brickley et al., 2002; Zhou and Snyder, 2005). The degradation of SGK1 is controlled through the amino-terminus in which amino acids 18-24 direct SGK1 to the endoplasmic reticulum following poly-ubiquitination of six lysine residues within this domain.

In breast cancer, SGK1 expression correlates significantly with pAkt levels, however there is no correlation with tumor grade or ER status. Studies have revealed that 40% of tumors overexpress SGK1 and concurrently elevated pAkt1 at S473 (Sahoo et al., 2005). Immunohistochemical analysis reveals that 48% of breast tumors overexpress SGK1 (Sahoo et al., 2005). Other studies have documented approximately 75% SGK1 overexpression in breast cancer using tissue microarrays (Zhang et al., 2005). However, no studies have to date examined SGK1 activity in human tumors, primarily due to the lack of available tools to accurately determine kinase SGK activity. However, a recent study by the Alessi laboratory identified SGK1 as an alternate pathway for breast cancers treated with Akt inhibitors (Sommer et al., 2013). In this study a significant correlation is detected in cells that overexpress SGK1 and are also resistant to Akt inhibitors. Additionally, these cell lines reveal high phosphorylation levels of NDRG1, a surrogate for high SGK activity (Sommer et al., 2013). Proliferation is also significantly reduced in Akt inhibitor-resistant cells upon SGK1 knockdown, highlighting a novel role for SGK1 as a therapeutic target in breast cancer.

Serum and Glucocorticoid-regulated Kinase Activation Mechanisms

SGK isoforms share the same upstream kinases with Akt, PDK-1 and mTORC2. As with Akt, both PDK-1 and mTORC2 phosphorylation are required to maximally activate SGK (Garcia-Martinez and Alessi, 2008; Kobayashi et al., 1999). mTORC2 phosphorylates the carboxyl-terminal HM of SGK1(Ser422) (Garcia-Martinez and Alessi, 2008). SGK2 and SGK3 are also likely mTORC2 substrates for the HM at Ser356 and

Ser486, respectively, although this has not formally been proven. PDK-1 has been shown to phosphorylate the activation-loop of all SGKs (SGK1, Thr256; SGK2, Thr193; SGK3, Thr320) (Kobayashi et al., 1999). However, there are some clear distinctions from Akt in the mechanism of regulation of SGK isoforms. For example, the PI 3-K-dependence for SGK1 activation lies with the PDK-1 phosphorylation of the activation-loop phosphorylation. In this context, the With No lysine (K) 1 (WNK1) kinase is required for efficient PDK-1 docking and phosphorylation of SGK1 (Xu et al., 2005). WNK1 Thr58 phosphorylation is required for the correct confirmation of WNK1 to serve as scaffold, whereas its kinase domain is dispensable for SGK1 activation. Interestingly, Akt and SGK both phosphorylate WNK1 at Thr58 indicative of a possible feedback loop to promote SGK1 activity (Xu et al., 2005). Although the precise mechanism by which PI 3-K contributes to SGK2 and SGK3 activation has yet to be defined, PI 3-K inhibitors to block SGK2 and SGK3 activity in cell-based assays (Kobayashi et al., 1999). In the case of SGK3, studies have shown that a functional PX domain and PI 3-K are necessary critical for maximal SGK3 phosphorylation at Thr320 and Ser486, as well as SGK3 catalytic activity (Tessier and Woodgett, 2006a). To this end, a point mutation (Arg90Ala) in the SGK3 PX domain which abolishes PI(3)P binding completely blocks SGK3 phosphorylation, indicating that both PI(3)P binding and PI 3-K signaling converge to activate this SGK isoform (Tessier and Woodgett, 2006a).

Serum and Glucocorticoid-regulated Kinase 3 Regulation

A recent study from the Garraway laboratory demonstrated that SGK3 can function to mediate Akt-independent signaling and cell proliferation in cells harboring oncogenic *PIK3CA* mutations (Vasudevan et al., 2009). This is relevant since studies have shown that a significant proportion of breast cancers are resistant to Akt inhibitors even in the context of oncogenic PI 3-K signaling. In the Garraway study, cell lines that display low levels of Akt phosphorylation have elevated SGK3 activity. Furthermore, breast cancer cell lines that show little or no dependence on Akt for anchorage-independent growth instead require SGK3 activity for proliferation and survival (Vasudevan et al., 2009). However, since SGK3 does not harbor a functional PH domain capable of sensing PI(3,4,5)P₃ and PI(3,4)P₂, the question remains how *PIK3CA* can utilize SGK3 as a bona fide effector.

As discussed above, the PX domain of SGK3 binds PI(3)P and studies have shown that this event localizes SGK3 primarily to endosomal membranes that are enriched for this lipid. Vacuolar Protein Sorting 34 (VPS34), the only Class III PI 3-Kinase, is thought to be largely if not exclusively responsible for the generating the pool of PI(3)P at the endosome (Backer, 2008). Importantly, as with Akt, SGK3 activity loses the PX domain and PI(3)P dependence after phosphorylation of the HM (Tessier and Woodgett, 2006a). Additionally mutation of the PDK-1 Interacting Fragment (PIF) pocket of SGK3 attenuates Thr320 phosphorylation by PDK-1 (Tessier and Woodgett, 2006a). This indicates that PDK-1 requires the PIF pocket to dock within the HM of SGK3, as with other AGC family kinases such as S6K1/2. Furthermore, PI 3-K inhibitors combined

with PDK-1 overexpression does not inhibit the SGK3 Thr320 phosphorylation, suggesting that SGK1, SGK3 is not PI 3-K-dependent due to stabilization by PDK-1 docking. Instead, it is more likely that SGK3 depends upon PI 3-K for HM phosphorylation mediated by mTORC2, or for its localization and substrate interactions.

Although the *SGK3* gene is not regulated by glucocorticoids, it is transcriptionally upregulated by ER (Wang et al., 2011a). SGK3 protein levels correlate with ER status in both breast cancer cell lines and tumor samples, and SGK3 has been shown to induce estrogen-mediated survival of breast cancer cells (Wang et al., 2011a; Xu et al., 2012). The transcriptional induction by ER is of particular interest in Luminal subtype A and Luminal subtype B breast cancers, since approximately 75% breast cancers are ER+ve and thus likely also display elevated SGK3.

3. N-MYC DOWN-REGULATED GENE 1

N-myc down-regulated gene (*NDRG*) represents a family of four members encoded by distinct genes that share ~50% sequence homology: NDRG1, NDRG2, NDRG3 and NDRG4 (**Figure 1-5**). The NDRG family is categorized within a subgroup of α/β hydrolase enzymes, although NDRG isoforms lack any hydrolytic catalytic activity (Melotte et al., 2010). NDRG isoforms contain an NDR domain and a non-functional α/β hydrolase fold. No enzymatic activity of any kind has been ascribed to NDRG isoforms. NDRG1 is ubiquitously expressed in all human tissues, although elevated levels are detected in epithelial tissues (Sun et al., 2013a). NDRG2 is primarily expressed in the brain, heart, spinal cord, and skeletal muscle. NDRG2 and NDRG4 isoforms display multiple splice variants and expressed exclusively in the brain and heart. Interestingly, NDRG3 is expressed in all tissues except brain and heart (Melotte et al., 2010).

NDRG1 is the only isoform that contains a carboxyl-terminal tandem 3X decapeptide repeat (Melotte et al., 2010). Within each decapeptide are three SGK phosphorylation sites (Thr346, Thr356, Thr366) that are not phosphorylated by Akt. Each SGK site primes NDRG1 for phosphorylation by GSK3 β at the -4 residue (Ser342, Ser352 and Ser362) (Murray et al., 2004). Therefore, in order to phosphorylate NDRG1, GSK3 β requires prior NDRG1 phosphorylation by SGK3. The overall consequence of these phosphorylation events at the cellular level remains to be determined. The GSK3 β and SGK3 sites in NDRG1 are conserved across species and to *Danio rerio*. (**Figure 1-6**) Although NDRG1 is primarily cytoplasmic, some studies show that NDRG1 can be recruited to the plasma membrane, endosomes, mitochondrial membranes, and the




Figure 1-5: NDRG family isoforms

NDRG isoforms 1-4 share common N-myc Down-Regulated (NDR) domains and non-functional α/β hydrolase domains. NDRG1 has a unique C-terminal 3X decapeptide repeat.

Homo sapiens	321: trlmrsrtas	gssvtsldgt	rsrshtsegt	rsrshtsegt	rsrshtsega
Mus musculus	321: trlmrsrtas	gssvtslegt	rsrshtsegp	rsrshtsegs	rsrshtseda
Xenopus tropicalus	321: trlmrsrtgs	aassssqdgn	rsrshtnegs	rsrshtgdgn	rsrahtgdgn
Danio rerio	307: trlvrsrtas	gssitsfdgn	rsrshtnegn	rsrshtneg-	rarahtsenq

Figure 1-6: NDRG1 3X decapeptide conservation

NDRG1 3X decapeptide repeat is conserved from *Homo sapiens* to *Danio rerio*. The decapeptide repeat is highlighted in grey and SGK substrate phosphorylation motif is written in red.

nucleus (Sun et al., 2013a). Although NDRG1 has no established nuclear localization sequence, it is known to associate with transport proteins such as Heat-Shock Cognate Protein 70 (HSC70) (Sun et al., 2013a). Moreover, membrane-associated NDRG1 is localized to adherens junctions, indicating a possible interaction with the cytoskeletal components that cooperate with these junctions.

In addition to post-translational modification, NDRG1 is regulated at the transcriptional level. NDRG isoforms possess a 5' CpG island within their promoter regions suggesting their expression is regulated by DNA methylation (Melotte et al., 2010). Oncogenes such as N-neuroblastoma-derived myelocytomatosis (N-myc) and Cellular V-myc myelocytomatosis viral oncogene homolog (C-myc) down-regulate NDRG expression, hence their gene nomenclature. In addition, NDRG1 is regulated by a wide range of other cellular factors and extracellular stimuli and agents, including Hypoxia-Inducible Factor 1 (HIF1), p53, nickel, cobalt, vitamin A, vitamin D, steroids, heavy metal chelators, and oxidative stress (Melotte et al., 2010).

NDRG1 Regulation During the Epithelial-Mesenchymal Transition

NDRG1 has been documented to function as a metastasis suppressor (Sun et al., 2013a). In this context, initial studies identified a role for NDRG1 in the vesicular recycling of E-cadherin (Kachhap et al., 2007). NDRG1 interacts with membrane-bound Rab4a GTPase at the recycling endosomes of the Trans Golgi network to shuttle E-cadherin to the plasma membrane, thereby stabilizing the adherens junction complex (Kachhap et al., 2007). In turn, stabilization of the actin cytoskeleton leads to decreased

cell motility and reduced invasive migration. The elevated levels of E-cadherin at adherens junctions also reduce the rate of Epithelial- Mesenchymal Transition (EMT), a critical step in the progression to metastasis (**Figure 1-7**).

NDRG1 has been shown to modulate EMT by promoting the down-regulation of the TGF β signaling pathway (Chen et al., 2012). For example, NDRG1 suppresses the expression of TGF β targets Snail, Slug and Smad leading to suppression of EMT and metastasis. NDRG1 has also been implicated in inhibiting metastasis through Wingless-related integration site (Wnt) signaling, by binding the Low-density Lipoprotein Receptor-related Protein 6 (LRP6), a coreceptor for the canonical Wnt pathway (Liu et al., 2012). NDRG1 binding blocks Wnt downstream signaling, thus preventing accumulation and nuclear translocation of β -catenin. The nuclear entry of β -catenin upregulates the activity of the T-Cell Factor (TCF) family of transcription factors. TCF family members induce the transcription of oncogenic proteins such as Myc, Cyclin D, Cluster of Differentiation 44 (CD44), and Matrix Metalloproteinase 7 (MMP7) that promote cell cycle progression, tumor growth, and cancer metastasis (Liu et al., 2012).

Clinical Significance of NDRG1 Expression and Function

NDRG1 protein and mRNA levels have been found to be decreased in breast, prostate, colon, and glioma cancers relative to normal tissue (Sun et al., 2013a). Therefore, there is increasing evidence that supports NDRG1 as a tumor suppressor and/or a metastasis suppressor. In breast tumors, an inverse correlation in NDRG1 expression and ER α status has been documented (Sun et al., 2013a). Similarly, ectopic




Figure 1-7: EMT

An EMT involves a functional transition of polarized epithelial cells into mobile and ECM component-secreting mesenchymal cells. The epithelial and mesenchymal cell markers commonly used by EMT researchers are listed. Colocalization of these two sets of distinct markers defines an intermediate phenotype of EMT, indicating cells that have passed only partly through an EMT. Detection of cells expressing both sets of markers makes it impossible to identify all mesenchymal cells that originate from the epithelia via EMT, as many mesenchymal cells likely shed all epithelial markers once a transition is completed. For this reason, most studies in mice use irreversible epithelial cell-lineage tagging to address the full range of EMT-induced changes. ZO-1, zona occludens 1; MUC1, mucin 1, cell surface associated; miR200, microRNA 200; SIP1, survival of motor neuron protein interacting protein 1; FOXC2, forkhead box C2. Taken from (Kalluri and Weinberg, 2009).

expression of ER α in ER α negative cells induces down-regulation of NDRG1 and suppression of NDRG1 leads to increased invasive migration that can be rescued by reintroduction of NDRG1.

In a study of 240 colorectal cancers, NDRG1 levels inversely correlated with tumor grade, metastatic lesions, and differentiation status (Mao et al., 2013). Importantly, NDRG1 expression is a positive prognostic marker for long-term survival at 5+ years. Similarly in neuroblastoma patients, decreased NDRG1 mRNA is linked to poor prognosis and metastatic dissemination (Matsushita et al., 2013). Similarly, in hepatic cancers cells NDRG1 suppresses growth through cell cycle arrest, and loss of NDRG1 in ovarian carcinoma cells leads to enhanced invasive migration (Zhao et al., 2011). In pancreatic cancer NDRG1 is a positive prognostic marker for long-term patient survival, and loss of NDRG1 expression in pancreatic cancer is indicative of invasive tumors with high levels of angiogenesis and overall tumor growth. In this model, rescued expression of NDRG1 leads to suppression of angiogenic phenotypes and reduced tumor growth via suppression of NF κ B signaling (Hosoi et al., 2009).

More recently, epigenetic regulation of NDRG1 through a previously undocumented microRNA pathway has been identified. miR 182 promotes prostate cancer proliferation, growth, and invasion through the down-regulation of NDRG1 (Liu et al., 2013). The microRNA binds the 3' untranslated region of NDRG1 leading to its suppression. Thus, the dynamic changes in NDRG1 expression and its potential function as a regulator of EMT and metastasis make it an attractive therapeutic target. In this context, iron chelators have been proposed as a possible chemotherapeutic

strategy due to their ability to induce NDRG1 expression (Sun et al., 2013b). Iron chelators are a new potential class of anti-metabolites. In colon adenocarcinoma iron chelators inhibit EMT driven by TGF β and Wnt pathways (Chen et al., 2012).

It is important to clarify that NDRG1 likely possess tissue-specific functions. There is evidence of reciprocal function of NDRG1 in certain cancers. For example, there are conflicting reports addressing the function of NDRG1 in gastric cancer, whereby one study claims that NDRG1 is a suppressor of invasion while another demonstrates that NDRG1 promotes angiogenesis and tumor growth (Liu et al., 2011; Ureshino et al., 2012). Additionally, oral cancers display extensive correlations with NDRG1 expression using combinatorial microarray analysis and IHC in 103 oral and oropharyngeal squamous cell carcinomas (Dos Santos et al., 2012). Furthermore, lung cancers also show positive correlation with NDRG1 expression in tumors and absence in normal non-neoplastic tissue (Wang et al., 2013). NDRG1 expression in lung cancers promotes angiogenesis and predicts poor prognosis.

4. THE UBIQUITIN PROTEASOME SYSTEM

The Ubiquitin Proteasome System (UPS) is a central node of regulation monitoring protein levels of virtually all signaling networks in all cells and tissues. The UPS controls the abundance of proteins that are critical mediators of metabolism, cell cycle progression, cytoskeletal changes, motility, survival and proliferation. Intracellular protein levels cell are regulated by the concerted action of UPS components: ubiquitin-activating enzymes (E1); ubiquitin-conjugating enzymes (E2); and ubiquitin-protein ligases (E3) (Lau et al., 2012). E1, E2, and E3 enzymes cooperate to poly-ubiquitinate proteins leading to their degradation by the 26S proteasome (**Figure 1-8**). E3 ligases are the enzymes responsible for protein target selection and thus the diversity of the UPS. E3 ligases function as the substrate recognition domain of the UPS system to recognize and bind substrates intended for degradation. There are approximately 1000 E3 ligases in the human proteome allowing sufficient specificity to regulate the entire network of intracellular proteins (Lau et al., 2012). Additionally, phosphorylation or hydroxylation is often required to promote E3 ligase binding. A post-translational modification prerequisite facilitates precise modulation of the spatiotemporal expression of proteins throughout the cell cycle. E1 enzymes activate ubiquitin through an ATP-dependent process where the E1 enzyme forms a thiol ester bond with an ubiquitin molecule. This activated form of ubiquitin is next transferred to the E2 molecule, which facilitates transfer of the ubiquitin to the substrate through E2 interaction with E3 ligases. The carboxyl-terminus of ubiquitin is bound to the epsilon-amino group of a lysine on the substrate (Lau et al., 2012).




Figure 1-8: Ubiquitin Reaction Pathways

Initially, the E1 enzyme activates, in an ATP-dependent manner, the 76 amino acid ubiquitin molecule by forming a high-energy thiol ester bond with ubiquitin. This activated molecule is then transferred to the E2 conjugating enzyme. The E3 ligase then positions the target substrate near the E2 enzyme allowing for the transfer of ubiquitin. In the case of HECT E3 ligases however, the E3 ligase directly transfers the ubiquitin molecule onto the target substrate. Once a chain of four or more ubiquitin molecules is placed onto the substrate protein, the molecule is then targeted for proteolysis by the 26 proteasome. Taken from (Lau et al., 2012).

A single ubiquitin bound to a substrate is characterized as monoubiquitination. A monoubiquitination can either lead to polyubiquitination or it can instead label a protein for vesicular trafficking, DNA repair, or endocytosis. There are 7 lysines in the 76 amino acid ubiquitin sequence that can participate in ubiquitin chain elongation. Lys48 is the most well studied acceptor site leading to polyubiquitination. A chain of 4 or more Lys48 linked ubiquitins targets the substrate protein for proteasomal degradation by the 26S proteasome (Fasanaro et al., 2010). Alternately, Lys63-linked polyubiquitination targets the substrate for non-proteolytic cellular processes such as DNA repair, endocytosis, inflammation, and translation. Lys6, Lys11, Lys27, Lys29, and Lys33 polyubiquitination are less well studied and are not comprehensively understood (Zhang and Sidhu, 2013). Likewise, branched ubiquitination chains with multiple forms of linkage are known to exist, but their cellular functions are unclear.

De-Ubiquitinating Enzymes

Ubiquitination is a bi-directional system in which De-Ubiquitinating enzymes (DUBs) can reverse the E1-3 coordinate ubiquitin tagging by cleaving the ubiquitin moiety from the protein substrate (Fasanaro et al., 2010). DUB activity may terminate non-proteolytic functions and rescue polyubiquitinated substrates from proteolysis through the removal of the ubiquitin chain. Additionally, DUBs may recycle ubiquitin from substrates undergoing proteolysis through the removal of ubiquitin moieties as the substrate enters the 26S proteasome. DUB functions are completed by 5 subgroups of enzymes that include Jab1, Mov34, MPR1, Pad1, N-Terminal (JAMM)/(MPN+)

metalloproteases, Josephins, Ovarian tumor-like proteases (OTUs), ubiquitin C-terminal hydrolases (UCHs), and ubiquitin-specific proteases (USPs) (Zhang and Sidhu, 2013). Josephins, OTUs, UCHs, and USPs are cysteine protease DUB groups, whereas JAMM is the only identified metalloprotease subgroup.

The 26S proteasome

The 26S proteasome is the most common pathway for protein degradation in eukaryotes. Each 26S proteasome consists of one 20S core subunit and two additional 19S subunits. The 20S core is assembled using 7 α subunits (α 1-7) and 7 β subunits (β 1-7) (Jung and Grune, 2013). In the 'modern' or eukaryotic form, the 20S core is composed of 4 stacked rings. The two outer rings each consist of 7 α subunits. The α subunits serve structural roles and allow regulatory proteins to dock in addition to performing gating functions with their amino-terminal region to restrict inappropriate access to the core center. The two heptameric inner rings are composed of β subunits. The β 1-3 subunits possess active protease sites and provide the catalytic activity of the 20S core (Jung and Grune, 2013). Alternatively, in mammals there are a set of β subunits inducible by TGF α and Interferon Gamma (IFN γ) for *de novo* synthesis of the 20S core (Jung and Grune, 2013). This 20S core can bind the 11S regulatory subunit. Together the 20S and 11S subunits can degrade short peptides but not entire proteins. The lack of ATP-binding and hydrolysis likely leads to the inability to unfold complete proteins.

The 20S core is only capable of independently degrading unfolded proteins. Damaged and misfolded proteins can be proteolytically degraded by the β subunits within the 20S core. In order to degrade folded proteins, the 20S core must bind the 19S subunits. The 19S regulatory subunits consist of a 9 subunit base that binds to the α heptameric ring and a 10 subunit lid. 6 of the 9 base subunits are ATPases Associated with diverse cellular Activities (AAA) ATPase units, which allow the binding of the 19S regulator to the 20S core (Bar-Nun and Glickman, 2012). ATP binding to the hexameric AAA ATPase subunits is required for 19S and 20S binding. ATP hydrolysis is only required for the unfolding of the substrate protein, but not for subunit interaction.

E3 LIGASES

The mechanism of E3 ligase ubiquitin-substrate conjugation is unique to E3 ligases. There are 3 primary families of E3 ligases, categorized as follows: Homologous to E6-associated protein C-Terminus (HECT); U-box; and Really Interesting New Gene (RING) domains (Fasanaro et al., 2010). HECT E3 ligases directly conjugate the ubiquitin moiety to the substrate. HECT E3s contain an active Cysteine residue that functions as an intermediary binding site to transfer the ubiquitin molecule to the substrate (Lau et al., 2012). U-box and RING E3 ligases are scaffolding proteins that facilitate the co-localization of the E2 conjugating enzyme and the substrate.

The SCF family of E3 ubiquitin ligases

SCF complex family of ligases is composed of the Cul1 scaffolding subunit, the Rbx RING subunit, the Skp1 adaptor subunit, and an F-box protein that functions as the substrate recognition domain for the complex (Lau et al., 2012). The F-box protein varies in accordance with the substrate. The F-box subunit is the primary means to induce diversity in the recognition of substrates for proteolytic degradation. The SCF complex contributes to the regulation of cellular processes such as cell cycle progression, apoptosis, and lipid metabolism. The deregulation of the SCF complex can lead to carcinogenesis due to the aberrant signaling that stems from uncontrolled levels of pathway regulators.

F-box proteins interact with substrates through a carboxyl-terminal protein binding sequence (**Figure 1-9**). There are three categories of F-box proteins as defined by their substrate-binding sequence. F-box categories include WD40 repeats (FBXW), leucine rich repeats (FBXL) or other domains (FBXO) (Lau et al., 2012). Most F-box proteins require post-translational modification of the substrate within a degron (phospho-degron) to promote substrate and F-box protein interaction.

FBW7

The protein structure of F-Box and WD repeat domain-containing 7 (FBW7) contains 8 C-terminal WD-40 repeats in addition to its WD-40 F-box motif and a D domain required for FBW7 dimerization (Cheng and Li, 2012). Within the substrate binding motif there




Figure 1-9: SCF Family of E3 ligases

An SCF-type E3-ligase is a multi-subunit complex consisting of three invariable subunits and one variable subunit. The three static subunits include a catalytic RING subunit (Rbx1) that interacts with the E2, a scaffolding subunit (Cul1), and an adaptor subunit (Skp1). The variable molecule is known as the F-box protein (FBP). The major function of the F-box protein is to recruit specific substrates to the E3 complex via substrate interaction domains. The two largest classes of interaction domains found on FBPs are WD40 repeats and leucine-rich repeats (LRRs). A third type of FBP also exists which contains neither WD40 repeats nor LRRs. This third class of F-box proteins contains other types of interaction domains or no recognizable domain at all. To date, there have been approximately 69 FBPs identified in the human genome. Furthermore, unlike HECT E3 ligases that can directly conjugate ubiquitin onto the target, SCF complexes bridge the interaction between the E2 enzyme and the substrate. Taken from (Lau et al., 2012).

are three sequential Arg residues that interact with phosphorylated target substrates. The typical FBW7 phospho-degron is phosphorylated by GSK3 β at a (L)-X-pT/pS-P-(P)-X-pS/pT/E/D sequence (Lau et al., 2012). There are three amino-terminal splice variants of FBW7 (α , β , γ) that display distinct tissue and cellular localization (Cheng and Li, 2012). At the cellular level FBW7 α is nucleoplasmic, FBW7 β is cytoplasmic, and FBW7 γ is nucleolar. FBW7 has been characterized as a tumor suppressor in T-cell Acute Lymphoblastic Leukemia (T-ALL) largely through its degradation of a large panel of oncogenes. FBW7 regulation includes oncogenic substrates such as Cyclin E, C-Myc, and Notch-1 (Wang et al., 2012). In 6% of all human primary tumors *FBXW7* is mutated, 43% of those cases occur within a hotspot sequence existing in the RRR phospho-degron binding region (Wang et al., 2012). *FBWX7* mutations affect numerous cellular processes and thus highlight the oncogenic potential of deregulation in the UPS.

5. CONTRIBUTION OF THIS THESIS

This thesis focuses on Akt-independent PI 3-K signaling mechanisms. Chapter 2 identifies a previously unknown mechanism of PI 3-K-dependent activation of SGK3. My studies show that INPP4B promotes SGK3 activation via its conversion of PI(3,4)P₂ to PI(3)P. This same event inhibits Akt signaling due to suppression of PI(3,4)P₂. I thus propose that INPP4B is a signaling switch between Akt and SGK3 signaling downstream of PI 3-K. These findings indicate an oncogenic capacity for INPP4B, which as up until now been proposed to function exclusively as a tumor suppressor.

Chapter 2 also characterizes SGK3 and INPP4B tumorigenic phenotypes such as promotion of anchorage-independent growth and invasive migration under conditions of suppressed Akt activation. SGK3 regulates these phenotypes in part through phosphorylation of NDRG1, a known metastasis suppressor and SGK-specific substrate. SGK3 phosphorylation primes NDRG1 for GSK3 β phosphorylation leading binding by FBW7. FBW7 is the substrate recognition domain of the E3 ligase SCF complex, which signals NDRG1 for proteolytic degradation by the proteasome. SGK3-induced NDRG1 degradation is a novel mechanism of PI 3-K-driven oncogenic signaling.

Chapter 3 examines SGK1 and the regulation of its stability in the context of PI 3-K. The data reveal that Rictor, a component of the mTORC2 complex, forms a complex with Cullin1 to function as an E3 ligase directing SGK1 polyubiquitination and proteolytic degradation. This is the first mTORC2-independent function of Rictor that has been identified. Additionally, an AGC phosphorylation site on Rictor1 is identified, and

phosphorylation of this site leads to the disassembly of this E3 complex that functions as a feedback loop. Chapter 3 elucidates a mechanism by which PI 3-K hyperactivation can drive SGK1 overexpression. This SGK1 overexpression will then lead to hyperactivation of its substrates perpetuating the aberrant pathway signaling.

CHAPTER II

SGK3 MEDIATES INPP4B-DEPENDENT PI 3-KINASE SIGNALING IN BREAST CANCER

This chapter represents a manuscript that has been submitted for publication at *Molecular Cell*.

Gasser JA, Inuzuka H, Lau AW, Wei W, Beroukhim R, Toker A. 2013 *SGK3 mediates INPP4B-dependent PI 3-Kinase signaling in breast cancer*. Manuscript under review at Molecular Cell

1. ABSTRACT

Oncogenic mutations in *PIK3CA*, the gene encoding the catalytic subunit of PI 3-K, occur with high frequency in breast cancer. The protein kinase Akt is considered to be the primary effector of *PIK3CA*, though the mechanisms by which PI 3-K mediates tumorigenic signals in an Akt-independent manner remain obscure. We show that the SGK3 is amplified in breast cancer and activated downstream of *PIK3CA* in a manner dependent on the phosphoinositide phosphatase INPP4B. Expression of INPP4B leads to enhanced SGK3 activation and suppression of Akt phosphorylation. Activation of SGK3 downstream of *PIK3CA* and INPP4B is required for 3D proliferation and invasive migration. We further show that SGK3 targets the metastasis suppressor NDRG1 for degradation by FBW7. We propose a model in which breast cancers harboring oncogenic *PIK3CA* and INPP4B expression activate SGK3 signaling while suppressing Akt, indicative of an oncogenic function for both INPP4B and SGK3 in these tumors.

2. INTRODUCTION

Somatic mutations, amplifications and other genetic lesions in genes that encode proteins in the PI 3-K pathway play a critical role in breast cancer etiology and progression by regulating phenotypes such as cell proliferation, survival and metastasis. The importance of PI 3-K signaling is highlighted by identification of activating oncogenic mutations of *PIK3CA*, the gene that encodes the p110 α catalytic subunit of class I PI 3-K. Oncogenic *PIK3CA* mutations are frequent in breast cancers, particularly in estrogen receptor positive disease where approximately 40% of cases harbor one of the two most frequent mutations, H1047R and E545K (Cancer Genome Atlas, 2012; Engelman et al., 2006; Lee et al., 2005; Samuels et al., 2004). Class I PI 3-K activate signaling cascades by generating the phosphoinositides PI(3,4)P₂ and PI(3,4,5)P₃ (Manning and Cantley, 2007). Arguably the most studied and best understood effector of PI 3-K is the serine/ threonine protein kinase Akt/protein kinase B (PKB). Activation of Akt is initiated through interaction of the Pleckstrin homology (PH) domain with either PtdIns-3,4-P₂ or PtdIns-3,4,5-P₃ (Chin and Toker, 2009; Franke et al., 1997; Woodgett, 2005). This is followed by phosphorylation of Akt by the PDK-1 and mTORC2 locking the enzyme in the catalytically competent conformation (Mora et al., 2004; Sarbassov et al., 2005).

Signal termination of PI 3-K and Akt signaling is mediated by PTEN, a tumor suppressor protein that dephosphorylates PI(3,4,5)P₃ converting it back to PI(4,5)P₂ (Li et al., 1997; Maehama and Dixon, 1998). LOH, inactivating mutations or deletions in *PTEN* are frequent in many cancers, and lead to excessive PI(3,4,5)P₃ accumulation

and hyperactivation of downstream effectors, including Akt (Engelman et al., 2006). An alternative mechanism of negative regulation of the Akt pathway is through the SHIP family of proteins that dephosphorylate PI(3,4,5)P₃ and generate PI(3,4)P₂, (Choi et al., 2002; Scheid et al., 2002). In turn, PI(3,4)P₂ signaling is terminated by dephosphorylation, mediated by INPP4A and INPP4B, resulting in PI(3)P generation (Gewinner et al., 2009; Norris et al., 1997; Norris and Majerus, 1994). INPP4A and INPP4B both function as suppressors of Akt activity (Ivetac et al., 2009), however, INPP4A expression is primarily restricted to the brain while INPP4B is expressed most tissues, including breast (Fedele et al., 2010).

Despite numerous studies pointing to Akt as a primary transducer of the PI 3-K signal, *PIK3CA* mutant tumors have strikingly low levels of phosphorylated (hence activated) Akt, indicating that other PI(3,4)P₂ and PI(3,4,5)P₃ effectors link PI 3-K to tumorigenesis (Stemke-Hale et al., 2008; Vasudevan et al., 2009). Such effectors include the Tec family kinases Btk and Itk (Luo et al., 2003; Miao et al., 2010). Moreover, GTPase activating proteins for Rho family GTPases also transduce PI 3-K signaling, such as GRP1 (Shiota et al., 2006). A more recent study showed that *PIK3CA*-mediated breast cancer cell growth and survival is dependent on SGK3, in cases where Akt was dispensable (Vasudevan et al., 2009). SGK3 is an AGC protein kinase family member along with two other isoforms, SGK1 and SGK2. SGK isoforms share ~55 % sequence identity with the Akt1-3 catalytic domains (Firestone et al., 2003; Kobayashi et al., 1999; Tessier and Woodgett, 2006b). SGK and Akt isoforms also phosphorylate the same consensus substrate motif, RXRXXS/T, and thus possess a

large number of shared substrates (Murray et al., 2004). SGK isoforms are also activated by the same upstream kinases as Akt, PDK-1 at the activation loop residue and TORC2 at the hydrophobic motif (Garcia-Martinez and Alessi, 2008; Kobayashi and Cohen, 1999; Kobayashi et al., 1999; Liu et al., 2000). As with Akt, SGK phosphorylation at these residues is necessary for catalytic activity. However, unlike Akt, SGKs have unique regulatory regions. In the case of SGK3, this includes an amino-terminal PX domain (Xu et al., 2001). The SGK3 PX domain binds to PI(3)P, thereby localizing a pool of the kinase to endosomal membranes (Tessier and Woodgett, 2006a; Xu et al., 2001).

Despite the nomenclature, SGK3 expression is not regulated by glucocorticoids, instead ER signaling has been shown to induce SGK3 transcription (Wang et al., 2011a; Xu et al., 2012). Interestingly, *INPP4B* is also an ER-induced gene (Fedele et al., 2010). Luminal breast cancers are defined by their expression of estrogen and progesterone receptors, distinguishing them from HER2 and basal-like (triple-negative) subtypes (Fedele et al., 2010; Sorlie et al., 2001). *INPP4B* inactivation by LOH is a frequent event in basal-like cancers, and its loss leads to Akt hyperactivation (Cancer Genome Atlas, 2012; Fedele et al., 2010; Gewinner et al., 2009). Conversely, *INPP4B* has been proposed to be a novel biomarker for luminal-type breast cancers, which also harbor frequent *PIK3CA* oncogenic mutations.

The mechanisms linking *PIK3CA* to SGK3 signaling and downstream phenotypes have not been defined. Here we show that *INPP4B* mediates *PIK3CA*-dependent SGK3 activation in breast cancer cells. We also show that SGK3 regulates N-Myc downstream

regulated 1 (NDRG1) leading to ubiquitination and degradation mediated by the E3 ligase F-box and WD repeat domain-containing 7 (FBW7). Finally, we show that SGK3 functions as a PI 3-K effector in the control of oncogenic signals promoting cell growth and migration of breast cancer.

3. MATERIALS AND METHODS

Cell culture and transfection

BT-20, DLD-1, HEK293T, HCC1937, HeLa, MDA-MB-435, MDA-MB-231, NIH/3T3 and MCF7 cells were cultured in Dulbecco's modified Eagle medium (DMEM; Cellgro) supplemented with 10% Fetal Bovine Serum (FBS; Gibco). ZR-75-1 cells were grown in RPMI 1640 medium supplemented with 10% FBS. MCF10A cells were maintained in DMEM/Ham's F12 medium supplemented with 5% equine serum (Cellgro), 10 μ g/ml insulin, 500 ng/ml hydrocortisone (Sigma-Aldrich), 20 ng/ml epidermal growth factor (EGF) (R&D systems) and 100 ng/ml cholera toxin (List Biological Labs). T47D and BT-549 were cultured in RPMI 1640 supplemented with 10% FBS and 10 μ g/ml insulin. SUM159PT were grown in HAM's F12 supplemented with 5% FBS and 5 μ g/ml insulin and 1 μ g/ml hydrocortisone. Hs578T were growing in DMEM supplemented with 10% FBS and 0.01 mg/ml bovine insulin. *VPS34* fl/fl MEFs were provided by Wei-Xing Zong (Stony Brook University) and cultured as previously described (Guertin and Sabatini, 2007). Transient transfections were performed using X-tremeGENE HP (Roche).

Growth factors and inhibitors

Cells were stimulated for 20 min with 100 ng/ml recombinant human IGF-1 (R&D systems). MG132 (Cayman Chemicals) was used at 10 μ M for 16 hr. Cycloheximide was used at 10 μ g/ml. Inhibitors were as follows: BKM120, 1 μ M; A66, 1 μ M; rapamycin, 100nM; GSK650394, 10 μ M; and SB415286, 25 μ M.

Plasmids

SGK3-GST was provided by Sandra Marmioli (University of Modena and Reggio Emilia). FLAG- p110 α / pCMV2 (#16643) FLAG-p110 α H1047R/ pCMV2 (#16639) and FLAG-p110 α E545K/ pCMV2 (#16642) plasmids were obtained from Addgene. HA-FBW7 and HA-GSK3 were described previously (Wei et al., 2005). NDRG1-FLAG was provided by Sushant Kachhap (Johns Hopkins Medical Institute) (Kachhap et al., 2007). pEAK-FLAG/INPP4B was provided by Lewis Cantley (Weill Cornell Medical College). FLAG-VPS34 was provided by Junying Yuan (Harvard Medical School). pHAGE-N-eGFP was provided by Wade Harper (Harvard Medical School). His-Ub was previously published (Reiling and Sabatini, 2006). FLAG-INPP4B.C842A was generated by site-directed mutagenesis with the following primers: sense, 5'-

AATGGTATTCGTTTCACCTGTGCTAAAAGTGCCAAAGACAGGAC -3'; anti-sense: 5'-GTCCTGTCTTTGGCACTTTTAGCACAGGTGAAACGAATACCATT-3'. FLAG-1A-

NDRG1 was constructed by site- directed mutagenesis with the following primers: 346A-sense: 5'-ACCCGCAGCCGCTCCCACGCCAGCGAGGGCA-3'; 346A-anti-sense, 5'-TGCCCTCGCTGGCGTGGGAGCGGCTGCGGGT-3'. FLAG-8A-NDRG1 was generated using site- directed mutagenesis and the following primers: 328A/ 330A-sense, 5'

TGCGGTCCCGCGCAGCCGCTGGTTCCAGC 3'; 328A/ 330A-anti-sense, 5'

GCTGGAACCAGCGGCTGCGCGGGACCGCA 3'; 342A -sense, 5'

GATGGCACCCGCGCCCGCTCCCACGC 3'; 342A-anti-sense, 5'

GCGTGGGAGCGGGCGCGGGTGCCATC 3'; 352A/362A-sense, 5'

CGAAGCCGCTCCCACGCCAGCGAGGGCACCCGCAGCCGCTC 3'; 352A/362A-anti-

sense, 5' CTCGCTGGCGTGCGAGCGGCTGCGGGTGCCCTCGCTGGCGTGGGAGC
3'; 346A-sense: 5' ACCCGCAGCCGCTCCCACGCCAGCGAGGGCA 3'; 346A-anti-
sense, 5' TGCCCTCGCTGGCGTGGGAGCGGCTGCGGGT 3'; 356A/366A-sense,
5'AAGCCGCTCCCACGCCAGCGAGGGCACCCGCAGCCGCTCGCAC 3'; 356A/ 366A-
antisense, 5'

CTCGCTGGCGTGCGAGCGGCTGCGGGTGCCCTCGCTGGCGTGGGAGCGGCTT 3'.

shRNA-resistant SGK3 and INPP4B were made by Gateway Cloning (Life
Technologies) into lentiviral pHAGE-N-eGFP vector followed by site-directed
mutagenesis. SGK3.shRNA2-resistant SGK3-GFP (SGK3*) was generated by site-
directed mutagenesis with the following primers: sense, 5'

AGATTTTATTAAACAAAGACGAGCAGGACTGAATGAGTTTATTCAGAACCTAGTTAG
GTATCCAGAACTT 3': anti-sense, 5'

AAGTTCTGGATACCTAACTAGGTTCTGAATAAACTCATTTCAGTCCTGCTCGTCTTTG
TTTAATAAAATCT 3'. INPP4B.shRNA2-resistant INPP4B-GFP (INPP4B*) was

generated using site-directed mutagenesis with the following primers: sense, 5'-

TTCATCCTTGCGATGCAAGGATCTCGTGGCACCAGTGAGGGATCGTAAACTGAATAC
ACTGGTGC-3': anti-sense, 5'-

GCACCAGTGTATTCAGTTTACGATCCCTCACTGGTGCCACGAGATCCTTGCGATGCA
AGGATGAA-3'. All point mutations were verified by DNA sequencing.

shRNA-containing vectors: shRNA-mediated silencing of Fbw7, INPP4B, SGK3, and
Akt1 each required the synthesis of a set of oligonucleotides composed of a target

shRNA sequence and its complement against each respective gene. Two hairpins were generated against each gene as follows: Fbw7.shRNA1-sense, 5'-AACCTTCTCTGGAGAGAGAAA-3'; Fbw7.shRNA1-anti-sense, 5'-TTTCTCTCTCCAGAGAAGGTT-3'; Fbw7.shRNA6-sense, 5'-CCAGAGACTGAAACCTGTCTA-3'; Fbw7.shRNA6-anti-sense, 5'-TAGACAGGTTTCAGTCTCTGG-3'; INPP4B.shRNA2-sense, 5'-CCGGCCATCTGAGTATCCCATCTATCTCGAGATAGATGGGATACTCAGATGGTTTTT-3'; INPP4B.shRNA2-anti-sense, 5'-AATTCAAAAACCATCTGAGTATCCCATCTATCTCGAGATAGATGGGATACTCAGATGG-3'; INPP4B.shRNA6-sense, 5'-CCGGAGATACTCCAGCACCGAAATTCTCGAGAATTTCCGGTGCTGGAGTATTTTTTG-3'; INPP4B.shRNA6-anti-sense, 5'-AATTCAAAAAGATACTCCAGCACCGAAATTCTCGAGAATTTCCGGTGCTGGAGTATCT-3'; SGK3.shRNA1-sense, 5'-CCGGGCGAGACCCTAGTTAAGAGAACTCGAGTTCTCTTAAGGTCTCGCTTTTT-3'; SGK3.shRNA1-anti-sense, 5'-AATTCAAAAAGCGAGACCCTAGTTAAGAGAACTCGAGTTCTCTTAAGGTCTCGCTGC-3'; SGK3.shRNA2-sense, 5'-CCGGGCAGGACTAAACGAATTCATTCTCGAGAATGAATTCGTTTAGTCCTGCTTTTT-3'; SGK3.shRNA2-anti-sense, 5'-AATTCAAAAAGCAGGACTAAACGAATTCATTCTCGAGAATGAATTCGTTTAGTCCTGC-3'; Akt1.shRNA, sense, 5'-

CCGGGAGTTTGAGTACCTGAAGCTGCTCGAGCAGCTTCAGGTACTCAAACCTCTTTT
TG-3'; Akt1.shRNA, anti-sense, 5'-

AATTCAAAAAGAGTTTGAGTACCTGAAGCTGCTCGAGCAGCTTCAGGTACTCAAAC
TC-3'

The primer sets were each annealed and ligated into pLKO. Lentiviral supernatants were produced by transfection of HEK293T cells with VSVG, Δ 8.2, and control-PLKO, Fbw7, INPP4B, or SGK3 shRNA-containing vectors for 48 hr.

Antibodies

Anti-Akt (#4685), anti-phospho-Akt Ser473 (#4060), anti-phospho-Akt Thr308 (#9275), anti-Cyclin E (#4129), anti-GSK3 β (#9315), anti-phospho-GSK3 β (#9336), anti-NDRG1 (# 5196), anti-phospho-NDRG1 Thr346 (#3217), anti-p110 α (#4249), anti-S6K (#2705), anti-phospho-S6K Thr389 (#9205), anti-SGK3 (#8156), anti-Vps34 (#4263) and anti- β -actin (#4970) were purchased from Cell Signaling Technologies. Anti-FLAG M2 (#F3165) was from Sigma-Aldrich. Anti-phospho-SGK3 Thr320 (# S1010-85W8) was from US Biologicals. Anti-GFP (# sc-9996), anti-GST (# sc-459) and anti-INPP4B (#sc-12318) were from Santa Cruz. Anti-FBW7 (#A301-720A) was from Bethyl Laboratories. Anti-SGK3 (#LS-C132061) for immunoprecipitation was from LifeSpan BioSciences. Anti-HA was generated and purified from the 12CA5 hybridoma. Anti-p85 was generated in house and has been previously described (Kapeller et al., 1995). Horseradish peroxidase-conjugated anti-goat was from Millipore. Horseradish

peroxidase-conjugated anti-rabbit and anti-mouse immunoglobulin G (IgG) antibodies were from Chemicon.

In vitro protein kinase assays

MCF7 cells infected with pLKO-control or INPP4B.shRNA-pLKO were transfected with SGK3-GST. 24 hr post-transfection cells were serum-starved for 16 hr followed by 20 min stimulation with IGF-1. SGK3 was isolated with glutathione beads and incubated with 75ng GST-GSK3 β substrate peptide and 250 μ M cold ATP in kinase assay buffer (Cell Signaling Technologies) for 35 min at 30°C. The kinase reaction was terminated by the addition of 1x SDS-PAGE loading buffer. Alternatively, 293T cells were co-transfected with SGK3-GST and wild type, E545K, or H1047R *PIK3CA*. SGK3 was precipitated and used for *in vitro* kinase assays as described in the above protocol.

Transwell migration and invasion assays

Transwell assays were carried out essentially as previously described (Chin and Toker, 2010). Briefly, NIH 3T3 conditioned media was added to the lower chamber of 8 μ m pore Transwells (Corning). For invasion assays, filters were coated with 10 mg Matrigel (BD Biosciences). 10×10^5 cells were added to the upper chamber, in triplicate and migration allowed to proceed for 2-24 hr at 37°C, depending on the cell line. Cells that migrated or invaded to the lower chamber were fixed, stained using Hema-3® stain kit (Protocol; Fisher Scientific; Pittsburgh), and counted.

Immunoblotting

Immunoblotting was carried out as previously described (Chin and Toker, 2010). Briefly, cell lysates were separated on SDS-PAGE followed electrophoretic transfer to nitrocellulose membranes. Membranes were blocked in 5% nonfat dry milk/TBST (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20, pH 7.6) for 30 min. Blots were rinsed in TBST, and incubated at 4°C in primary antibody dilutions in 5% nonfat dry milk/ TBST for 16 hr. Membranes were then incubated with horseradish peroxidase-conjugated secondary antibody for 1 hr at 25°C. Membranes were rinsed in TBST and developed with chemiluminescence HRP substrate (Millipore).

Quantitative RT-PCR analysis

RNA was extracted using the Qiagen RNeasy. Reverse transcription reaction was carried out with ABI Taqman Reverse Transcriptional Reagent (N808-0234). After mixing the resulting cDNA template with *NDRG1* (sense: 5'-CCTGAGATGGTAGAGGGTCTC-3' and antisense: 5'-CCAATTTAGAATTGCATTCCACC-3') or glyceraldehyde-3-phosphate dehydrogenase (sense: 5'-GCAAATTCCATGGCACCGT-3' and antisense: 5'-TCGCCCCACTTGATTTTGG-3') primers quantitative RT-PCR was performed using SYBR Green PCR master mix in an ABI Prism 7500 sequence detector (Applied Biosystems, Foster City, CA).

Copy number analysis

The algorithm GISTIC (Genomic Identification of Significant Targets in Cancer) was used to analyze chromosome 8 gene copy numbers of the Tumorscape database. Tumorscape data analysis was performed as described (Beroukhi et al., 2010). SGK3 GISTIC profile was generated using 3131 cell lines and tumors. GISTIC analysis for breast cancer was performed using 243 breast samples and a limit of Q-value < 0.250 for focal peak amplification. Significance values were determined using the FDR (false discovery rate) test.

3D Culture Assay

3D cultures were performed as described (Debnath et al., 2003). Chamber slides were coated with growth factor-reduced Matrigel (BD Biosciences) and allowed to solidify at 37°C for 30 min. Subsequently, 3000 cells were seeded to each chamber slide in assay media (10% FBS/RPMI, 2 µg/ml puromycin, and 2% Matrigel). The assay media was aspirated and replaced 4 days after seeding. Quantitation was conducted using ImageJ quantitation of 2D surface area on Day 8(NIH).

Soft Agar Colony Formation Assay

Soft agar assays were performed by coating 6 cm³ tissue culture plates with 5 mL of 0.8% Noble agar / growth media (10% FBS/DMEM and 2 µg/ml puromycin) and allowed to solidify at 20°C. 5x10⁴ MCF7 breast cancer cells were plated in 1 mL top layer 0.4% Noble agar/ growth media (10% FBS/DMEM and 2 µg/ml puromycin). Soft agar was solidified at 20°C for 4 hr then transferred to 37°C incubator for the duration of the

assay. Growth media (10% FBS/DMEM and 2 μ g/ml puromycin) was added every 4 days and cells were counted and measured 28 days after seeding. Quantitation was performed using MatLab software (MathWorks).

Ubiquitination Assay

Cell based *in vivo* ubiquitination assays was performed as described (Chan et al., 2012). 293T cells were transfected with indicated plasmids for 48 hr followed by lysis in denatured buffer (6M guanidine-HCl, 0.1M Na₂HPO₄/NaH₂PO₄, 10 mM imidazole). The cell lysates were incubated with nickel beads for 3 hr, washed, and subjected to immunoblotting analysis.

4. RESULTS

SGK3 is amplified and hyperactivated in breast cancer

A recent study demonstrated that SGK3 is required for the survival of certain breast cancer cell lines with oncogenic *PIK3CA* mutations. These same cells showed minimal Akt activity and furthermore, Akt was dispensable for survival (Vasudevan et al., 2009). The Akt PH domain binds the PI 3-K lipids PI(3,4)P₂ and PI(3,4,5)P₃, however the SGK3 regulatory region lacks a functional PH domain. Instead, SGK3 regulation is in part mediated by the PX domain that primarily binds PI(3)P (Tessier and Woodgett, 2006a). Since PI(3)P is not a product of class I PI 3-kinases, the mechanism by which SGK3 functions as an effector of *PIK3CA* remains undefined.

Somatic activating mutations in the *SGK3* gene have not been identified with any appreciable frequency. We examined whether amplifications or deletions of *SGK3* exist in human cancers and cancer cell lines in a published database of 3131 cancers (Beroukhi et al., 2010). Amplifications were present in 30% of tumors. In 4.8% of cases, these were focal events encompassing less than half of chromosome 8q, a rate significantly above the genome-wide average ($q=0.00168$) (**Figure 2-1**). Among the 243 breast cancers in the study, 54% exhibited amplifications of *SGK3*, including 12% with focal alterations ($q=0.186$), and indeed SGK3 is one of 64 genes within the "peak region" where these amplifications most overlap (**Figure 2-2**). Chromosome 8q also includes *MYC*, which is the most commonly amplified gene among these cancers. However, the SGK3 peak was significant even after discounting amplifications which encompassed *MYC*.




Figure 2-1: SGK3 is amplified in cancer

Copy-number profiles across chromosome 8 (y-axis) for 3,131 cancer samples (x-axis). A magnified view of the region including the *SGK3* gene locus is shown in the inset. Analysis was performed from a data set obtained from a study of 3,131 cancers of over 25 subtypes. Samples are sorted by frequency of amplification at the *SGK3* locus.




Figure 2-2: SGK3 is focally amplified in breast cancer

Copy-number profiles from 243 breast cancers selected from the data set described in (Figure2-1).

We next analyzed SGK3 protein levels in a panel of breast cancer cell lines informed by the Tumorscape analysis to have amplified SGK3, along with *PIK3CA* and *PTEN* mutation status (**Table 2-1**). Cells were serum-starved and stimulated with insulin-like growth factor-1 (IGF-1) to activate PI 3-K and Akt signaling (**Figure 2-3**). We used an antibody against the SGK3 activation loop site Thr320, targeted by PDK-1, as a surrogate for SGK3 activation. Concomitantly, we evaluated Akt phosphorylation at the activation loop residue (Thr308), also targeted by PDK-1, and hydrophobic motif (Ser473), phosphorylated by the TORC2 complex. An antibody that recognizes the endogenous SGK3 hydrophobic motif site at Ser486 is not available. We also used total and phospho-NDRG1 antibodies as surrogates for the activity of SGK3, noting that NDRG1 is a pan-SGK substrate (Murray et al., 2004; Najafov et al., 2011). We find that in cells that harbor oncogenic *PIK3CA* mutations, SGK3 is basally phosphorylated and further stimulated by IGF-1 (ZR-75-1, MCF7, T47D, Figure 1C). Interestingly, in these same cells total levels of NDRG1 are significantly lower, and since NDRG1 is an SGK substrate, this suggests that phosphorylation by SGK3 may lead to NDRG1 degradation.

Not all breast cancer cell lines that harbor *PIK3CA* mutations or *PTEN* inactivation display elevated SGK3 phosphorylation (e.g., SUM159PT, BT-549) (**Figure 2-3**). We therefore considered additional PI 3-K pathway alterations that would account for SGK3 phosphorylation. INPP4B is 4' phosphoinositide phosphatase that exclusively dephosphorylates the PI 3-K lipid PI(3,4)P₂, converting it to PI(3)P.




Figure 2-3: SGK3 expression analysis in cell lines

Cell lysates derived from the indicated breast epithelial and cancer cell lines, serum-starved (-) or stimulated with IGF-1 for 20 min (+) were immunoblotted (IB) with the indicated antibodies.

Table 2-1: Table of breast cancer cell lines

Cell line name	Tissue of origin	Tumorigenicity	Mutation	ER	PR	P53	HER2	Others
BT20	Breast	+	<i>PIK3CA</i> (H1047R)	-	-	mutant	-	<i>EGFR</i> amplified
BT-549	Breast	+	<i>PTEN</i> truncation	-	-	mutant	-	
HCC1937	Breast	+	<i>PTEN</i> deletion	-	-	mutant	-	
Hs578T	Breast	+	<i>PIK3R1</i> <i>HRas</i> (G12D)	-	-	mutant	-	
MCF10A	Breast	-		-	-	WT	-	
MCF7	Breast	+	<i>PIK3CA</i> (E545K)	+	+	WT	-	
MDA-MB231	Breast	+	<i>KRAS</i> (G13D)	-	-	mutant	-	
MDA-MB435	Breast	+	<i>BRaf</i> (V600E)	-	-	mutant	-	
SUM159PT	Breast	+	<i>PIK3CA</i> (H1047L)	-	-	mutant	-	
T47D	Breast	+	<i>PIK3CA</i> (H1047R)	+	+	mutant	-	
ZR-75-1	Breast	+	<i>PTEN</i> missense	+	-	WT	-	

Loss of *INPP4B* by LOH is frequently observed in basal-like cancers and leads to elevated PI(3,4)P2 levels and in turn, Akt hyperactivation (Fedele et al., 2010; Gewinner et al., 2009). However, *INPP4B* loss is not observed in estrogen receptor-positive breast cancers, where *PIK3CA* mutations occur with the highest frequency (Cancer Genome Atlas, 2012). In our comparative analysis, we find that elevated SGK3 phosphorylation correlates directly with both elevated INPP4B expression and *PIK3CA* mutation status (**Figure 2-3**).

To provide cause-and-effect evidence for SGK3 as a PI 3-K effector, we used pathway inhibitors in cells with *PIK3CA* mutation and high INPP4B, as well as robust SGK3 phosphorylation. Since phosphorylation-state antibodies such as pThr320 (for SGK3) or pThr308 and pSer473 (for Akt) do not directly measure protein kinase activity, we developed a kinase assay to measure SGK3 activity. Endogenous SGK3 was immunoprecipitated and used in *in vitro* kinase assays with a peptide substrate derived from GSK-3 β that is a defined optimal Akt and SGK substrate, since they share a similar consensus phosphorylation motif (Murray et al., 2004). Using this assay, we show that SGK3 activity is stimulated by IGF-1, concomitant with increased Thr320 phosphorylation and increased NDRG1 phosphorylation (**Figure 2-4**). SGK3 activation is attenuated by both BKM-120 and A66, pan class I and p110 α specific inhibitors, respectively (Buonamici et al., 2010; Jamieson et al., 2011). Conversely, inhibition of TORC1 using Rapamycin does not block SGK3 activation, consistent with the notion that SGK isoforms are TORC2 targets (Garcia-Martinez and Alessi, 2008). A




Figure 2-4: inhibitor analysis of SGK3 signaling

T47D cells were serum-starved for 24 hr, then pretreated with the invoked inhibitors, rapamycin (100nM), A66 (1 μ M) or BKM120 (1 μ M) for 20 min, then stimulated with IGF-1 for a further 20 min. SGK3 was immunoprecipitated with anti-SGK3 and subjected to an *in vitro* kinase assay (IVK) using GSK-3 β peptide substrate. Peptide substrate phosphorylation was detected using anti-GSK-3 β phospho-antibody. SGK3 phosphorylation was detected using anti-SGK3 pT320. Total SGK3 was evaluated as control. Whole cell lysates (WCL) were immunoblotted with the indicated antibodies. All results are representative of at least 3 independent experiments.

requirement for *PIK3CA* in SGK3 activation is further substantiated by the fact that both basal and IGF-1-stimulated SGK3 activity is enhanced in cells ectopically expressing wild-type and oncogenic *PIK3CA* mutants (**Figure 2-5**). Collectively, these data demonstrate that SGK3 is amplified in breast cancer and its activity is dependent on oncogenic PI 3-K signaling.

INPP4B regulates SGK3 activation

PtdIns-3-P directly binds to the SGK3 PX domain (Tessier and Woodgett, 2006a). Since high INPP4B levels correlate with the ability of IGF-1 to stimulate SGK3 in *PIK3CA* mutant cells (**Figure 2-3**), and INPP4B generates PI(3)P, we reasoned that INPP4B levels are rate-limiting for SGK3 activation downstream of PI 3-K. SGK3 activity measured by *in vitro* kinase assay is significantly enhanced in cells co-expressing INPP4B, whereas Akt phosphorylation is attenuated, as expected (**Figure 2-6**). Moreover, endogenous SGK3 phosphorylation is also stimulated by expression of wild-type INPP4B, but not by a catalytically- inactive phosphatase mutant (**Figure 2-7**). Although the primary route of PI(3)P synthesis is through the class III PI 3-K VPS34, expression of an active VPS34 allele does not promote SGK3 phosphorylation (**Figure 2-7**). Moreover, *VPS34* null MEFs (fl/fl) display the same level of IGF-1-stimulated SGK3 and NDRG1 phosphorylation as control cells (**Figure 2-8**).

Silencing INPP4B using lentiviral shRNA completely attenuates SGK3 phosphorylation in response to IGF-1, with a concomitant decrease in phospho-NDRG1




Figure 2-5: Oncogenic PIK3CA mutants hyperactivate SGK3

HEK293 cells were transfected with SGK3-GST alone or in combination with PIK3CA.WT, PIK3CA.H1047R, or PIK3CA.E545K followed by 24 hr serum- starvation before stimulation with IGF-1. Glutathione agarose was used to isolate SGK3 prior to incubation with GST-GSK3 β peptide in an *in vitro* kinase (IVK) assay. Whole cell lysates (WCL) and *in vitro* kinase assay were immunoblotted as indicated.




Figure 2-6: INPP4B positively regulates SGK3 activity

HeLa cells were transfected with SGK3-GST alone or with INPP4B and serum-starved for 24 hr, prior to stimulation with IGF-1 for 20 min. SGK3 was isolated from cell lysates with glutathione beads, and incubated with GST-GSK3 β peptide in an in vitro kinase assays (IVK). Peptide substrate phosphorylation was detected using anti-GSK-3 β phospho-antibody. Total SGK3 was evaluated as control. Whole cell lysates were immunoblotted with the indicated antibodies.




Figure 2-7: INPP4B catalytic activity specifically promotes SGK3 phosphorylation

HEK293T cells were transfected with wild-type INPP4B, catalytically-inactive INPP4B.C842A or VPS34, then serum-starved for 24 hr and stimulated with IGF-1 for 20 min. Whole cell lysates were immunoblotted with the indicated antibodies.




Figure 2-8: VPS34 loss does not affect SGK3 phosphorylation

VPS34 fl/fl MEFs were infected with control (CTL) or Cre adenovirus. Control and VPS34-null MEFs were starved for 18 hr and stimulated for 20 min with IGF-1. Whole cell lysates were immunoblotted with the indicated antibodies.

(**Figure 2-9**). Similarly, reduced SGK3 phosphorylation induced by INPP4B silencing is rescued by expression of an shRNA-resistant INPP4B allele (**Figure 2-10**). Inhibition of both exogenous and endogenous SGK3 protein kinase activity is also observed in cells transduced with INPP4B shRNA (**Figure 2-11**). We conclude that INPP4B is required for the ability of PI 3-K to activate SGK3, and that the phosphatase activity of INPP4B is essential. Moreover, we propose that VPS34 is dispensable for *PIK3CA*-mediated SGK3 activation.

SGK3 promotes proliferation in 3D and anchorage independence of growth

To explore the functional significance of SGK3 downstream of *PIK3CA*, we investigated the ability of SGK3 and INPP4B to drive anchorage independent growth, since *PIK3CA* has been shown to promote this phenotype (Isakoff et al., 2005). MCF7 cells (*PIK3CA* E545K, high SGK3 and high INPP4B, **Figure 2-3**) were transduced with vector control, or two distinct SGK3 and INPP4B shRNA's, and colonies allowed to form (**Figure 2-12A and 2-12C**). Whereas control cells form robust colonies in soft agar, silencing either SGK3 or INPP4B significantly inhibits the number of colonies growing in an anchorage-independent manner (**Figure 2-12B**). Additionally, introduction of shRNA-resistant SGK3 and INPP4B cDNAs partially rescues the defect in anchorage-independent growth (**Figure 2-12**). Representative images of each condition are shown in Figure 2-12A.

Growth of cancer cells in 3 dimensional (3D) culture more faithfully recapitulates phenotypes that control tumor growth *in vivo* (Debnath and Brugge, 2005).




Figure 2-9: INPP4B silencing attenuate SGK3 phosphorylation

ZR-75-1 cells were infected with shRNA lentivirus targeting INPP4B, or control pLKO, serum-starved and stimulated with IGF-1 for 20 min. Cell lysates were immunoblotted with the indicated antibodies.




Figure 2-10: shRNA-resistant INPP4B allele rescues SGK3 phosphorylation

MCF7 cells were infected shRNA lentivirus targeting INPP4B, followed by retroviral infection with INPP4B cDNA rescue virus. Cell lysates were immunoblotted with the indicated antibodies. All results are representative of at least 3 independent experiments.





Figure 2-11: INPP4B silencing inhibits SGK3 activity


(A) MCF7 cells were infected with INPP4B.shRNA2 prior to transfection with SGK3-GST. Cells were serum-starved for 18 hr before stimulation with IGF-1. Glutathione agarose beads were used to isolate SGK3 from cell lysates, and incubated with GST-GSK3 β in an *in vitro* kinase (IVK) assay.

(B) T47D cells were infected with SGK3.shRNA2 and INPP4B.shRNA2 prior to serum-starvation for 18 hr prior to IGF-1 stimulation. SGK3 antibody was used to immunoprecipitate SGK3 for 2 hr. In vitro kinase (IVK) assay was then performed with isolated SGK3 and GST-GSK3 β peptide. Whole cell lysates (WCL) were immunoblotted with the indicated antibodies.

A MCF7



B



C




Figure 2-12: SGK3 promotes anchorage independent growth

(A) MCF7 cells infected with pLKO vector control, or two distinct INPP4B and SGK3 shRNA lentiviral vectors and grown in agar/growth media for 28 days. Additional conditions included retroviral infection of INPP4B (INPP4B*) and SGK3 (SGK3*) cDNA rescue virus. Representative images of culture dishes used for the analysis in (B and C) Results are representative of at least 3 independent experiments.

(B) Number of colonies in soft agar obtained in (A) was quantitated using MatLab.

(C) Western blot analysis of MCF7 cells with indicated antibodies.

3D Matrigel growth of ZR-75-1 breast cancer cells (*PTEN* missense, high SGK3, high INPP4B) is also significantly attenuated upon silencing either SGK3 or INPP4B with 2 distinct shRNA sequences each (**Figure 2-13A, 2-13B, and 2-13C**). Inhibition of 3D Matrigel growth upon SGK3 or INPP4B silencing is also observed in MCF7 cells (**Figure 2-14**).

SGK3 promotes breast cancer cell invasive migration

Signaling through *PIK3CA* also modulates breast cancer cell migration and invasion, pre-requisite phenotypes for metastatic dissemination of tumor cells (Pang et al., 2009). We therefore examined if SGK3 is required for breast cancer cell invasive migration. Using *in vitro* Transwell migration assays, we first evaluated SUM159PT cells that express low levels of endogenous SGK3 (**Figure 2-3**). Ectopic expression of SGK3 robustly enhances SUM159PT cell migration (**Figure 2-15A**). Conversely, silencing SGK3 with shRNA significantly attenuates MCF7 cell migration (**Figure 2-15B**). A catalytic small molecule pan-SGK inhibitor, GSK650394 (Sherk et al., 2008) also significantly blocks MCF7 cell migration (**Figure 2-15C**). Finally, ectopic expression of SGK3 also promotes invasive migration through Matrigel (**Figure 2-15D**). Therefore, SGK3 kinase activity is both necessary and sufficient to promote invasive migration of breast cancer cells.

SGK3 mediates NDRG1 proteolytic processing

Finally, since NDRG1 is an established metastasis suppressor and is also an SGK substrate (Kachhap et al., 2007; Murray et al., 2004; Najafov et al., 2011), we evaluated




Figure 2-13: SGK3 regulates 3D growth of breast cancer cells

(A) ZR-75-1 cells were infected with control pLKO or two distinct SGK3 shRNA or INPP4B shRNA's and grown for 8 days in 3D Matrigel/cell culture media. Representative images spheroids at 4x magnification are shown.

(B) Quantitation of 2D spheroid size from (A) was performed using ImageJ software. Error bars represent mean \pm SEM. * P < 0.05 ; ** P < 0.01; *** P < 0.001. Results are representative of at least 3 independent experiments.

(C) Western blot analysis of 3D culture ZR-75-1 cell lysates with indicated antibodies.




Figure 2-14: SGK3 regulates 3D growth of PIK3CA mutant breast cancer cells

MCF7 cells were infected with control pLKO or one of two distinct SGK3 or INPP4B shRNA lentivirus and grown for 8 days in 3D Matrigel/culture media. Representative spheroid images for each condition are shown at 4X magnification.




Figure 2-15: SGK3 promotes breast cancer cell invasive migration

(A) SUM159PT breast cancer cells were infected with SGK3 or control pLEGFP-N1 and followed by 2 hr migration through Transwell assays. Relative migration is measured along the Y-axis as the ratio of migrated cells in the test condition versus the control condition.

(B) MCF7 breast cancer cells were infected with SGK3 shRNA lentiviral vector or control empty vector for 48 hr followed by Transwell migration assays.

(C) MCF7 cells were inhibited with SGK inhibitor, GSK650394 (10uM), or control DMSO for 20 min prior to Transwell migration assays.

(D) HS578T breast cancer cells were infected with SGK3 or control pLEGFP-N1 followed by Transwell Matrigel invasion assays.

the mechanism by which SGK3 controls NDRG1 stability. We initially noted a correlation of NDRG1 protein levels and SGK3 phosphorylation (**Figure 2-3**). Consistent with this, silencing SGK3, but not Akt1, results in a decrease in phosphorylated NDRG1 (pThr346), with a concomitant increase in total NDRG1 (**Figure 2-16A**). A cycloheximide chase experiment reveals that the half-life of NDRG1 in serum-containing media is approximately 1 hour (**Figure 2-16B**). We also examined NDRG1 protein stability in cells treated with a proteasome inhibitor, and find that NDRG1 levels are dramatically enhanced upon inhibition of the 26S proteasome with MG132 (**Figure 2-16C**). Curiously, in T47D cells, NDRG1 levels are not affected by MG132. T47D cells are PIK3CA H1047R mutant, have high SGK3 and INPP4B, and moreover are *FBXW7* null (Mao et al., 2008). FBW7 is an F-box E3 ubiquitin ligase and substrate recognition domain of the SKP1-cullin-F-box (SCF) ubiquitin ligase complex. To determine whether FBW7 mediates SGK3-dependent NDRG1 degradation, we first used wild-type and FBW7 null DLD-1 colon carcinoma cells (Rajagopalan et al., 2004). FBW7 deletion leads to a dramatic increase in NDRG1 protein levels, compared to wild-type cells, whereas *NDRG1* message levels remain unchanged (**Figure 2-17A** and **Figure 2-17B**). Moreover, silencing of FBW7 using two distinct shRNA sequences leads to significantly increased NDRG1 protein levels compared to control cells (**Figure 2-18A**). Increased NDRG1 levels upon FBW7 silencing are also observed in a distinct breast cancer cell line, BT-20 (**Figure 2-18B**). Importantly, the fold increase in NDRG1 is comparable to that observed with Cyclin E, a known FBW7 substrate (**Figure 2-18A**).




Figure 2-16: NDRG1 is degraded by the 26S proteasome

(A) MCF7 cells infected with SGK3. shRNA, Akt1. shRNA or control pLKO, serum-starved then stimulated with IGF-1 for 20 min. Cell lysates were immunoblotted with the indicated antibodies.

(B) MCF10A cells were treated with cycloheximide or control DMSO for the indicated times and cell lysates immunoblotted with anti-NDRG1 and anti-p85.

(C) T47D, MCF10A, MCF7, and ZR-75-1 cells were treated with MG132 for 16 hr and immunoblotted with anti-NDRG1 and anti-p85.




Figure 2-17: FBW7 regulates NDRG1 expression at the protein level

(A) Cell lysates of wild-type (FBW7 WT) or DLD-1 colon cancer cells null for *Fbw7* (*Fbw7*^{-/-}) were immunoblotted with the indicated antibodies.

(B) Quantitative RT-PCR analysis to determine the relative mRNA expression of *NDRG1* in wild-type or *Fbw7*^{-/-} DLD-1 cell lines.





Figure 2-18: Fbw7 regulates NDRG1 protein levels in breast cancer cells

(A) MCF7 cells were infected with two distinct Fbw7 shRNA's or control pLKO, and lysates immunoblotted with the indicated antibodies

(B) BT-20 cells were infected with two distinct Fbw7 shRNA or control pLKO, and cell lysates were immunoblotted with the indicated antibodies

Studies have shown NDRG1 phosphorylation by SGK3 at Thr346/Thr356/Thr366 primes for phosphorylation by GSK-3 β at Ser342/Ser352/Ser462 (Murray et al., 2004). GSK-3 β phosphorylation is a common priming event for FBW7 substrate binding (Wang et al., 2011b). To assess whether NDRG1 stability is dependent on the concerted action of SGK3, GSK-3 β and FBW7, we co-expressed each component in combination and measured NDRG1 stability. Maximal NDRG1 degradation is only observed when both SGK3 and GSK-3 β are simultaneously co-expressed with FBW7 (**Figure 2-19A**). Treatment of cells with SGK inhibitor, GSK650394, or GSK3 inhibitor, SB415286, conversely causes an increase in NDRG1 levels, while dual treatment with both GSK650394 and SB415286 heightens NDRG1 stability even further (**Figure 2-19B**). Finally, we used an established, cell-based ubiquitination assay to evaluate NDRG1 ubiquitination. NDRG1 ubiquitination is increased when FBW7 is co-expressed, and ubiquitination is maximal when SGK3 and GSK-3 β are co-expressed. In the absence of MG132, NDRG1 ubiquitination is completely eliminated. Furthermore, NDRG1 ubiquitination is significantly attenuated in a mutant that lacks SGK3 and GSK-3 β consensus phosphorylation sites. Therefore, NDRG1 stability is regulated by SGK3 activity and subsequent FBW7-mediated degradation. To address FBW7 binding to NDRG1 a GST-binding assay was performed. NDRG1.T346A has reduced ability to bind FBW7-GST and the 8A-NDRG1 eliminates binding to FBW7, demonstrating SGK3 and GSK3 phosphorylation is necessary for FBW7 binding (**Figure 2-20B**). In order to determine the phenotypic significance of SGK3 regulation of NDRG1 we investigated the ability of

A



B




Figure 2-20: NDRG1 is an FBW7 substrate

(A) A His-Ubiquitin assay was performed after transfection of HEK293T cells with FLAG-NDRG1, GST-Fbw7, HA-GSK3 β .S9A, SGK3-GFP, and His-Ub, followed by treatment with MG132 for 12 hr. Nickel NTA beads were used to isolate His-ubiquitin complexes, followed by immunoblotting with the indicated antibodies.

(B) HEK293 were transfected with GST-Fbw7 and NDRG1, 8A-NDRG1, or NDRG1.T346A and treated with MG132 for 18 hr. Glutathione agarose was used to isolate Fbw7 and associated proteins. Pulldown and whole cell lysates (WCL) were immunoblotted with the indicated antibodies.

NDRG1 to mediate migration. In ZR-75-1 cells the expression of NDRG1 dramatically inhibits Transwell cellular migration, while co-expression with SGK3, GSK3 β , and FBW7 causes a dramatic increase in migration rescuing the NDRG1 suppression of motility (**Figure 2-21**). We therefore argue that NDRG1 degradation provides a significant contribution to the SGK3 downstream signaling.




Figure 2-21: NDRG1 inhibits breast cancer cell migration

ZR-75-1 cells were transfected for 24 hr with pcDNA3, NDRG1, or NDRG1, Fbw7, GSK3 β , and SGK3 followed by an 18 hr Transwell migration assay.

5. DISCUSSION

The frequency of PI 3-K pathway mutations in many human solid tumors, including breast cancer, has led to the development of numerous small molecule inhibitors currently in phase I and II clinical trials (Baselga, 2011). These include inhibitors to *PIK3CA*, such as the pan class I PI 3-K inhibitor BKM-120, as well as p110 α -specific inhibitors such as BYL-719 and A66. Various Akt catalytic inhibitors are also undergoing pre-clinical validation for many tumor types (Cleary and Shapiro, 2010; Courtney et al., 2010). Arguably, most studies that have evaluated the mechanism by which PI 3-kinases transduce signals to phenotypes associated with malignancy have focused on Akt as the effector molecule. However, other PI 3-K targets have been shown to signal downstream of PI(3,4,5)P₃, for example the Tec family kinases such as Btk in hematological malignancies (Davids and Brown, 2012). A more recent study pointed to SGK3 as a critical effector of oncogenic *PIK3CA*-mutant breast cancer cells in which Akt is dispensable (Vasudevan et al., 2009). This finding provides insight into an additional target for the development of new drugs for combination therapy in PI 3-K pathway mutant tumors.

Since SGK3 does not possess a PH domain in the regulatory region that would bind PI(3,4,5)P₃, the mechanism by which *PIK3CA* can activate SGK3 has remained obscure (Tessier and Woodgett, 2006b). We reasoned that such a mechanism would have to take into account the lipid-binding property of the SGK3 PX domain, which bind PI(3)P (Tessier and Woodgett, 2006a). Although PI 3-K has been shown to activate SGK isoforms through PDK-1 and TORC2 (Garcia-Martinez and Alessi, 2008), it has

also been shown that a PX domain lipid-binding mutant of SGK3 is catalytically inactive (Tessier and Woodgett, 2006a). This same PX domain mutant is not phosphorylated at the corresponding Thr320 and Ser486 sites, indicating PI(3)P binding as a pre-requisite for phosphorylation and activation. Since class I PI 3-kinases do not synthesize PI(3)P directly, an intermediate step(s) is required for SGK3 activity. Our data show that INPP4B is both necessary and sufficient to transduce the *PIK3CA* signal to SGK3 activation. INPP4B is a PI(3,4)P₂ phosphatase, such that inactivation of INPP4B by LOH in human tumors leads to Akt hyperactivation (Fedele et al., 2010; Gewinner et al., 2009). Conversely, one would predict that in tumors with normal or elevated expression of INPP4B, the synthesis of PI(3)P would promote the activation of an alternative effector(s). We propose that SGK3 is one such effector, whose activation by *PIK3CA* is mediated by INPP4B in breast cancer cells. This model is supported by several lines of evidence. First, breast cancer cell lines with high INPP4B levels show elevated SGK3 phosphorylation and activity, whereas lines with low or undetectable INPP4B do not (Figure 1C). Expression of catalytically active, but not inactive INPP4B leads to activation of SGK3 with a concomitant inhibition of IGF-1-stimulated Akt phosphorylation (Figure 2A). Moreover, silencing INPP4B with shRNA attenuates SGK3 activation, and also leads to inhibition of anchorage-independent growth and proliferation in 3D (**Figure 2-9, Figure 2-12 and Figure 2-13**). In a previous study, silencing INPP4B with shRNA was shown to result in increased anchorage-independent growth, also in MCF7 cells (Fedele et al., 2010). The reason for the discrepancies between the two studies is unclear, but could be due to differences in shRNA sequences used. In our studies, two

distinct shRNA sequences were used, and introduction of INPP4B cDNA rescued the phenotype. Regardless, our data support a model in which INPP4B functions as both an oncogene and a tumor suppressor. A tumor suppressor function is evident in basal-like tumors, which show a high frequency of INPP4B LOH, and a concomitant increase in Akt activity (Fedele et al., 2010). Conversely, an oncogenic role for INPP4B is supported by breast cancer cell lines derived from luminal tumors that show elevated SGK3 activation and high INPP4B expression.

INPP4B dephosphorylates PI(3,4)P₂ to generate PI(3)P, and our results show that INPP4B catalytic activity is required for SGK3 activation. Since the SGK3 PX domain binds PI(3)P, this would argue that SGK3 activation would occur at sites of PtdIns-3-P accumulation. PI(3)P is also generated by class I and II PI 3-kinases. Specifically, a significant pool of PI(3)P is generated by the class III enzyme VPS34 at endosomal membranes (Backer, 2008). Previous studies have shown that SGK3 is localized at the endosome in a manner that depends on an intact PX domain (Tessier and Woodgett, 2006a). Since SGK3 phosphorylation and subsequent activation are dependent on a functional PX domain, this would argue that SGK3 activation occurs primarily at the endosome. However, in our studies we find that *PIK3CA*-mediated activation of SGK3 does not require VPS34 (**Figure 2-8**). The products of *PIK3CA*, PI(3,4,5)P₃ and PI(3,4)P₂ are synthesized primarily at the plasma membrane, indicating that the pool of PI(3)P generated by INPP4B would also reside at the plasma membrane. In turn, a plasma membrane pool of PI(3)P would recruit SGK3 leading to its activation. Although we cannot formally rule out that the PI(3)P generated by INPP4B recruits SGK3 at the

endosome, this is unlikely because studies have demonstrated that the endosomal recruitment of SGK3 is PI 3-K-independent (Tessier and Woodgett, 2006a). Tools for detecting endogenous SGK3 localization, such as activation-state antibodies, are not of sufficient sensitivity for use in immunofluorescence or immunohistochemistry, and to date our results aimed at localizing SGK3 in response PI 3-K and INPP4B signaling have been inconclusive. Future studies using more specific reagents will be required to address the relevant localization of SGK3 downstream of *PIK3CA*.

Oncogenic *PIK3CA* mutations are particularly prevalent in ER-positive breast cancers (Cancer Genome Atlas, 2012). Interestingly, INPP4B has been identified as a potential biomarker for luminal-type breast cancers (Fedele et al., 2010). Moreover, both INPP4B and SGK3 are transcriptionally regulated by estrogen (Harvell et al., 2006; Wang et al., 2011a; Xu et al., 2012). This suggests that the *PIK3CA*/INPP4B/SGK3 signaling axis is particularly important at promoting tumorigenesis in hormone receptor-positive cancers. It is also interesting to note that the original characterization of SGK3 as a required target for *PIK3CA*-mediated growth and survival was conducted MCF7 cells, which express estrogen receptor (Vasudevan et al., 2009). Whether ER expression is necessary or rate-limiting for the *PIK3CA*/INPP4B/SGK3 pathway remains to be determined, since other mechanisms contribute to the transcriptional induction of both INPP4B and SGK3.

The majority of SGK3 substrates identified to date have also been shown to be phosphorylated by Akt, and thus likely share overlapping phenotypes during tumor progression (Tessier and Woodgett, 2006b). However, NDRG1 is the only known

specific SGK substrate, although the functional consequence of SGK-mediated phosphorylation of NDRG1 is not known. We explored NDRG1 as a target of SGK3 in breast cancer cells, since NDRG1 is a known metastasis suppressor and its expression inversely correlates with breast cancer grade (Kovacevic and Richardson, 2006). Our results show that SGK3 is required for invasive migration, a pre-requisite for metastatic dissemination (**Figure 2-15**). We also find that NDRG1 protein levels are inversely correlated with SGK3 activity, suggesting that SGK3 might control NDRG1 stability (**Figure 2-3**). It has been shown that SGK3 phosphorylation of NDRG1 primes for subsequent phosphorylation by GSK3 β (Murray et al., 2004). Our studies provide additional insight into NDRG1 regulation, as we show that SGK3 and GSK-3 β control the interaction of NDRG1 with the substrate recognition domain of the E3 ligase SCF complex, FBW7 (**Figure 2-19 and Figure 2-20**). FBW7 targets NDRG1 for degradation by the 26S- proteasome. In turn, loss of NDRG1 expression is known to reduce the recycling of E-cadherin to the plasma membrane, increase cell migration and eventual metastatic dissemination (Kachhap et al., 2007). Consistent with this, we find that silencing SGK3 inhibits cell migration, an effect that is phenocopied by expression of NDRG1 (**Figure 2-15 and Figure 2-21**). In this model, *PIK3CA*-mutant tumor cells with elevated SGK3 activity would maintain low NDRG1 levels, resulting in enhanced invasive migration.

6. CONCLUSION

In summary, we have identified a new mechanism by which *PIK3CA* transduces tumorigenic phenotypes in breast cancer, specifically through SGK3 activation. INPP4B catalytic activity is required for the ability of breast cancer cells with oncogenic *PIK3CA* to activate SGK3. This provides an alternative mechanism for *PIK3CA* to drive cancer progression under conditions in which Akt is inactive. These findings advocate for the development of small molecule inhibitors targeting SGK3, for *PIK3CA*-addicted tumors resistant to Akt inhibition.

Acknowledgements

We thank Lewis Cantley, John Blenis, Wade Harper and members of the Toker and Wei laboratories for productive discussions; Wade Harper, John Blenis, Lewis Cantley, Donald P. McDonnell, Sandra Marmioli, Junying Yuan, Wei-Xing Zong, and Sushant Kachhap for providing reagents. This study was supported in part by grants from the Department of Defense Breast Cancer Research Program (J.A.G., BC093630), the National Institutes of Health (A.T., CA177910; R.B., U54CA143798; W.W., GM089763 and GM094777), and Men's Collaborative for Women's Cancers (R.B.).

CHAPTER III

RICTOR FORMS A COMPLEX WITH CULLIN-1 TO PROMOTE SGK1 UBIQUITINATION AND DESTRUCTION

This chapter is abstracted from a manuscript that has been published in *Molecular Cell*:

Gao D, Wan L, Inuzuka H, Berg AH, Tseng A, Zhai B, Shaik S, Bennett E, Tron AE, Gasser JA, Lau A, Gygi SP, Harper JW, DeCaprio JA, Toker A, Wei W. Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. *Mol Cell*. 2010 Sep 10;39(5):797-808.

J.Gasser contributed unpublished data which initiated the investigations on which the manuscript is based. The data from J.Gasser showed SGK1 stability changes upon IGF-1 stimulation and 26S proteasome inhibition. Additionally, J. Gasser contributed a number of SGK1 reagents to the manuscript.

1. ABSTRACT

The Rictor/mTOR complex (also known as mTORC2) plays a critical role in cellular homeostasis by phosphorylating AGC kinases such as Akt and SGK at their hydrophobic motifs to activate downstream signaling. However, the regulation of mTORC2 and whether it has additional function(s) remains largely unknown. Here we report that Rictor associates with Cullin-1 to form a functional E3 ubiquitin ligase. Rictor, but not Raptor or mTOR alone promotes SGK1 ubiquitination. Loss of Rictor/Cullin-1-mediated ubiquitination leads to increased SGK1 protein levels as detected in Rictor null cells. Moreover, as part of a feedback mechanism, phosphorylation of Rictor at T1135 by multiple AGC kinases disrupts the interaction between Rictor and Cullin-1 to impair SGK1 ubiquitination. These findings indicate that the Rictor/Cullin-1 E3 ligase activity is regulated by a specific signal relay cascade and that misregulation of this mechanism may contribute to the frequent overexpression of SGK1 in various human cancers.

(Gao et al., 2010)

2. INTRODUCTION

The mammalian target of Rapamycin (mTOR) plays a critical role in regulation of cellular homeostasis, cell growth and survival pathways by acting as a sensor for upstream inputs from multiple growth-promoting signals which are then transduced to downstream effectors (Guertin and Sabatini, 2007; Reiling and Sabatini, 2006). In order to fulfill this complex regulatory function, the mTOR kinase assembles into at least two distinct complexes termed mTORC1 and mTORC2 (Guertin and Sabatini, 2007; Reiling and Sabatini, 2006). These two multi-component subcomplexes differ both structurally and functionally and signal to distinct downstream substrates. mTORC1 is composed of mTOR, Raptor, PRAS40 and mLST8/G β L (G protein β -subunit-like protein). The best characterized mTORC1 kinase substrates include S6K (p70 S6 ribosomal kinase) and 4E-BP1 (phosphorylated 4E-binding protein). The mTORC2 complex includes mTOR, Rictor, mLST8/G β L, PROTOR (protein observed with Rictor-1)/PRR5 and Sin1 (Jacinto et al., 2006; Shiota et al., 2006). mTORC2 phosphorylates the hydrophobic motif of Akt at Ser473 (Sarbasov et al., 2005) and SGK1 at Ser422 (Garcia-Martinez and Alessi, 2008), leading to full kinase activation. Since aberrant activation of Akt is a hallmark of many types of cancers (Manning and Cantley, 2007), hyperactivation of mTORC2 activity has been implicated in cancer progression (Guertin and Sabatini, 2007).

The activity of the mTORC1 complex is highly regulated in cells exposed to growth factors and nutrients. In response to mitogens, activation of PI 3-K leads to phosphorylation of the TSC2 and PRAS40 proteins by Akt, culminating in activation of

mTORC1 (Manning and Cantley, 2007). The activity of mTORC1 can also be stimulated by the Rag GTPase in response to nutrient stimulation (Sancak et al., 2008). Additionally, phosphorylation of Raptor by AMPK (5' AMP-activated protein kinase) in response to a low energy state provides a negative regulatory mechanism to repress mTORC1 activity (Gwinn et al., 2008). Although mTORC2 is a key upstream kinase complex that functions to control Akt phosphorylation and downstream signaling, relatively little is known regarding the regulation of mTORC2. Recent studies indicate that the mTOR complexes might be multi-functional and contain activities other than protein kinases. For example, Raptor has been shown to form a complex with the Cullin-4 E3 ligase and this complex might be critical for mTOR kinase activity (Ghosh et al., 2008). Rictor has also been shown to associate with Cullin-4, although unlike Raptor it is not a WD40-repeat-containing protein (Ghosh et al., 2008). However, additional function(s) for Rictor and mTORC2 remain largely unknown.

The serum and glucocorticoid-inducible kinase (SGK) belongs to the AGC (protein kinase A, G and C) family of kinases, and its activity is stimulated by growth factors (Lang et al., 2006). There are three closely related family members designated SGK1, SGK2 and SGK3 (Loffing et al., 2006). One of the best-characterized SGK1 downstream targets is Foxo3a, which is involved in the regulation of apoptosis (Brunet et al., 2001). SGK1 has also been indicated in the regulation of Na⁺ retention through phosphorylation of NEDD4-2 to impair its ability to degrade the epithelial Na⁺ channel (ENaC) (Debonneville et al., 2001; Ichimura et al., 2005). SGK isoforms share

approximately 55% similarity in the kinase domains with other AGC family kinases including Akt and S6K. In vitro SGK recognizes the same phosphorylation consensus motif (RXRXXS/T, where X represents any amino acid) as Akt and S6K (McCormick et al., 2004). However, unlike Akt and S6K whose expression is relatively stable, SGK1 is a short-lived protein whose stability is controlled by the ubiquitin-proteasome pathway (Loffing et al., 2006). Both the NEDD4-2 (Brickley et al., 2002; Zhou and Snyder, 2005) and CHIP (C-terminal Hsc70-interacting protein) E3 ligases have been shown to ubiquitinate SGK1 (Belova et al., 2006). The first 60 amino acids of SGK1 are critical for NEDD4-2 mediated destruction of SGK1 (Bogusz et al., 2006; Brickley et al., 2002). In addition to growth factor stimulation, cellular stresses including osmotic stress, heat shock, oxidative stress and ultraviolet irradiation induce SGK1 expression by transcriptional mechanisms and thus influence cell survival, proliferation and differentiation (Lang and Cohen, 2001; Loffing et al., 2006). However, it remains unclear how SGK1 destruction by NEDD4-2 and CHIP are regulated by these cellular stresses and whether other unidentified E3 ligase(s) play a critical role in governing SGK1 destruction in response to these signaling events. Finally, both Akt and SGK are frequently amplified and/or overexpressed in cancers (Sahoo et al., 2005), although the underlying molecular mechanisms are unknown.

Here we evaluate the mechanism by which Rictor controls SGK1 stability. We found that by specific association with Cullin-1 and Rbx1, Rictor forms a functional E3 ubiquitin ligase complex that promotes the ubiquitination of SGK1, but not Akt1 or S6K1.

We also show that the AGC kinases phosphorylate Rictor at Thr1135 to disrupt the Rictor/Cullin-1 complex and impair its E3 ligase activity and subsequent SGK1 ubiquitination. Our findings demonstrate a kinase-independent function for the Rictor protein and provide a mechanistic explanation for the observed elevation of SGK1 expression in various human tumors.

(Gao et al., 2010)

3. MATERIALS AND METHODS

Cell culture and Cell Synchronization

Cell culture, including synchronization and transfection, has been described (Gao et al., 2009). Lentiviral shRNA virus packaging and subsequent infection of various cell lines were performed according to the protocol described previously (Boehm et al., 2005). Rictor $-/-$ MEFs and control MEFs were kind gifts from Dr. Mark Magnuson (Shiota et al., 2006). Kinase inhibitors LY294002 (Sigma, L9908), Rapamycin (Calbiochem, 553210), Wortmannin (Sigma, 95455) and Akt 1/2 Inhibitor VIII (Calbiochem, 124018) were used as indicated.

***In vitro* Kinase Assay**

mTORC2 *in vitro* kinase assay was performed as described previously (Sarbasov et al., 2005).

***In vivo* Ubiquitination Analysis**

Cells were transfected with a plasmid encoding HA- Δ 60-SGK1 along with Flag- or His-tagged ubiquitin. myc-Rictor or other expression vectors were co-transfected to assess their effects on SGK ubiquitination. Thirty-six hours after transfection, 10 μ M MG132 was added to block proteasome degradation, and cells were harvested in EBC buffer or denaturing buffer (6 M Guanidine-HCL, 0.1 M NaH_2PO_4 , 10 mM Tris-HCL, 10 mM imidazole, pH 8.0) containing protease inhibitor. 2 mg whole cell lysates were incubated with Flag beads or Ni-NTA resin for 4–10 hrs, followed by washing 4 times with NETN buffer or denaturing washing buffer (8 M urea, 0.1 M NaH_2PO_4 , 10 mM Tris-

HCL, 10 mM imidazole, pH 6.3). Then the washed pellet was boiled in SDS-containing lysis buffer and resolved on SDS-PAGE.

In vitro ubiquitination assay

The *in vitro* ubiquitination assays were performed as described previously (Jin et al., 2005). To purify the Cullin-1/Rictor E3 ligase complex, 293T cells were transfected with vectors encoding HA-Cullin-1, Myc-Rictor (WT or T1135E), and Flag-Rbx1. The Cullin-1/Rictor (E3) complexes were purified from the whole cell lysates using HA-agarose beads. Purified, recombinant SGK protein (purchased from Genway) were incubated with purified Cullin-1/Rictor (E3) complexes in the presence of purified, recombinant active E1, E2 (UbcH5a and UbcH3), ATP and ubiquitin. The reactions were stopped by the addition of 2X SDS-PAGE sample buffer and the reaction products were resolved by SDS-PAGE gel and probed with the indicated antibodies.

Gel Filtration Chromatography for Separation of Rictor Complexes

Two 10 cm plates of HeLa cells were washed with phosphate buffered saline, lysed in 0.5 ml of CHAPS lysis buffer (25 mM HEPES pH7.4, 150 mM NaCl, 1 mM EDTA, 0.3% CHAPS), and filtered through a 0.45 µm syringe filter. Total protein concentration was 6 mg/ml. 500 µl of lysate was loaded onto a Superdex 200 10/300 GL column (GE Lifesciences Cat. No. 17-5175-01). The experiment in was performed with this same column attached in series to a Superose 6 10/300 GL (GE Lifesciences Cat. No.17-5172-01). The sample was separated in the Superose 6 column first, and then the

Superdex 200 column. The gel filtration beads in each column have different size exclusion characteristics that complement each other and allow separation of very large and also smaller proteins. Chromatography was performed using an AKTAFPLC (GE Lifesciences Cat. No. 18-1900-26) and protein complexes were resolved by eluting with the same CHAPS buffer at 0.5 ml/min over 3 hours. Eluent was collected in either 250 μ l or 500 μ l fractions. 50 μ l aliquots of these fractions were loaded onto SDS-PAGE minigels for SDS-PAGE and western blot analysis of the fractionated protein complexes. Prior to running cell lysates, the molecular weight resolution of the columns was first estimated by running native molecular weight markers (urease ~545 kDa, mouse monoclonal IgG ~180 kDa, human serum albumin ~68 kDa) and determining their retention times on Coomassie-stained SDS-PAGE protein gels.

4. RESULTS

SGK1 Protein Expression is Regulated by Rictor

SGK1 is an unstable protein and previous studies have shown that in response to serum and growth factors, activation of PI 3-K leads to the induction of SGK1 (Park et al., 1999). Induced SGK1 expression occurs partially through the increased transcriptional levels of SGK1 mRNA, and partially through other layers of post-translational regulation (Loffing et al., 2006). However, the exact molecular mechanism(s) remain elusive. Recent studies have shown that the *Rictor*-containing mTORC2 complex phosphorylates SGK1 at Ser422 in the hydrophobic motif to fully activate SGK1 kinase activity (Garcia-Martinez and Alessi, 2008). We therefore first investigated if Rictor signaling can also influence SGK1 expression. We found that *Rictor*^{-/-} MEFs have elevated SGK1 expression levels under serum-deprived conditions (**Figure 3-1A**). In agreement with previous studies (Webster et al., 1993), re-addition of serum led to a significant induction of SGK1 protein in both wild type and *Rictor*^{-/-} MEFs. Elevated SGK1 expression in *Rictor*^{-/-} MEFs has been reported (Huang et al., 2009), although the underlying molecular mechanism has not been characterized. Loss of Rictor is the primary mechanism for the observed elevation of SGK1 expression since re-introduction of wild-type *Rictor* into *Rictor*^{-/-} MEFs dramatically reduced SGK1 expression (**Figure 3-1B**). Consistent with this, depletion of Rictor, but not Raptor, in HeLa cells also led to an accumulation of SGK1 protein, primarily in the early G1 phase of the cell cycle (**Figure 3-1C**). However, Akt1 and S6K1




Figure 3-1: SGK1 expression is regulated by the Rictor pathway

(A) Whole cell lysates were isolated from wild type or Rictor $-/-$ mouse embryonic fibroblasts (MEFs) in serum starvation conditions for 24 hours. In another experimental condition, 10% FBS was added to the serum-starved cells for 1.5 hours before harvesting. Equal amounts of whole cell lysates were immunoblotted with the indicated antibodies.

(B) Immunoblot analysis of wild type or Rictor $-/-$ MEFs transfected with the Myc-Rictor plasmid (with empty vector as a negative control) together with pBabe-Puro retroviral empty vector constructs. Twenty-four hours post-transfection, the cells were treated with 1 μ g/ml puromycin for 48–72 hours to kill the non-transfected cells prior to collecting the whole cell lysates for immunoblots.

(C) HeLa cells were infected with the indicated lentiviral shRNA constructs and selected with 1 μ g/ml puromycin to eliminate the non-infected cells. The resulting HeLa cell lines were arrested in the M phase by incubation with nocodazole for 18 hours and then released into the G1 phase. At the indicated time points, cell lysates were collected for immunoblot analysis.

(D) Quantitative RT-PCR analysis to determine the relative mRNA expression of *SGK1* in wild-type or *Rictor* $-/-$ cell lines.

expression was not affected by depletion of endogenous Rictor in HeLa cells (**Figure 3-1C**). Depletion of Rictor does not significantly affect SGK1 mRNA levels (**Figure 3-1D**), indicating that post-translational modification(s) might contribute to the regulation of SGK1 by Rictor.

Rictor Promotes SGK1 Ubiquitination in a Cullin-1-dependent Manner

In support of the finding that Rictor regulates SGK1 stability, we detected an interaction between Rictor and SGK1 (**Figure 3-2A**). We used a cell-based ubiquitination assay to address whether Rictor and other mTOR components could promote SGK1 ubiquitination. To exclude the possible contribution of other known SGK1 E3 ligases, including NEDD4-2 and CHIP, we used a deletion mutant of SGK1 that lacks the amino-terminal 60 amino acids ($\Delta 60$ -SGK1), which cannot be efficiently ubiquitinated by NEDD4-2 and CHIP (Brickley et al., 2002; Zhou and Snyder, 2005). Surprisingly, E3 ligase activity towards SGK1 is unique to Rictor as neither Raptor nor mTOR promotes SGK1 ubiquitination (**Figure 3-2B**). SGK1 was recently identified to be a specific downstream substrate of mTORC2 (Rictor), but not mTORC1 (Raptor) (Garcia-Martinez and Alessi, 2008). Therefore, we reasoned that SGK1 may specifically interact with Rictor, but not Raptor, which could explain why Raptor does not promote SGK1 ubiquitination, despite the fact that Raptor was recently shown to exist in a complex with Cullin 4 (Ghosh et al., 2008).




Figure 3-2: R Rictor promotes SGK1 ubiquitination in a Cullin-1 dependent manner

(A) Immunoblot analysis of whole cell lysates and immunoprecipitates derived from 293T cells transfected with Flag-Δ60-SGK1 and Myc-Rictor constructs. Thirty hours post-transfection, cells were treated with 10 μM MG132 for 10 hours to block the proteasome pathway before harvesting.

(B) Immunoblot analysis of whole cell lysates and anti-HA immunoprecipitates derived from 293T cells transfected with the indicated plasmids. Twenty hours post-transfection, cells were treated with the proteasome inhibitor MG132 overnight before harvesting.

(C) Immunoblot analysis of whole cell lysates and immunoprecipitates derived from 293T cells transfected with the indicated Myc-Cullin constructs. Thirty hours post-transfection, cells were treated with 10 μM MG132 for 10 hours to block the proteasome pathway before harvesting.

Since Rictor itself does not contain the ring-finger, PHD or HECT domain that possesses intrinsic E3 ligase activity, it is possible that Rictor associates with other co-factor(s) to form an E3 ligase complex. The Cullin-Ring complex comprises the largest family of E3 ubiquitin ligases (Petroski and Deshaies, 2005). Thus, we first determined which Cullin family member might contribute to SGK1 ubiquitination. We showed that Rictor specifically interacts with Cullin-1, but not other Cullin family members Cullin-2, 3 and 4 (**Figure 3-2C**). These data are indicative of a role for Cullin-1 in SGK1 ubiquitination.

Rictor forms a complex with Cullin-1, Rbx1 to promote SGK1 destruction

In support of a possible physiological role for both Rictor and Cullin-1 in regulating SGK1 stability, we detected the endogenous interaction between Rictor and Cullin-1 (**Figure 3-3A-B**). Furthermore, the endogenous interaction between Rictor and Cullin-1 could be detected in NP-40 containing EBC buffer (**Figure 3-3B**), a condition that has been shown to disrupt the mTORC2 complex (Hara et al., 2002; Kim et al., 2002), indicating that the intact Rictor/mTOR complex might not be required for interaction with Cullin-1. In support of this idea, we showed that Rictor, but not Sin1 or mTOR, specifically interacts with endogenous Cullin-1 (**Figure 3-3C**). Furthermore, Cullin-1 only specifically interacts with Rictor, but not Raptor, or other known mTORC2 components including mTOR, GβL and Sin1, (**Figure 3-3D**). Although mTOR interacts with Rictor more strongly than Cullin-1 in CHAPS buffer, mTOR/Rictor interaction is not detected in




Figure 3-3: Rictor interacts with Cullin-1 and Rbx1

(A) Immunoblot (IB) analysis of 293T whole cell lysates (WCL) and anti-Cullin-1 immunoprecipitates (IP). Mouse IgG was used as a negative control for the IP. WCL were collected with CHAPS and IPs were washed with CHAPS buffer.

(B) IB analysis of 293T WCL and anti-Rictor IP. Rabbit IgG was used as a negative control for the IP procedure. WCL were collected with EBC buffer and IPs were washed with NETN buffer.

(C) IB analysis of 293T WCL and anti-Rictor, anti-Sin1, and anti mTOR IP. Rabbit IgG was used as a negative control for the IP. WCL were collected with EBC buffer and IPs were washed with NETN buffer.

(D) IB analysis of WCL and IP derived from HeLa cells transfected with the HA-Cullin-1 construct.

(E) IB analysis of WCL and IP derived from 293T cells transfected with Myc-Rictor together with the indicated HA-Rbx1 constructs. Thirty hours post-transfection, cells were pretreated with 10 μ M MG132 for 10 hours to block the proteasome pathway before harvesting.

(F) IB analysis of WCL and IP derived from 293T cells transfected with HA-Rictor or HA-Fbw7 constructs together with the indicated Myc-Cullin-1 or Myc-Skp1 constructs. Thirty hours post-transfection, cells were pretreated with 10 μ M MG132 for 10 hours to block the proteasome pathway before harvesting.

EBC buffer **Figure 3-3E**) (Hara et al., 2002; Kim et al., 2002). These results suggest that Cullin-1 interacts with Rictor *in vivo*.

Cullin-1 is an extensively studied member of the Cullin family (Cardozo and Pagano, 2004; Harper et al., 2002; Nakayama and Nakayama, 2005). It complexes with Rbx1, Skp1 and various F-box proteins to form a multi-protein SCF (Skp1, Cullin-1, F-box protein) E3 ligase complex (Cardozo and Pagano, 2004; Schulman et al., 2000). To further understand the physiological components of the Rictor/Cullin-1 complex, we performed gel filtration chromatography. This unpublished data suggests there might be two different pools of Rictor complex. One complex was estimated at a size over 600KD (fractions 22–26), co-migrating with activated mTOR (as evidenced by S2481 phosphorylation) and Sin1, which might represent the mTORC2 complex. The other Rictor-containing complex was detected at 300–400 KD (fractions 30–34), and co-migrates with both Cullin-1 and Rbx1, but not Sin1. Since Sin1 is required for mTORC2 complex formation (Jacinto et al., 2006; Yang et al., 2006), the lack of Sin1 precludes a possible existence of the mTORC2 complex in these fractions. In contrast, one Raptor complex (mTORC1 complex) is detected, estimated to be over 600KD and co-migrating with mTOR. Another detected Raptor peaks at around 180–250KD (fractions 36–40), which might represent the free Raptor monomer. Consistent with the co-immunoprecipitation data (**Figure 3-3D**), there is no detected co-migration between Raptor and Cullin-1 at fractions 29–34 with anticipated size (around 250–400KD) corresponding to a possible Raptor/Cullin-1 complex.

Using a series of Rbx1 mutants that are unable to interact with Cullin-1, we showed that the presence of Cullin-1 is required for Rbx1 and Rictor interaction (**Figure 3-3E**). However, we found that under ectopic overexpression conditions Rictor does not interact with Skp1 (**Figure 3-3F**). Altogether, these data support the hypothesis that a unique complex composed of Rictor, Cullin-1 and Rbx1 (and possibly other unknown partners) is involved in regulating SGK1 abundance. However, it requires further investigation to fully understand the role of Skp1 in this process.

Rictor is Phosphorylated by AGC Kinases at T1135

Although Rictor is a key regulator of both Akt and SGK1, it remains largely unknown how its activity is regulated. In agreement with recent reports (Dibble et al., 2009; Julien et al., 2010; Treins et al., 2010) we found that S6K1 phosphorylates Rictor at Thr1135 (**Figure 3-4A-B**). Furthermore, ectopically expressed Rictor is phosphorylated in cells by Akt1 and SGK1 as well (**Figure 3-4A-B**). Moreover, although depletion of S6K leads to a reduction in Thr1135 phosphorylation, depletion of Akt1 or SGK1 delivers similar effects and depletion of any individual AGC kinase does not significantly affect endogenous Rictor Thr1135 phosphorylation as depletion of mTOR does (data not shown). This possibly indicates that all three AGC family kinases might function in a redundant manner towards Rictor phosphorylation at Thr1135. A similar mechanism has been reported for Foxo3a phosphorylation by AGC kinases (Tran et al., 2003; Vogt et al., 2005).




Figure 3-4: Rictor is phosphorylated at T1135.

(A) Immunoblot (IB) analysis of whole cell lysates (WCL) and immunoprecipitates (IP) derived from 293T cells transfected with the indicated Myc-Rictor constructs together with various HA-tagged AGC family kinases.

(B) Sequence alignment of the putative Rictor T1135 phosphorylation site across different species.

Phosphorylation of Rictor at T1135 disrupts the Cullin-1/Rictor interaction

Next we investigated the consequence of Rictor Thr1135 phosphorylation on mTORC2 complex activity. Using gel filtration chromatography, we detected co-migration of p-Thr1135-Rictor with an active form of mTOR (p-Ser2481) corresponding to the mTORC2 complex (fractions 14–20). However, p-Thr1135-Rictor did not co-migrate with Cullin-1 at 300–400KD (fractions 21–26). Similarly, wild-type-Rictor, but not phospho-mimetic Thr1135E-Rictor, co-migrated with Cullin-1 (**Figure 3-5A** and data not shown), indicating that phosphorylation of Rictor at Thr1135 might serve to disrupt the Rictor/Cullin-1 complex.

As shown in Figure 5B, insulin addition into serum starved HeLa cells leads to activation of the S6K and Akt kinase pathways (as shown by the increased Ser473-Akt and Thr389-S6K signals), which results in increased Rictor phosphorylation at Thr1135, coupled with a decrease in Cullin-1/Rictor interaction and enhanced 14-3-3/Rictor interaction, and consequently, increased SGK1 abundance. In a reciprocal set of experiments, we treated HA-Cullin-1 expressing cells cultured in 10% FBS-containing DMEM medium with LY290042 to inactivate PI 3-K and then monitored how this affects the Cullin-1/Rictor interaction. LY treatment induced a time-dependent decrease of Rictor Thr1135 phosphorylation, presumably due to the inactivation of S6K and Akt. Rictor phosphorylation at Thr1135 is inversely correlated with its ability to interact with Cullin-1.




Figure 3-5: Phosphorylation of Rictor at T1135 disrupts the interaction between Rictor and Cullin-1

(A) HeLa cells were transiently transfected with HA-WT-Rictor and Myc-T1135-Rictor constructs. Thirty hours post-transfection, whole cell lysates were collected in CHAPS buffer and subjected to gel filtration chromatography. The relative band intensities for HA-WT-Rictor, Myc-T1135E-Rictor and p-T1135-Rictor at the indicated fractionations were quantitated.

(B) HA-Cullin-1 expressing HeLa cells transiently transfected with the Flag-14-3-3 construct. Eighteen hours post-transfection, cells were serum-starved for 24 hours. After the addition of 100nm Insulin, whole cell lysates (WCL) were collected at the indicated time points for immunoblot analysis with the indicated antibodies, for Flag-IP and GST pull-down assays to determine Rictor/14-3-3 interaction, and for HA-IP to determine Rictor/Cullin-1 interaction.

(C) HA-Cullin-1 expressing HeLa cells were treated with 20mM LY294002. At the indicated time points, whole cell lysates (WCL) were collected for immunoblot analysis with the indicated antibodies, for HA-IP to determine Rictor/Cullin-1 interaction, and GST-pulldown assays to determine Rictor/14-3-3 interaction.

Phosphorylation of Rictor at T1135 reduces the ability of Rictor to ubiquitinate SGK1

As a result of reduced interaction with Cullin-1, T1135E Rictor is defective in promoting SGK1 ubiquitination (**Figure 3-6A**). Since T1135E has similar affinity as wild-type Rictor in binding to SGK1, the impaired E3 ligase activity towards ubiquitination of SGK1 might primarily be due to the disruption of the Cullin-1/Rictor association. Moreover, in keeping with impaired E3 ligase activity, compared with wild-type Rictor, T1135E Rictor is also compromised in promoting SGK1 degradation (**Figure 3-6B**). In summary, these data demonstrate that in addition to complexing with mTOR to form the mTORC2 complex as a means to phosphorylate Akt and SGK, by complexing with Cullin-1 and Rbx1, Rictor might have an additional function as an E3 ligase complex that controls the stability of SGK1 and likely additional targets (**Figure 3-7**). We also show that the E3 ligase activity of Rictor is subject to negative regulation by a variety of AGC kinases. Since PI 3-K positively regulates AGC kinase activity, frequent hyperactivation of this signaling axis might contribute to the elevated SGK1 expression levels detected in various cancers (**Figure 3-7**).




Figure 3-6: Phosphorylation of Rictor at T1135 reduces the ability of Rictor to ubiquitinate SGK1

(A) Immunoblot (IB) analysis of whole cell lysates (WCL) and immunoprecipitates (IP) derived from 293T cells Transfected with HA-D60-SGK1 together with His-Ub and various Myc-Rictor constructs. Twenty hours post-transfection, cells were treated with the proteasome inhibitor MG132 overnight before harvesting. The whole cell lysates were collected in EDTA-free lysis buffer and the His-pull down was carried out in the presence of 8M Urea to disrupt possible protein interactions.

(B) Wild type or Rictor^{-/-} MEFs were transfected with the indicated Rictor plasmids (with empty vector as a negative control) together with the pBabe-Puro retroviral empty vector. Twenty-four hours post-transfection, the cells were treated with 1 μ g/ml puromycin for 48–72 hours to kill the non-transfected cells prior to collecting the whole cell lysates for immunoblots




Figure 3-7: Proposed model for the Rictor/ Cullin-1 pathway to control SGK1 turnover

5. DISCUSSION

The data presented above provides experimental evidence for a possible function of Rictor in the ubiquitination of SGK1. To date, the only function attributed to Rictor in the mTORC2 complex is phosphorylation of the hydrophobic motifs of downstream targets such as Akt and SGK. Our data points to a specific association of Rictor with Cullin-1 and Rbx1 as part of a possible functional E3 ubiquitin ligase complex (**Figure 3-7**).

Although our results indicate that mTOR may not be required for Rictor E3 ligase activity (**Figure 3-2B**), it remains unclear whether these two complexes share common scaffolding proteins and what the crosstalk is between these two complexes. Recent studies demonstrate that many other kinase complexes also possess E3 ligase activity (Lu et al., 2002; Maddika and Chen, 2009). Since many ubiquitination processes require a prior phosphorylation event, the coupling of both the kinase and the E3 ligase in proximity provides for more efficient destruction (Carrano et al., 1999). It is possible that there are unknown Rictor ubiquitination substrate(s) that require prior phosphorylation by Rictor.

Using gel filtration assays, in addition to the well-known mTORC2 complex migrating at over 600KD, we detected a second possible Rictor-containing complex, co-migrating with Cullin-1 and Rbx1 at 300–400KD. This finding was supported by endogenous co-immunoprecipitation assays showing that only Rictor, but not other mTORC2 complex components including mTOR, GβL and Sin1 associates with Cullin-1 (**Figure 3-3A-D**). We also found that although Sin1 could efficiently immunoprecipitate endogenous Rictor, it could not immunoprecipitate endogenous Cullin-1 as Rictor IP

does (**Figure 3-3D**). Since Sin1 is required for formation of the mTORC2 complex (Jacinto et al., 2006; Yang et al., 2006), these results suggest that Rictor might exist in two distinct complexes, the Sin1-containing mTORC2 complex, and the Cullin-1-containing complex. This was further supported by the observation that depletion of Rictor, Cullin-1 and Rbx1, but not mTOR, Raptor or Sin1 leads to upregulation of SGK1. However, additional studies are required to fully understand the possible role of mTOR and other TORC2 complex components in Rictor-mediated SGK1 turnover.

Our data also demonstrate that unlike Rictor, Raptor does not promote the ubiquitination of Akt1, SGK1 and S6K1 (**Figure 3-2B**). This suggests that the E3 ligase activity might be unique to the Rictor/Cullin-1 complex. However, under ectopic expression conditions, Skp1 is not detected in the Rictor/Cullin-1 complex. It is known that Skp1 serves as a bridging molecule to hold Cullin-1 and the F-box protein in a complex. The possible lack of Skp1 in the Cullin-1/Rictor complex suggests that Rictor might play a role equivalent to Skp1. However, further experimental investigation is required to fully understand the role of Skp1 for the Rictor/Cullin-1 complex to ubiquitinate SGK1, and more studies are also needed to determine whether a specific F-box protein is involved in this process.

6. CONCLUSIONS

Although SGK1 has been shown to be degraded by other E3 ligases including NEDD4-2 and CHIP, in both cases it is not known how the destruction is regulated and whether it is mediated by PI 3-K signaling. Our data suggest an alternative mechanism whereby multiple AGC kinases can negatively regulate Rictor/Cullin-1 E3 ligase activity without affecting its kinase activity, and this suggests a positive feedback loop to boost SGK1 activity post-stimulation. However, more studies are required to determine whether the ability of NEDD4-2 and CHIP to degrade SGK1 is also affected by the PI 3-K/Akt signaling. SGK1 overexpression has been reported in multiple cancers including breast cancer. Most interestingly, although SGK1 has been suggested to have redundant functions with Akt, simultaneous overexpression of both Akt and SGK1 has also been reported in breast cancers (Sahoo et al., 2005). Our work suggests that since SGK1, but not Akt, is subject to ubiquitination by the Rictor/Cullin-1 complex, elevated Akt activity might block the function of Rictor/Cullin-1, leading to accumulation of SGK1 (data not shown). Collectively, our results provide insight into how Rictor can influence SGK1 signaling by promoting its ubiquitination. Furthermore, we define a feedback mechanism that can negatively regulate the E3 ligase activity of the Rictor/Cullin-1 complex. This provides functional insight into Rictor regulation, as well as mechanistic information regarding the SGK1 stability controlled by the PI 3-K pathway, and how misregulation of this process contributes to SGK1 overexpression in human cancers.

CHAPTER IV
DISCUSSION

1. SUMMARY OF THESIS

The objective of my thesis work was to investigate Akt-independent mechanisms of PI 3-K signaling in breast cancer. Gaining a greater understanding of PI 3-K pathways that mediate oncogenic *PIK3CA* signals will help to identify new therapeutic targets and better understand the utility of current targets. In chapter 2, I identify a mechanism of PI 3-K-dependent SGK3 activation. I show that the phosphoinositide phosphatase INPP4B functions as the regulator between SGK3 and Akt signaling downstream of PI 3-K. Moreover, I establish that SGK3 in turn promotes oncogenic phenotypes under conditions of low Akt activity and *PIK3CA* mutation. I determine that the metastasis suppressor, NDRG1, is a critical SGK3 substrate that supports enhanced invasive migration in breast cancer cells. I further demonstrate that NDRG1 phosphorylation by SGK3 leads to FBW7 E3 ligase recruitment and subsequent proteolytic degradation. The carboxyl-terminal phosphorylation of NDRG1 is the first identified post-translational modification that targets its destruction. PI 3-K pathway control of NDRG1 degradation is a previously unknown mechanism of *PIK3CA*-mediated cancer signaling through its downregulation of a metastasis suppressor.

In chapter 3, I explore a novel mTORC2-independent function for Rictor. I identify the Rictor-Cullin1 complex as an SGK1 E3 ligase. Furthermore, I show that Rictor is phosphorylated by AGC family kinases and this inhibits E3 ligase formation, effectively serving as a positive signaling feedback loop to SGK1. The active Rictor-Cullin1 complex targets SGK1 directing degradation by the proteasome. Rictor-mediated SGK1 turnover is the first-identified PI 3-K-dependent post-translational regulation that

modulates SGK degradation. This mechanism highlights a mechanism by SGK1 is overexpressed in human cancers as a result of hyperactive PI 3-K signaling. The UPS plays a prominent coordinating role in both aspects of my thesis work, namely SGK1 regulation by Rictor-Cullin1 and SGK3 regulation by PI 3-K AND INPP4B. The implication of these findings in the broader context of PI 3-K signaling in breast cancer is discussed below.

2. DISCUSSION

The prevalence of mutations in genes in the PI 3-K pathway across human cancers has enabled the development of multiple small molecule inhibitors currently in pre-clinical and clinical evaluation (Zardavas et al., 2013). These inhibitors include drugs that target PI 3-K itself, or those target its upstream regulators such as RTKs, or its downstream effectors such as Akt (Baselga, 2011). Data emerging from the use of these inhibitors in vitro and in genetically engineered mouse models have revealed that although we know much concerning the major mechanisms by which PI 3-K relays signals to phenotypes associated with malignancy, we do not yet have a complete picture (Zardavas et al., 2013). Since the PI 3-K pathway harbors multiple genes that encode both oncogenes and tumors suppressors, and multiple feedback loops exist within the signal relay network, it is unlikely that a single linear signaling mechanism accounts for the majority of aberrations in cancer. Moreover, many of proteins that transduce PI 3-K signaling exist in multiple isoforms, arguing that one must consider redundancy and specificity as a major component of signal relay, that must also be taken into account when considering the development of small molecule inhibitors. In this context, the best-understood effector of PI 3-K is the Akt kinase and a multitude of studies have linked PI 3-K and Akt signaling in the regulation of proliferation, survival, metabolic, and motility processes with implications for oncogenic signaling (Luo et al., 2003). It is not surprising therefore that there are currently a number of small molecule Akt inhibitors under clinical evaluation, along with pan PI 3-K and isoform-specific PI 3-K inhibitors. Given that some compounds of these have demonstrated limited efficacy

either in the laboratory or in the clinic, there is an obvious and unmet need for the development of additional inhibitors that target effectors distinct from Akt (Zardavas et al., 2013). This is especially important since studies have revealed that *PIK3CA* and *PTEN*-mutant tumors do not always display elevated phospho-Akt levels, implying that additional effectors may be transducing the PI 3-K and PI(3,4,)P2 and PI(3,4,5)P3 signals (Vasudevan et al., 2009). A number of such effectors have received limited attention, including novel GEFs for Rho family GTPases, Tec family kinases and SGK isoforms (Cherfils and Zeghouf, 2013; Sommer et al., 2013; Vargas et al., 2013; Vasudevan et al., 2009). A recent study by the Garraway laboratory demonstrated that in certain *PIK3CA*-mutant cell lines and tumors that do not display high phospho-Akt levels and in which Akt is dispensable for growth and proliferation, the SGK3 isoform is required for *PIK3CA*-dependent signaling (Vasudevan et al., 2009).

Although the Garraway study clearly implicated SGK3 as an effector of *PIK3CA* in cancer, the mechanism by which SGK3 responds to either PI(3,4,)P2 and PI(3,4,5)P3 has remained elusive. This is especially difficult to rationalize since unlike Akt, SGK3 does not possess a PH domain capable of binding these two second messengers. Instead, SGK3 has a PX domain that binds PI(3)P exclusively, and PI(3)P is generally considered to be a phosphoinositide that is constitutively present in endomembranes and not function as a classical second messenger (Tessier and Woodgett, 2006b). Nonetheless, PI 3-K inhibitor experiments have clearly demonstrated that SGK3 is indeed a PI 3-K effector and must therefore respond to elevated PI(3,4,)P2 and PI(3,4,5)P3. The mechanism by which SGK3 is activated downstream of PI 3-K has

remained elusive, in part due to the lack of reagents and tools to study SGK3 phosphorylation and activation (Tessier and Woodgett, 2006a). My thesis work has focused on identifying such the mechanism by which SGK3 can be activated downstream of growth factor-stimulated PI 3-K. Specifically, I show that a critical component of this pathway is the INPP4B 4' lipid phosphatase, that interconverts PI(3,4)P₂ to PI(3)P. Expression of INPP4B enhances IGF-stimulated SGK3 phosphorylation, whereas catalytically-inactive INPP4B cannot. Conversely, INPP4B silencing with shRNA attenuates SGK3 phosphorylation, protein kinase activity and phosphorylation of the downstream substrate NDRG1 as determined in cell-based assays. Since the product of INPP4B activity, PI(3)P, can directly bind to SGK3, I propose that INPP4B is rate-limiting in the activation of SGK3 downstream of *PIK3CA*, and thus INPP4B levels ultimately determine whether Akt, or SGK3 is the primary effector of this pathway in human tumors. One important aspect is the source of PI(3)P in membranes. It is largely accepted that the class III PI 3-K VPS34 that is localized at endosomes is responsible for the synthesis of the main pool of PI(3)P in endomembranes (Backer, 2008). However, we show that expression of exogenous VPS34 does not enhance SGK3 activity. Moreover, VPS34 deletion in fl/fl MEFs also has no effect on the IGF-stimulated SGK3 phosphorylation. Therefore, the pool of PI(3)P generated by VPS34 is unlikely to be directly involved in SGK3 activation. Instead, I propose that it is the PI(3)P that is interconverted from PI(3,4)P₂ by INPP4B in cells that have elevated levels of this phosphatase combined with PI 3-K pathway mutations that lead to increased PI(3,4,)P₂ and PI(3,4,5)P₃. As such, this model

dictates that SGK3 is a positive transducer of INPP4B activity. The model that elevated INPP4B can positively regulate signaling, rather than simply being viewed as a tumor suppressor whose loss promotes Akt activation, also implies that other PX domain-containing proteins that sense PI(3)P could be regulated by this alternate pathway. Furthermore, the concept that INPP4B can promote PI 3-K signaling by its presence, and not just by its loss, characterizes new potential combination therapies in the *PIK3CA* pathway. Combination therapies targeting PI 3-K and SGK3 may hold promise for those tumors that harbor *PIK3CA* mutation, SGK3 amplification and constitutive or elevated INPP4B. Luminal ER positive tumors are likely to represent one such molecular subtype, since these tumor have the highest frequency of *PIK3CA* mutations, do not frequently lose INPP4B by LOH, and SGK3 is often over-expressed and/or amplified.

In Chapter 2, I show that SGK3 is focally amplified in breast cancer with an overall amplification rate of 54%. I then show that SGK3 and INPP4B regulate oncogenic phenotypes such as growth in 3D and invasive migration in cells that harbor oncogenic *PIK3CA* but display low-level Akt phosphorylation/activation. The relative number of tumors and tumor cell lines that exhibit minimal Akt activity and in which Akt is dispensable for proliferation emphasizes the importance of understanding alternate mechanisms of PI 3-K-driven cancer progression. The ability of SGK3 to mediate tumorigenic phenotypes is likely due in part to its overlapping substrates with Akt. The number of substrates shared between Akt and SGK3 emphasizes the ability of SGK3 to regulate oncogenic phenotypes via shared signaling pathways. However, identifying

specific mechanisms by which activated SGK3 might regulate cancer phenotypes that are not shared with Akt holds promise for new drug targets and biomarkers for clinical benefit. In my studies I identify an exclusive SGK substrate, NDRG1, as a mediator of PI 3-K signaling in the SGK3 pathway. Moreover, my data reveal the mechanism by which a post-translational modification leads to NDRG1 destruction by the proteasome. These data also highlight a novel mechanism by which PI 3-K/SGK3 regulates degradation of a breast cancer metastasis suppressor (**Figure 4-1**). In this model oncogenic *PIK3CA* promotes invasive migration in breast cancer through the INPP4B/SGK3 signaling axis. The ability of SGK3 to promote progression adds to our knowledge of the mechanisms of PI 3-K signal relay, and further indicate that SGK3 is an effector that can transduce signals in the absence of productive Akt activation.

Initial studies showed that INPP4B is primarily expressed in luminal A and luminal B molecular subtypes in breast cancer. The expression of INPP4B in ER positive cancers, and its loss by LOH in ER negative breast cancers implies that lipid phosphatase activity may not exclusively function in a signal termination capacity in the context of PI 3-K signaling, at least in ER positive cancers. Instead, I propose that in ER positive breast cancers, INPP4B catalytic activity diverts the signal towards PI(3)P and recruitment and activation of SGK3. This event in turn promotes downstream SGK3 signaling, while inhibiting *PIK3CA*-stimulated Akt activation, since PI(3,4,5)P₂ is eliminated. In this model, those rate-limiting factors that determine activation of Akt versus SGK3, are INPP4B protein levels and SGK3 amplification. Although other factors likely determine the ability of *PIK3CA* to drive SGK3 activation, I propose that the




Figure 4-1: Model of PI 3-K regulation of Metastasis Suppressor NDRG1 through SGK3

SGK3 activation via the PI 3-K is mediated by INPP4B catalytic activity likely through its conversion of PI(3,4)P₂ to produce PI(3)P which recruits and binds the SGK3 PX domain.

primary determinant is INPP4B expression. It is also worth noting that this is not necessarily an all-or-nothing mechanism. It is likely that in certain breast cancers both Akt and SGK3 are activated simultaneously, possibly under conditions where the levels of INPP4B allow for some *de novo* PI(3)P synthesis but the pool of PI(3,4,)P2 is also retained. The mutual induction of SGK3 and INPP4B in ER+ cells differentiates ER+ from ER- PI 3-K signaling.

The fact that INPP4B functions as a positive mediator of PI 3-K signaling in ER positive tumors, and not solely as a signal terminator changes the way we view INPP4B as a therapeutic target. In triple negative breast cancers, INPP4B has been shown to function as a tumor suppressor, such that *INPP4B* LOH is commonly observed (Gewinner et al., 2009). A tumor with this profile will likely respond very differently to Akt inhibitors compared to an ER positive tumor with high INPP4B and high SGK3. My studies highlight the emerging concept of personalized medicine and the evaluation of the specific genetic background of a tumor to be able to administer the appropriate drug treatment. As such, I propose that INPP4B can function both as an oncogene and tumor suppressive, depending on the genetic background, although this concept has not yet been tested *in vivo*. However, the notion that genes can function as both oncogenes and tumor suppressors depending on the context is not new. For example, studies in Notch signaling and Mouse Double Mutant 2 (MDM2) have helped to establish the concept of dual modalities of a single gene (Manfredi, 2010; South et al., 2012). Thus, the notion that a gene and its protein product have a unique function in all tumor settings is an over-simplification, and this must be taken into account when devising

treatment strategies. Although the model that *INPP4B* can function as an oncogene or tumor suppressor, and that SGK3 can mediate the oncogenic function, it is likely that there exist additional INPP4B effectors that are yet to be described, and that likely contribute to oncogenic function.

In Chapter 3 we identify a new E3 ubiquitin ligase complex composed of Rictor and Cullin1, which directs the degradation of SGK1 at the proteasome. The Rictor-Cullin1 E3 complex is the first example of an mTORC2-independent function for Rictor. Interestingly, the mTORC1 subunit, Raptor, was previously shown to have mTOR-independent E3 ligase functions in complex with Cullin4 (Ghosh et al., 2008). Duality in the abilities of kinase complexes to intersect and perform E3 ligase functions leading to degradation increases the probability of coordination in cellular events. This raises the probability that the two Rictor-containing complexes crosstalk or signal feedback to one another. The turnover rate for each complex is also likely to have diverse effects on the processing rate of the competing complex.

Rictor is phosphorylated at Thr1135 by members of the AGC family of kinases including Akt and S6K, and this event functions to negatively regulate the Rictor-Cullin complex. PI 3-K-mediated Thr1135 regulation modulates the levels of SGK1 and this mechanism increases our understanding of SGK regulation at the post-translational level. The participation of Akt in promoting SGK1 expression adds to its known role in the phosphorylation of WNK1, where by WNK1 functions as a scaffolding protein for PDK-1-mediated phosphorylation of SGK1 at Thr256. The dual mechanisms of Akt in the regulation of SGK1 activity and expression underscore the importance of signal

integration necessary for efficient pathway output. The Rictor-Cullin1 complex is the first SGK E3 ligase identified that functions in a PI 3-K-dependent manner. A logical extension of this finding is that oncogenic *PIK3CA* and *PTEN* mutations perturb SGK1 degradation. Under conditions of deregulated PI 3-K activity, SGK1 protein levels increase leading to hyperactivation of SGK1 downstream targets.

3. FUTURE DIRECTIONS

My work has identified a novel mechanism by which PI 3-K transduces lipid signals to SGK3, specifically through the activity of the lipid phosphatase INPP4B. In addition, I have identified a mechanism of regulation of the SGK substrate NDRG1. A number of open questions remain regarding the details by which SGK3 responds to PI 3-K signaling. One obvious question is the mechanism of localization that determines activation SGK3, given that previous studies have localized SGK3 primarily at the endosome, consistent with the notion that endosomal membranes contain the bulk of the intracellular PI(3)P pool. However, my model dictates that the activity of INPP4B on PI(3,4)P₂ thereby generating PI(3)P drives SGK3 activation. Since PI(3,4)P₂ and PI(3,4,5)P₃ are largely generated at the plasma membrane, this implies that the resulting PI(3)P must also accumulate at the plasma membrane, thus allowing for SGK3 recruitment through the PX domain leading to activation. By inference, INPP4B is unlikely to be responsible for PI(3)P production at the endosomal membrane, consistent with published findings demonstrating that endosomal localization of SGK3 is *PIK3CA*-independent (Tessier and Woodgett, 2006a). In this model, the two distinct pools of PI(3)P exist, one endosomal generated by VPS34 that primarily functions in vesicle trafficking, and a second INPP4B-generated pool at the plasma membrane that is responsible for mediating PIK3CA signals. In both cases, SGK3 senses PI(3)P, but may ultimately dictates specific functions. At the same time, we cannot exclude the possibility that the two pools are interchangeable, or that the plasma membrane pool of PI(3)P and SGK3 integrates with the endosomal pools. Regardless, obtaining formal proof for a

plasma membrane localization of PI(3)P and SGK3 has proven challenging. We attempted to make use of Total Internal Reflection Fluorescence (TIRF) microscopy to specifically detect SGK3 plasma membrane recruitment. Unfortunately, the overexpression of Green Fluorescent Protein (GFP)-tagged SGK3 generated considerable background fluorescence that precluded a consistent and robust evaluation of SGK3 membrane recruitment. An alternate method to investigate distinct SGK3 pools would be the use of self-quenching SNAP-tags to label SGK3 and examine SGK3 localization with fluorescent confocal and TIRF microscopy. SNAP-tags should theoretically have the advantage of reduced background allowing for increased resolution. Alternatively, the development of more specific and high affinity antibodies for phospho-SGK3 at pThr320 and pSer486 for use in IHC applications would be an important development. Such antibodies would allow for the examination of localization of endogenous SGK3 especially in cells and tissues with known PI 3-K genetic lesions. Further insight would be gained by examining the phosphoprotein profile IGF-1 stimulation or *PIK3CA* mutation in cells in which INPP4B has been silenced. Membrane interactions could be isolated after such treatments followed by mass spectrometry analysis to determine candidates of positively and negatively regulated INPP4B targets. This information would expand our understanding and add perspective to SGK3 signaling and may aid in the targeting of ER-positive breast cancers with combination therapy.

Another important step forward will be to generate genetically engineered mouse models that recapitulate finding that SGK3 can function as a *PIK3CA* and INPP4B effector. This would be especially interesting in the setting of ER-positive tumors, and examination of subsequent tumor growth and metastasis. One would predict that INPP4B silencing would mimic the phenotypes seen by SGK3 silencing. Although SGK3 isoform knockout mice have been made, they have only informed the contribution of SGK in embryonic development. Studies in adult mice in the context of tumor phenotypes have not been performed. Moreover, there is no combined SGK1/SGK2/SGK3 knockout mouse to address possible SGK familial signaling roles. Another gap in understanding is the nature of SGK3-specific substrates, or at least SGK-specific substrates that are not shared with Akt, other than NDRG1. Identifying such substrates will likely provide an important advance in our understanding of the mechanisms by which SGKs mediate cancer phenotypes. Finally, if specific total and phospho-specific SGK3 antibodies that are of sufficient quality for IF can be developed, one obvious application will also be to use confocal microscopy in the context of growth of tumor cells in 3D culture to determine changes in SGK1 and SGK3 localization, phosphorylation and activity to provide insight into spatial-temporal regulation of SGK.

The data pointing to NDRG1 as a metastasis suppressor through its modulation of Wnt signaling and E-cadherin recycling highlights a potential for a therapeutic strategy. However, a more detailed analysis of the NDRG1 phospho-degron remains an important issue, since NDRG1 does not possess a canonical FBW7 degron sequence. However, it does share similarities in the SGK3 and GSK3 β decapeptide repeat to

typical degrons. The priming of the phospho-degron by GSK3 β and the tandem phosphorylated serine and threonine sites are common characteristics of FBW7 sites. A logical extension of the studies presented in this thesis would be to mutate the NDRG1 carboxyl-terminal sites to alanine, and evaluate binding to FBW7 (**Figure 4-2**). Additionally, mass spectrometry analysis of the phosphorylation sites should be carried out under conditions of stimulation and in combination with a panel of protein kinase inhibitors (SGK, GSK3 β , PI 3-K).




Figure 4-2: Phospho-site analysis for NDRG1

Mapping of known phosphorylation sites for NDRG1 produced from mass spectrometry evaluation. Adapted from phosphosite.org.

The studies outlined in Chapter 3 provide evidence for an mTORC2- independent function for Rictor. One logical extension of these studies is to determine if scaffolding proteins common to Rictor in both the E3 ligase complex and mTORC2 exist. The absence of Skp1 in the Rictor-Cullin1 complex suggests that there may be alternate scaffolding proteins bridging Cullin1 to its F-box protein. The possibility remains that Rictor alone could mediate a bridging function or there could be additional components of the Rictor-Cullin1 complex that are essential to assemble a functional complex. Understanding which precise subunits within the E3 ligase complex directly interact will increase our understanding of complex formation. This knowledge will also guide the development of drugs that interrupt SGK1 degradation as a viable therapeutic option. Another important consideration is the consequence of the Rictor Thr1135 phosphorylation. There are two main models: Thr1135 phosphorylation could simply prevent the *de novo* assembly of Rictor-Cullin1, or alternatively Thr1135 phosphorylation could lead to spatial inhibition of the binding of complex components, and ultimate disassembly. The phosphorylation of Thr1135 generates a positive feedback loop that promotes the accumulation of SGK1. The deregulation of this feedback in cells with oncogenic PI 3-K pathway mutations may be causal with respect to SGK1 overexpression in human cancer. In this context, published studies have established a significant correlation between SGK1 overexpression and high levels of pAkt1 S473 in breast tumor samples (Sahoo et al., 2005). Additional examination of tumor samples with high SGK1 levels for enhanced Thr1135 Rictor phosphorylation will

help to establish the amplitude of the feedback loop. This same feedback loop negatively regulates Rictor, adding to our understanding of Rictor regulation and downstream signaling consequences. The existence of two Rictor complexes begs questions of stoichiometry between the pools. Although technically challenging, it will be interesting to examine the ability of one mTORC2 complex to sequester Rictor at the expense of the activity of the other. Our studies also establish the need to determine the extent of Rictor-Cullin1 as an E3 ligase and if its role in the UPS extends to other proteins or is exclusive to SGK1. It would be interesting to investigate the ability of Rictor to function as both a priming kinase within the phospho-degron and then to sequentially function as an E3 ligase for poly-ubiquitination. The synchronization of priming and poly-ubiquitination would challenge the participation of DUBs and provide insight into the mechanistic organization of cellular processes.

The synergy of Akt isoforms and SGK isoforms as effectors of *PIK3CA* and other PI 3-K pathway lesions likely leads to alterations in expression and activation of SGK1 and SGK3 under distinct phases of tumor development. Examining expression patterns of SGK1 in 3D spheroid growth and changes in expression resulting from altered Akt or SGK3 activity would help to explore the dynamic relationship between SGK isoforms and other AGC family kinase members. Moreover, since no specific SGK isoform-specific inhibitors have been developed, I propose our work provides the impetus for the development of such drugs, as they may provide an unmet need for tumors with specific pathway alterations.

4. FINAL NOTE

In summary, the data described in this thesis identifies two Akt-independent PI 3-K mediators, SGK1 and SGK3, that are hyperactivated in human cancers. The contribution of SGK3 amplification to *PIK3CA* signaling in breast cancers provides insight for a potentially novel therapeutic target. This thesis identifies INPP4B as a switch that determines pathway output to Akt or SGK3 in the PI 3-K pathway. I propose that INPP4B functions as both as an oncogene in luminal type breast cancer in the context of *PIK3CA* mutations, in addition to its well-documented role as a tumor suppressor in basal like/triple negative breast cancers. This concept reinforces the notion that complete understanding of the genetic context of a given tumor must be considered so that ultimately, the appropriate treatment regimen is prescribed. Furthermore, the work described in this thesis reveals a new pathway by which PI 3-K regulates the degradation of a metastasis suppressor, NDRG1, through SGK3. This finding also argues that there exists specificity between SGK and Akt signaling, rather than redundancy between the two kinase pathways. The identification of an mTORC2-independent function for Rictor proposes a more coordinated view of protein degradation. AGC kinase negative feedback regulation of Rictor ligase activity synergizing with Thr1135 phosphorylation highlights a mechanism by which PI 3-K activity promotes the overexpression of SGK1 and likely enhancement of *PI3KCA* signaling. The chapters of this thesis are related in that they focus on poly-ubiquitination and proteasomal degradation as a central feature to control signaling events. The deregulation of ubiquitination during oncogene-driven cancer progression

is also a central theme in this thesis. Most obvious is the concept that SGK isoforms contribute to breast cancer cell phenotypes in the context of PI 3-K signaling. These findings provide a more comprehensive understanding of PI 3-K biology and the emerging concept of importance of Akt-independent signaling. Finally, from a therapeutic perspective, the data outlined in this thesis advocate the development and implementation of combination therapies using small molecule inhibitors targeting SGK and Akt isoforms for maximal efficacy.

BIBLIOGRAPHY

Adjei, A.A. (2001). Blocking oncogenic Ras signaling for cancer therapy. *Journal of the National Cancer Institute* 93, 1062-1074.

AgoulNIK, I.U., Hodgson, M.C., Bowden, W.A., and Ittmann, M.M. (2011). INPP4B: the new kid on the PI3K block. *Oncotarget* 2, 321-328.

Arboleda, M.J., Lyons, J.F., Kabbinavar, F.F., Bray, M.R., Snow, B.E., Ayala, R., Danino, M., Karlan, B.Y., and Slamon, D.J. (2003). Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. *Cancer research* 63, 196-206.

Backer, J.M. (2008). The regulation and function of Class III PI3Ks: novel roles for Vps34. *The Biochemical journal* 410, 1-17.

Bar-Nun, S., and Glickman, M.H. (2012). Proteasomal AAA-ATPases: structure and function. *Biochimica et biophysica acta* 1823, 67-82.

Baselga, J. (2011). Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. *The oncologist* 16 Suppl 1, 12-19.

Belova, L., Sharma, S., Brickley, D.R., Nicolarsen, J.R., Patterson, C., and Conzen, S.D. (2006). Ubiquitin-proteasome degradation of serum- and glucocorticoid-regulated kinase-1 (SGK-1) is mediated by the chaperone-dependent E3 ligase CHIP. *The Biochemical journal* 400, 235-244.

Beroukhir, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J.S., Dobson, J., Urashima, M., *et al.* (2010). The landscape of somatic copy-number alteration across human cancers. *Nature* **463**, 899-905.

Boehm, J.S., Hession, M.T., Bulmer, S.E., and Hahn, W.C. (2005). Transformation of human and murine fibroblasts without viral oncoproteins. *Molecular and cellular biology* **25**, 6464-6474.

Bogusz, A.M., Brickley, D.R., Pew, T., and Conzen, S.D. (2006). A novel N-terminal hydrophobic motif mediates constitutive degradation of serum- and glucocorticoid-induced kinase-1 by the ubiquitin-proteasome pathway. *Febs J* **273**, 2913-2928.

Brickley, D.R., Mikosz, C.A., Hagan, C.R., and Conzen, S.D. (2002). Ubiquitin modification of serum and glucocorticoid-induced protein kinase-1 (SGK-1). *The Journal of biological chemistry* **277**, 43064-43070.

Brognard, J., and Newton, A.C. (2008). PHLiPPing the switch on Akt and protein kinase C signaling. *Trends in endocrinology and metabolism: TEM* **19**, 223-230.

Brognard, J., Siernecki, E., Gao, T., and Newton, A.C. (2007). PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. *Molecular cell* **25**, 917-931.

Brugge, J., Hung, M.C., and Mills, G.B. (2007). A new mutational AKTivation in the PI3K pathway. *Cancer cell* **12**, 104-107.

Brunet, A., Park, J., Tran, H., Hu, L.S., Hemmings, B.A., and Greenberg, M.E. (2001). Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHL1 (FOXO3a). *Molecular and cellular biology* **21**, 952-965.

Buonamici, S., Williams, J., Morrissey, M., Wang, A., Guo, R., Vattay, A., Hsiao, K., Yuan, J., Green, J., Ospina, B., *et al.* (2010). Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. *Science translational medicine* 2, 51ra70.

Cancer Genome Atlas, N. (2012). Comprehensive molecular portraits of human breast tumours. *Nature* 490, 61-70.

Cardozo, T., and Pagano, M. (2004). The SCF ubiquitin ligase: insights into a molecular machine. *Nature reviews. Molecular cell biology* 5, 739-751.

Carrano, A.C., Eytan, E., Hershko, A., and Pagano, M. (1999). SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. *Nature cell biology* 1, 193-199.

Chan, C.H., Li, C.F., Yang, W.L., Gao, Y., Lee, S.W., Feng, Z., Huang, H.Y., Tsai, K.K., Flores, L.G., Shao, Y., *et al.* (2012). The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. *Cell* 149, 1098-1111.

Chen, Z., Zhang, D., Yue, F., Zheng, M., Kovacevic, Z., and Richardson, D.R. (2012). The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). *The Journal of biological chemistry* 287, 17016-17028.

Cheng, Y., and Li, G. (2012). Role of the ubiquitin ligase Fbw7 in cancer progression. *Cancer metastasis reviews* 31, 75-87.

Cherfils, J., and Zeghouf, M. (2013). Regulation of small GTPases by GEFs, GAPs, and GDIs. *Physiological reviews* 93, 269-309.

Chin, Y.R., and Toker, A. (2009). Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. *Cell Signal* *21*, 470-476.

Chin, Y.R., and Toker, A. (2010). The Actin-Bundling Protein Palladin Is an Akt1-Specific Substrate that Regulates Breast Cancer Cell Migration. *Molecular cell* *38*, 333-344.

Chin, Y.R., and Toker, A. (2011). Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. *Cell adhesion & migration* *5*, 211-214.

Choi, Y., Zhang, J., Murga, C., Yu, H., Koller, E., Monia, B.P., Gutkind, J.S., and Li, W. (2002). PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. *Oncogene* *21*, 5289-5300.

Cleary, J.M., and Shapiro, G.I. (2010). Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. *Current oncology reports* *12*, 87-94.

Courtney, K.D., Corcoran, R.B., and Engelman, J.A. (2010). The PI3K pathway as drug target in human cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* *28*, 1075-1083.

Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M.E. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell* *91*, 231-241.

Davids, M.S., and Brown, J.R. (2012). Targeting the B cell receptor pathway in chronic lymphocytic leukemia. *Leukemia & lymphoma* *53*, 2362-2370.

Davies, M.A., Stemke-Hale, K., Tellez, C., Calderone, T.L., Deng, W., Prieto, V.G., Lazar, A.J., Gershenwald, J.E., and Mills, G.B. (2008). A novel AKT3 mutation in melanoma tumours and cell lines. *British journal of cancer* 99, 1265-1268.

Debnath, J., and Brugge, J.S. (2005). Modelling glandular epithelial cancers in three-dimensional cultures. *Nature reviews. Cancer* 5, 675-688.

Debnath, J., Muthuswamy, S.K., and Brugge, J.S. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods* 30, 256-268.

Debonneville, C., Flores, S.Y., Kamynina, E., Plant, P.J., Tauxe, C., Thomas, M.A., Munster, C., Chraibi, A., Pratt, J.H., Horisberger, J.D., *et al.* (2001). Phosphorylation of Nedd4-2 by Sgk1 regulates epithelial Na(+) channel cell surface expression. *The EMBO journal* 20, 7052-7059.

Dibble, C.C., Asara, J.M., and Manning, B.D. (2009). Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. *Molecular and cellular biology* 29, 5657-5670.

DiNitto, J.P., Delprato, A., Gabe Lee, M.T., Cronin, T.C., Huang, S., Guilherme, A., Czech, M.P., and Lambright, D.G. (2007). Structural basis and mechanism of autoregulation in 3-phosphoinositide-dependent Grp1 family Arf GTPase exchange factors. *Molecular cell* 28, 569-583.

Dos Santos, M., da Cunha Mercante, A.M., Nunes, F.D., Leopoldino, A.M., de Carvalho, M.B., Gazito, D., Lopez, R.V., Chiappini, P.B., de Carvalho Neto, P.B., Fukuyama, E.E.,

et al. (2012). Prognostic significance of NDRG1 expression in oral and oropharyngeal squamous cell carcinoma. *Molecular biology reports* 39, 10157-10165.

Elong Edimo, W., Vanderwinden, J.M., and Erneux, C. (2013). SHIP2 signalling at the plasma membrane, in the nucleus and at focal contacts. *Advances in biological regulation* 53, 28-37.

Engelman, J.A., Luo, J., and Cantley, L.C. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nature reviews* 7, 606-619.

Fasanaro, P., Capogrossi, M.C., and Martelli, F. (2010). Regulation of the endothelial cell cycle by the ubiquitin-proteasome system. *Cardiovascular research* 85, 272-280.

Fedele, C.G., Ooms, L.M., Ho, M., Vieuxseux, J., O'Toole, S.A., Millar, E.K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., *et al.* (2010). Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. *Proceedings of the National Academy of Sciences of the United States of America* 107, 22231-22236.

Firestone, G.L., Giampaolo, J.R., and O'Keeffe, B.A. (2003). Stimulus-dependent regulation of serum and glucocorticoid inducible protein kinase (SGK) transcription, subcellular localization and enzymatic activity. *Cell Physiol Biochem* 13, 1-12.

Franke, T.F., Kaplan, D.R., Cantley, L.C., and Toker, A. (1997). Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. *Science* 275, 665-668.

Gao, D., Inuzuka, H., Tseng, A., Chin, R.Y., Toker, A., and Wei, W. (2009). Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APC^{Cdh1}-mediated Skp2 destruction. *Nature cell biology* *11*, 397-408.

Gao, D., Wan, L., Inuzuka, H., Berg, A.H., Tseng, A., Zhai, B., Shaik, S., Bennett, E., Tron, A.E., Gasser, J.A., *et al.* (2010). Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. *Molecular cell* *39*, 797-808.

Garcia-Martinez, J.M., and Alessi, D.R. (2008). mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). *The Biochemical journal* *416*, 375-385.

Gewinner, C., Wang, Z.C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W.M., Rameh, L., Salmena, L., *et al.* (2009). Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. *Cancer cell* *16*, 115-125.

Ghosh, P., Wu, M., Zhang, H., and Sun, H. (2008). mTORC1 signaling requires proteasomal function and the involvement of CUL4-DDB1 ubiquitin E3 ligase. *Cell cycle* *7*, 373-381.

Guertin, D.A., and Sabatini, D.M. (2007). Defining the role of mTOR in cancer. *Cancer cell* *12*, 9-22.

Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., Turk, B.E., and Shaw, R.J. (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Molecular cell* *30*, 214-226.

Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., and Yonezawa, K. (2002). Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. *Cell* *110*, 177-189.

Harper, J.W., Burton, J.L., and Solomon, M.J. (2002). The anaphase-promoting complex: it's not just for mitosis any more. *Genes & development* *16*, 2179-2206.

Harvell, D.M., Richer, J.K., Allred, D.C., Sartorius, C.A., and Horwitz, K.B. (2006). Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. *Endocrinology* *147*, 700-713.

Hawkins, P.T., Anderson, K.E., Davidson, K., and Stephens, L.R. (2006). Signalling through Class I PI3Ks in mammalian cells. *Biochemical Society transactions* *34*, 647-662.

Hobert, J.A., and Eng, C. (2009). PTEN hamartoma tumor syndrome: an overview. *Genetics in medicine : official journal of the American College of Medical Genetics* *11*, 687-694.

Hogan, A., Yakubchuk, Y., Chabot, J., Obagi, C., Daher, E., Maekawa, K., and Gee, S.H. (2004). The phosphoinositol 3,4-bisphosphate-binding protein TAPP1 interacts with syntrophins and regulates actin cytoskeletal organization. *The Journal of biological chemistry* *279*, 53717-53724.

Hosoi, F., Izumi, H., Kawahara, A., Murakami, Y., Kinoshita, H., Kage, M., Nishio, K., Kohno, K., Kuwano, M., and Ono, M. (2009). N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through

attenuation of inhibitor of kappaB kinase beta expression. *Cancer research* 69, 4983-4991.

Huang, J., Wu, S., Wu, C.L., and Manning, B.D. (2009). Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. *Cancer research* 69, 6107-6114.

Ichimura, T., Yamamura, H., Sasamoto, K., Tominaga, Y., Taoka, M., Kakiuchi, K., Shinkawa, T., Takahashi, N., Shimada, S., and Isobe, T. (2005). 14-3-3 proteins modulate the expression of epithelial Na⁺ channels by phosphorylation-dependent interaction with Nedd4-2 ubiquitin ligase. *The Journal of biological chemistry* 280, 13187-13194.

Isakoff, S.J., Engelman, J.A., Irie, H.Y., Luo, J., Brachmann, S.M., Pearlman, R.V., Cantley, L.C., and Brugge, J.S. (2005). Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. *Cancer research* 65, 10992-11000.

Ivetac, I., Gurung, R., Hakim, S., Horan, K.A., Sheffield, D.A., Binge, L.C., Majerus, P.W., Tiganis, T., and Mitchell, C.A. (2009). Regulation of PI(3)K/Akt signalling and cellular transformation by inositol polyphosphate 4-phosphatase-1. *EMBO reports* 10, 487-493.

Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S.Y., Huang, Q., Qin, J., and Su, B. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. *Cell* 127, 125-137.

Jamieson, S., Flanagan, J.U., Kolekar, S., Buchanan, C., Kendall, J.D., Lee, W.J., Rewcastle, G.W., Denny, W.A., Singh, R., Dickson, J., *et al.* (2011). A drug targeting

only p110 α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. *The Biochemical journal* **438**, 53-62.

Jin, J., Ang, X.L., Shirogane, T., and Wade Harper, J. (2005). Identification of substrates for F-box proteins. *Methods in enzymology* **399**, 287-309.

Julien, L.A., Carriere, A., Moreau, J., and Roux, P.P. (2010). mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. *Molecular and cellular biology* **30**, 908-921.

Jung, T., and Grune, T. (2013). The proteasome and the degradation of oxidized proteins: Part I-structure of proteasomes. *Redox biology* **1**, 178-182.

Kachhap, S.K., Faith, D., Qian, D.Z., Shabbeer, S., Galloway, N.L., Pili, R., Denmeade, S.R., DeMarzo, A.M., and Carducci, M.A. (2007). The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. *PLoS One* **2**, e844.

Kalluri, R., and Weinberg, R.A. (2009). The basics of epithelial-mesenchymal transition. *The Journal of clinical investigation* **119**, 1420-1428.

Kapeller, R., Toker, A., Cantley, L.C., and Carpenter, C.L. (1995). Phosphoinositide 3-kinase binds constitutively to α / β -tubulin and binds to γ -tubulin in response to insulin. *The Journal of biological chemistry* **270**, 25985-25991.

Kim, D.H., Sarbassov, D.D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-Bromage, H., Tempst, P., and Sabatini, D.M. (2002). mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell* **110**, 163-175.

Kobayashi, T., and Cohen, P. (1999). Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. *The Biochemical journal* *339* (Pt 2), 319-328.

Kobayashi, T., Deak, M., Morrice, N., and Cohen, P. (1999). Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. *The Biochemical journal* *344 Pt 1*, 189-197.

Kovacevic, Z., and Richardson, D.R. (2006). The metastasis suppressor, Ndrp-1: a new ally in the fight against cancer. *Carcinogenesis* *27*, 2355-2366.

Lang, F., Bohmer, C., Palmada, M., Seebohm, G., Strutz-Seebohm, N., and Vallon, V. (2006). (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. *Physiological reviews* *86*, 1151-1178.

Lang, F., and Cohen, P. (2001). Regulation and physiological roles of serum- and glucocorticoid-induced protein kinase isoforms. *Science's STKE : signal transduction knowledge environment* *2001*, re17.

Langille, S.E., Patki, V., Klarlund, J.K., Buxton, J.M., Holik, J.J., Chawla, A., Corvera, S., and Czech, M.P. (1999). ADP-ribosylation factor 6 as a target of guanine nucleotide exchange factor GRP1. *The Journal of biological chemistry* *274*, 27099-27104.

Lau, A.W., Fukushima, H., and Wei, W. (2012). The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. *Frontiers in bioscience* *17*, 2197-2212.

Lee, J.W., Soung, Y.H., Kim, S.Y., Lee, H.W., Park, W.S., Nam, S.W., Kim, S.H., Lee, J.Y., Yoo, N.J., and Lee, S.H. (2005). PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. *Oncogene* 24, 1477-1480.

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., *et al.* (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [see comments]. *Science* 275, 1943-1947.

Liu, D., Yang, X., and Songyang, Z. (2000). Identification of CISK, a new member of the SGK kinase family that promotes IL-3-dependent survival. *Curr Biol* 10, 1233-1236.

Liu, R., Li, J., Teng, Z., Zhang, Z., and Xu, Y. (2013). Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1). *PloS one* 8, e68982.

Liu, W., Xing, F., Iizumi-Gairani, M., Okuda, H., Watabe, M., Pai, S.K., Pandey, P.R., Hirota, S., Kobayashi, A., Mo, Y.Y., *et al.* (2012). N-myc downstream regulated gene 1 modulates Wnt-beta-catenin signalling and pleiotropically suppresses metastasis. *EMBO molecular medicine* 4, 93-108.

Liu, Y.L., Bai, W.T., Luo, W., Zhang, D.X., Yan, Y., Xu, Z.K., and Zhang, F.L. (2011). Downregulation of NDRG1 promotes invasion of human gastric cancer AGS cells through MMP-2. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine* 32, 99-105.

Loffing, J., Flores, S.Y., and Staub, O. (2006). Sgk kinases and their role in epithelial transport. *Annual review of physiology* 68, 461-490.

Lu, D., Huang, J., and Basu, A. (2006). Protein kinase Cepsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death. *The Journal of biological chemistry* *281*, 22799-22807.

Lu, Z., Xu, S., Joazeiro, C., Cobb, M.H., and Hunter, T. (2002). The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. *Molecular cell* *9*, 945-956.

Luo, J., Manning, B.D., and Cantley, L.C. (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and promise. *Cancer cell* *4*, 257-262.

Maddika, S., and Chen, J. (2009). Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. *Nature cell biology* *11*, 409-419.

Maehama, T., and Dixon, J.E. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *The Journal of biological chemistry* *273*, 13375-13378.

Manfredi, J.J. (2010). The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. *Genes & development* *24*, 1580-1589.

Manning, B.D., and Cantley, L.C. (2007). AKT/PKB signaling: navigating downstream. *Cell* *129*, 1261-1274.

Mao, J.H., Kim, I.J., Wu, D., Climent, J., Kang, H.C., DelRosario, R., and Balmain, A. (2008). FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. *Science* *321*, 1499-1502.

Mao, Z., Sun, J., Feng, B., Ma, J., Zang, L., Dong, F., Zhang, D., and Zheng, M. (2013). The metastasis suppressor, N-myc downregulated gene 1 (NDRG1), is a prognostic biomarker for human colorectal cancer. *PloS one* 8, e68206.

Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G.N., and Ueno, N.T. (2012). Role of epidermal growth factor receptor in breast cancer. *Breast cancer research and treatment* 136, 331-345.

Matsushita, K., Uchida, K., Saigusa, S., Ide, S., Hashimoto, K., Koike, Y., Otake, K., Inoue, M., Tanaka, K., and Kusunoki, M. (2013). Low NDRG1 mRNA expression predicts a poor prognosis in neuroblastoma patients. *Pediatric surgery international* 29, 363-368.

McCormick, J.A., Feng, Y., Dawson, K., Behne, M.J., Yu, B., Wang, J., Wyatt, A.W., Henke, G., Grahammer, F., Mauro, T.M., *et al.* (2004). Targeted disruption of the protein kinase SGK3/CISK impairs postnatal hair follicle development. *Molecular biology of the cell* 15, 4278-4288.

McDonald, F.J. (2008). A new SGK1 knockout mouse. *American journal of physiology. Renal physiology* 294, F1296-1297.

Melotte, V., Qu, X., Ongenaert, M., van Criekinge, W., de Bruine, A.P., Baldwin, H.S., and van Engeland, M. (2010). The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 24, 4153-4166.

Miao, B., Skidan, I., Yang, J., Lugovskoy, A., Reibarkh, M., Long, K., Brazell, T., Durugkar, K.A., Maki, J., Ramana, C.V., *et al.* (2010). Small molecule inhibition of

phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. *Proceedings of the National Academy of Sciences of the United States of America* *107*, 20126-20131.

Miller, T.W., Rexer, B.N., Garrett, J.T., and Arteaga, C.L. (2011). Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. *Breast cancer research : BCR* *13*, 224.

Mora, A., Komander, D., van Aalten, D.M., and Alessi, D.R. (2004). PDK1, the master regulator of AGC kinase signal transduction. *Seminars in cell & developmental biology* *15*, 161-170.

Murray, J.T., Campbell, D.G., Morrice, N., Auld, G.C., Shpiro, N., Marquez, R., Peggie, M., Bain, J., Bloomberg, G.B., Grahammer, F., *et al.* (2004). Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. *The Biochemical journal* *384*, 477-488.

Najafov, A., Sommer, E.M., Axten, J.M., Deyoung, M.P., and Alessi, D.R. (2011). Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. *The Biochemical journal* *433*, 357-369.

Nakayama, K.I., and Nakayama, K. (2005). Regulation of the cell cycle by SCF-type ubiquitin ligases. *Seminars in cell & developmental biology* *16*, 323-333.

Norris, F.A., Atkins, R.C., and Majerus, P.W. (1997). The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. *The Journal of biological chemistry* *272*, 23859-23864.

Norris, F.A., and Majerus, P.W. (1994). Hydrolysis of phosphatidylinositol 3,4-bisphosphate by inositol polyphosphate 4-phosphatase isolated by affinity elution chromatography. *The Journal of biological chemistry* 269, 8716-8720.

Okkenhaug, K. (2013). Signaling by the phosphoinositide 3-kinase family in immune cells. *Annual review of immunology* 31, 675-704.

Pang, H., Flinn, R., Patsialou, A., Wyckoff, J., Roussos, E.T., Wu, H., Pozzuto, M., Goswami, S., Condeelis, J.S., Bresnick, A.R., *et al.* (2009). Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. *Cancer research* 69, 8868-8876.

Park, J., Leong, M.L., Buse, P., Maiyar, A.C., Firestone, G.L., and Hemmings, B.A. (1999). Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. *The EMBO journal* 18, 3024-3033.

Patani, N., Martin, L.A., and Dowsett, M. (2013). Biomarkers for the clinical management of breast cancer: international perspective. *International journal of cancer. Journal international du cancer* 133, 1-13.

Pearce, L.R., Komander, D., and Alessi, D.R. (2010). The nuts and bolts of AGC protein kinases. *Nature reviews. Molecular cell biology* 11, 9-22.

Petroski, M.D., and Deshaies, R.J. (2005). Function and regulation of cullin-RING ubiquitin ligases. *Nature reviews. Molecular cell biology* 6, 9-20.

Rajagopalan, H., Jallepalli, P.V., Rago, C., Velculescu, V.E., Kinzler, K.W., Vogelstein, B., and Lengauer, C. (2004). Inactivation of hCDC4 can cause chromosomal instability. *Nature* 428, 77-81.

Reiling, J.H., and Sabatini, D.M. (2006). Stress and mTOR signaling. *Oncogene* 25, 6373-6383.

Rexer, B.N., and Arteaga, C.L. (2013). Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. *Cancer research* 73, 3817-3820.

Sahoo, S., Brickley, D.R., Kocherginsky, M., and Conzen, S.D. (2005). Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer. *Eur J Cancer* 41, 2754-2759.

Saito, K., Scharenberg, A.M., and Kinet, J.P. (2001). Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk. *The Journal of biological chemistry* 276, 16201-16206.

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., *et al.* (2004). High frequency of mutations of the PIK3CA gene in human cancers. *Science* 304, 554.

Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-Peled, L., and Sabatini, D.M. (2008). The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. *Science* 320, 1496-1501.

Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* 307, 1098-1101.

Scheid, M.P., Huber, M., Damen, J.E., Hughes, M., Kang, V., Neilsen, P., Prestwich, G.D., Krystal, G., and Duronio, V. (2002). Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3,4)P2 is

required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. *The Journal of biological chemistry* **277**, 9027-9035.

Schulman, B.A., Carrano, A.C., Jeffrey, P.D., Bowen, Z., Kinnucan, E.R., Finnin, M.S., Elledge, S.J., Harper, J.W., Pagano, M., and Pavletich, N.P. (2000). Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. *Nature* **408**, 381-386.

Sherk, A.B., Frigo, D.E., Schnackenberg, C.G., Bray, J.D., Laping, N.J., Trizna, W., Hammond, M., Patterson, J.R., Thompson, S.K., Kazmin, D., *et al.* (2008). Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. *Cancer research* **68**, 7475-7483.

Shiota, C., Woo, J.T., Lindner, J., Shelton, K.D., and Magnuson, M.A. (2006). Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. *Developmental cell* **11**, 583-589.

Singh, A., Ye, M., Bucur, O., Zhu, S., Tanya Santos, M., Rabinovitz, I., Wei, W., Gao, D., Hahn, W.C., and Khosravi-Far, R. (2010). Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. *Molecular biology of the cell* **21**, 1140-1152.

Sommer, E.M., Dry, H., Cross, D., Guichard, S., Davies, B.R., and Alessi, D.R. (2013). Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. *The Biochemical journal* **452**, 499-508.

Song, M.S., Salmena, L., and Pandolfi, P.P. (2012). The functions and regulation of the PTEN tumour suppressor. *Nature reviews. Molecular cell biology* **13**, 283-296.

Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., *et al.* (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proceedings of the National Academy of Sciences of the United States of America* *98*, 10869-10874.

South, A.P., Cho, R.J., and Aster, J.C. (2012). The double-edged sword of Notch signaling in cancer. *Seminars in cell & developmental biology* *23*, 458-464.

Stalder, D., and Antonny, B. (2013). Arf GTPase regulation through cascade mechanisms and positive feedback loops. *FEBS letters* *587*, 2028-2035.

Stemke-Hale, K., Gonzalez-Angulo, A.M., Lluch, A., Neve, R.M., Kuo, W.L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., *et al.* (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. *Cancer research* *68*, 6084-6091.

Sun, J., Zhang, D., Bae, D.H., Sahni, S., Jansson, P., Zheng, Y., Zhao, Q., Yue, F., Zheng, M., Kovacevic, Z., *et al.* (2013a). Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. *Carcinogenesis* *34*, 1943-1954.

Sun, J., Zhang, D., Zheng, Y., Zhao, Q., Zheng, M., Kovacevic, Z., and Richardson, D.R. (2013b). Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. *Molecular pharmacology* *83*, 454-469.

Tessier, M., and Woodgett, J.R. (2006a). Role of the Phox homology domain and phosphorylation in activation of serum and glucocorticoid-regulated kinase-3. *The Journal of biological chemistry* *281*, 23978-23989.

Tessier, M., and Woodgett, J.R. (2006b). Serum and glucocorticoid-regulated protein kinases: variations on a theme. *Journal of cellular biochemistry* *98*, 1391-1407.

Toker, A. (2000). Protein kinases as mediators of phosphoinositide 3-kinase signaling. *Molecular pharmacology* *57*, 652-658.

Toker, A. (2012). Achieving specificity in Akt signaling in cancer. *Advances in biological regulation* *52*, 78-87.

Toker, A., and Yoeli-Lerner, M. (2006). Akt signaling and cancer: surviving but not moving on. *Cancer research* *66*, 3963-3966.

Tran, H., Brunet, A., Griffith, E.C., and Greenberg, M.E. (2003). The many forks in FOXO's road. *Science's STKE : signal transduction knowledge environment* *2003*, RE5.

Treins, C., Warne, P.H., Magnuson, M.A., Pende, M., and Downward, J. (2010). Rictor is a novel target of p70 S6 kinase-1. *Oncogene* *29*, 1003-1016.

Ureshino, H., Murakami, Y., Watari, K., Izumi, H., Kawahara, A., Kage, M., Arao, T., Nishio, K., Yanagihara, K., Kinoshita, H., *et al.* (2012). N-myc downstream regulated gene 1 (NDRG1) promotes metastasis of human scirrhous gastric cancer cells through epithelial mesenchymal transition. *PloS one* *7*, e41312.

Vander Haar, E., Lee, S.I., Bandhakavi, S., Griffin, T.J., and Kim, D.H. (2007). Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. *Nature cell biology* *9*, 316-323.

Vanhaesebroeck, B., Stephens, L., and Hawkins, P. (2012). PI3K signalling: the path to discovery and understanding. *Nature reviews. Molecular cell biology* 13, 195-203.

Vargas, L., Hamasy, A., Nore, B.F., and Smith, C.I. (2013). Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. *Scandinavian journal of immunology* 78, 130-139.

Vasudevan, K.M., Barbie, D.A., Davies, M.A., Rabinovsky, R., McNear, C.J., Kim, J.J., Hennessey, B.T., Tseng, H., Pochanard, P., Kim, S.Y., *et al.* (2009). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. *Cancer cell* 16, 21-32.

Vogt, P.K., Jiang, H., and Aoki, M. (2005). Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. *Cell cycle* 4, 908-913.

Wang, Q., Li, L.H., Gao, G.D., Wang, G., Qu, L., Li, J.G., and Wang, C.M. (2013). HIF-1 α up-regulates NDRG1 expression through binding to NDRG1 promoter, leading to proliferation of lung cancer A549 cells. *Molecular biology reports* 40, 3723-3729.

Wang, Y., Zhou, D., Phung, S., Masri, S., Smith, D., and Chen, S. (2011a). SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. *Molecular endocrinology* 25, 72-82.

Wang, Z., Fukushima, H., Gao, D., Inuzuka, H., Wan, L., Lau, A.W., Liu, P., and Wei, W. (2011b). The two faces of FBW7 in cancer drug resistance. *Bioessays* 33, 851-859.

Wang, Z., Inuzuka, H., Zhong, J., Wan, L., Fukushima, H., Sarkar, F.H., and Wei, W. (2012). Tumor suppressor functions of FBW7 in cancer development and progression. *FEBS letters* 586, 1409-1418.

Webster, M.K., Goya, L., Ge, Y., Maiyar, A.C., and Firestone, G.L. (1993).

Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. *Molecular and cellular biology* 13, 2031-2040.

Wee, S., Wiederschain, D., Maira, S.M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.M., and Lengauer, C. (2008). PTEN-deficient cancers depend on PIK3CB. *Proceedings of the National Academy of Sciences of the United States of America* 105, 13057-13062.

Wei, W., Jin, J., Schlisio, S., Harper, J.W., and Kaelin, W.G., Jr. (2005). The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. *Cancer cell* 8, 25-33.

Woodgett, J.R. (2005). Recent advances in the protein kinase B signaling pathway. *Curr Opin Cell Biol* 17, 150-157.

Xia, H., Nho, R.S., Kahm, J., Kleidon, J., and Henke, C.A. (2004). Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. *The Journal of biological chemistry* 279, 33024-33034.

Xu, B.E., Stippec, S., Lazrak, A., Huang, C.L., and Cobb, M.H. (2005). WNK1 activates SGK1 by a phosphatidylinositol 3-kinase-dependent and non-catalytic mechanism. *The Journal of biological chemistry* 280, 34218-34223.

Xu, J., Liu, D., Gill, G., and Songyang, Z. (2001). Regulation of cytokine-independent survival kinase (CISK) by the Phox homology domain and phosphoinositides. *J Cell Biol* 154, 699-705.

Xu, J., Wan, M., He, Q., Bassett, R.L., Jr., Fu, X., Chen, A.C., Shi, F., Creighton, C.J., Schiff, R., Huo, L., *et al.* (2012). SGK3 is associated with estrogen receptor expression in breast cancer. *Breast cancer research and treatment* 134, 531-541.

Yang, Q., Inoki, K., Ikenoue, T., and Guan, K.L. (2006). Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. *Genes & development* 20, 2820-2832.

Yoeli-Lerner, M., Yiu, G.K., Rabinovitz, I., Erhardt, P., Jauliac, S., and Toker, A. (2005). Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. *Molecular cell* 20, 539-550.

Yuan, T.L., and Cantley, L.C. (2008). PI3K pathway alterations in cancer: variations on a theme. *Oncogene* 27, 5497-5510.

Zardavas, D., Baselga, J., and Piccart, M. (2013). Emerging targeted agents in metastatic breast cancer. *Nature reviews. Clinical oncology* 10, 191-210.

Zhang, L., Cui, R., Cheng, X., and Du, J. (2005). Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I κ B kinase. *Cancer research* 65, 457-464.

Zhang, W., and Sidhu, S.S. (2013). Development of inhibitors in the ubiquitination cascade. *FEBS letters*.

Zhao, G., Chen, J., Deng, Y., Gao, F., Zhu, J., Feng, Z., Lv, X., and Zhao, Z. (2011). Identification of NDRG1-regulated genes associated with invasive potential in cervical and ovarian cancer cells. *Biochemical and biophysical research communications* 408, 154-159.

Zhou, R., and Snyder, P.M. (2005). Ned4-2 phosphorylation induces serum and glucocorticoid-regulated kinase (SGK) ubiquitination and degradation. *The Journal of biological chemistry* 280, 4518-4523.